document incorporate referencepart iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statement incorporate reference report reportitem p art business general segment b usiness geographic reas raw aterial patent trademark seasonality competition environment regulation employee h uman c apital anagement available nformation risk f actors b unresolved taff c omments c cybersecurity property legal p roceeding afety isclosure executive fficer r egistrant p art ii market r egistrant c ommon e quity r elated tockholder atter ssuer p urchase e quity ecuritie reserve management iscussion nalysis r esult peration f inancial c ondition quantitative q ualitative isclosure bout arket r sk cautionary note forwardlooke statement annual report johnson johnsons publicly available document contain forwardlooke statement mean safe harbor provision united states private security litigation reform act management representatives johnson johnson subsidiaries company time time forwardlooke statement forwardlooke statement relate strictly historical current fact reflect management assumption view plan objective projection future forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation expect operating result financial performance impact plan acquisition disposition impact time restructuring initiative include associate cost saving benefit company strategy growth product development activity regulatory approval market position expenditure forwardlooke statement base current belief expectation assumption future event subject uncertainty risk change difficult predict outside company control investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize company actual result financial condition vary materially expectation projection express imply forwardlooke statement investor caution rely forwardlooke statement risk uncertainty include limited risk relate product development market success competition challenge uncertainty inherent innovation development new improved product technology company continue growth success depend include uncertainty clinical outcome additional analysis exist clinical datum obtain regulatory approval health plan coverage customer access initial continue commercial success challenge company ability obtain protect adequate patent intellectual property right new exist product technologies united states important market impact patent expiration typically follow introduction compete generic biosimilar product result revenue market share loss increasingly aggressive frequent challenge company patent competitor seek launch compete generic biosimilar product increase receptivity court united states patent trademark office decision maker challenge potentially result loss market exclusivity rapid decline sale relevant product soon expect competition research development new improved product process technology result product process obsolescence competition reach agreement party collaboration licensing development marketing agreement product technology competition base costeffectiveness product performance technological advance patent attain competitor allegation company product infringe patent intellectual property right party adversely affect company ability sell product question require payment money damage future royalty risk relate product liability litigation regulatory activity product efficacy safety concern base scientific evidence potentially result product withdrawal recall regulatory action united states food drug administration fda international counterpart decline sale reputational damage increase litigation expense share price impact impact include decline sale reputational damage significant litigation government action adverse company include product liability claim allegation relate pharmaceutical marketing practice contracting strategy impact adverse judgment settlement adequacy reserve relate legal proceeding include patent litigation product liability personal injury claim security class action government investigation employment legal proceeding increase scrutiny healthcare industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business failure meet compliance obligation compliance agreement government government agency result significant sanction potential change applicable law regulation affect united states international operation include relate approval new product license patent right sale promotion healthcare product access reimbursement pricing healthcare product service environmental protection source raw material compliance local regulation law restrict company ability manufacture sell product relevant market include requirement comply medical device report regulation requirement european union medical device regulation change domestic international tax law regulation increase audit scrutiny tax authority world exposure additional tax liability potentially excess exist reserve issuance new revise accounting standard financial accounting standard board regulation securities exchange commission risk relate company strategic initiative healthcare market trend realization benefit separation company consumer health business pricing pressure result trend healthcare cost containment include continued consolidation healthcare provider market participant trend manage care shift government increasingly primary payor healthcare expense significant new entrant healthcare market seek reduce cost government pressure company voluntarily reduce cost price increase restrict spend pattern individual institutional governmental purchaser healthcare product service economic hardship budgetary constraint challenge company ability realize strategy growth include externally source innovation development collaboration strategic acquisition license marketing agreement potential heighten cost external arrangement competitive pressure potential expect strategic benefit opportunity plan complete acquisition divestiture company realize long realize expect potential expect benefit opportunity relate past ongoing restructure action realize long realize expect company ability divest company remain ownership interest kenvue inc kenvue realize anticipated benefit separation kenvue ability succeed standalone publicly trade company risk relate economic condition financial market operate internationally risk associate global operation company customer supplier include foreign government country company operate impact inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin potential change exportimport trade law regulation policy united states country include increase trade restriction tariff potential drug reimportation legislation impact international operation financial instability international economy sovereign risk possible imposition governmental control restrictive economic policy unstable international government legal system impact global public health crisis pandemic change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation impact global economic change event include global tension war impact armed conflict terrorist attack united states part world include social economic disruption instability financial market risk relate supply chain operation difficulty delay manufacture internally thirdparty provider supply chain lead voluntary involuntary business interruption shutdown product shortage withdrawal suspension product market potential regulatory action interruption breach company information technology system company vendor result reputational competitive operational business harm financial cost regulatory action reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect supply source pricing material company product potential expect benefit opportunitie related restructuring action realize long realize expect include require approval applicable regulatory authority investor carefully read risk factor describe item annual report description certain risk thing cause company actual result differ materially express forwardlooke statement investor understand possible predict identify factor consider risk describe item complete statement potential risk uncertainty company undertake publicly update forwardlooke statement time time result new information future event developmentspart item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activity company business segment innovative medicine previously refer pharmaceutical medtech strategic parameter provide committee senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment limited exception manage resident country locate segment business follow completion separation consumer health business kenvue august company organize business segment innovative medicine medtech additional information require item incorporate reference narrative tabular description segment operate result item management discussion analysis result operation financial condition report note segment business geographic area note consolidated financial statement include item report innovative medicine innovative medicine segment focus follow therapeutic area immunology eg rheumatoid arthritis psoriatic arthritis inflammatory bowel disease psoriasis infectious disease eg hivaid neuroscience eg mood disorder neurodegenerative disorder schizophrenia oncology eg prostate cancer hematologic malignancy lung cancer bladder cancer cardiovascular metabolism eg thrombosis diabete macular degeneration pulmonary hypertension eg pulmonary arterial hypertension medicine segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use key product innovative medicine segment include remicade infliximab treatment number immunemediate inflammatory disease simponi golimumab subcutaneous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis active polyarticular juvenile idiopathic arthritis pjia people year age old stelara ustekinumab treatment adult child moderate severe plaque psoriasis adult active psoriatic arthritis adult moderately severely active crohn disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adult moderate severe plaque psoriasis active psoriatic arthritis edurant rilpivirine prezista darunavir prezcobixrezolsta darunavircobicistat antiretroviral medicine treatment human immunodeficiency virus hiv combination antiretroviral product symtuza darunavircobicistatemtricitabine tenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extend release tablet cii treatment attention deficit hyperactivity disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adult invega trinzatrevicta paliperidone palmitate treatment schizophrenia patient adequately treat invega sustenna month spravato esketamine nasal spray oral antidepressant treat adult treatmentresistant depression trd depressive symptom adult major depressive disorder mdd suicidal thought action carvykti ciltacabtagene autoleucel chimeric antigen receptor cartcell therapy treatment patient withrelapsedrefractory multiple myeloma zytiga abiraterone annual report acetate treatment patient prostate cancer erleada apalutamide generation androgen receptor inhibitor treatment patient prostate cancer imbruvica ibrutinib treatment certain bcell malignancy blood cancer chronic graft versus host disease darzalex daratumumab treatment multiple myeloma darzalex faspro daratumumab hyaluronidasefihj treatment multiple myeloma light chain al amyloidosis xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt lead pulmonary embolism pe patient undergo hip knee replacement surgery reduce risk stroke systemic embolism patient nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe reduce risk major cardiovascular event patient coronary artery disease cad peripheral artery disease pad treatment secondary prevention thromboembolism pediatric patient thromboprophylaxis pediatric patient follow fontan procedure opsumit macitentan monotherapy combination indicate longterm treatment pulmonary arterial hypertension pah uptravi selexipag approve oral intravenous selective ip receptor agonist target prostacyclin pathway pah medicine develop collaboration strategic partner license company maintain active lifecycle development programs medtech medtech segment include broad portfolio product interventional solution orthopaedic surgery vision category interventional solution include electrophysiology product biosense webster treat heart rhythm disorder heart recovery portfolio abiome include technology treat severe coronary artery disease require highrisk pci ami cardiogenic shock neurovascular care cerenovus treat hemorrhagic ischemic stroke orthopaedic portfolio depuy synthe include product enable technology support hip knee trauma spine sport surgery portfolio include advanced general surgery technology ethicon solution focus breast aesthetic mentor ear nose throat acclarent procedure johnson johnson vision product include acuvue brand contact lense tecni intraocular lense cataract surgery product distribute wholesaler hospital retailer predominantly professional field physician nurse hospital eye care professional clinic geographic areas johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbeing product sell international business include describe segment business innovative medicine medtech principal market product method distribution international business vary country culture product sell international business include develop subsidiary abroad investment activity country outside subject high risk comparable activity investment commercial climate influence financial instability international economy restrictive economic policy political legal system uncertaintie raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent company subsidiary practice obtain patent protection product process possible license significant number patent country relate product product use formulation manufacturing process aggregate believe material importance company operation business company subsidiary face patent challenge party include challenge seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product significant legal proceeding claim involve company patent intellectual property describe note legal proceedingsintellectual property note consolidated financial statement include item report sale company large product stelara ustekinumab account approximately company total revenue fiscal accordingly patent relate product believe material company janssen biotech inc whollyowne subsidiary johnson johnson own patent specifically relate stelara late expiring united states composition matter patent expire result settlement agreement party company anticipate launch biosimilar version stelara january united states late expire european composition matter patent supplementary protection certificate expire sale company second large product collectively darzalex daratumumab darzalex faspro daratumumab hyaluronidasefihj account approximately company total revenue fiscal accordingly patent relate product believe material company genmab own patent family relate darzalex janssen biotech inc exclusive license patent family patent family expire united states europe compound patent protection select country extend janssen biotech inc own separate patent portfolio relate darzalex faspro trademark company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend typically heavy fourth quarter year quarter reflect increase spending decision principally research development activity competition product line company subsidiary compete company locally globally competition exist product line regard number size compete company involve competition research internally externally source involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research environment company subject variety environmental law regulations united states jurisdiction company believe operation comply material respect applicable environmental law regulation companys compliance requirement expect material effect capital expenditure cash flow earning competitive position annual report regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation enforcement company subject costly complex foreign law governmental regulation adverse regulatory action materially adversely affect company financial condition business operation pharmaceutical product medical technology industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda approval new drug device correspond increase expense product introduction similar trend evident major market outside new medical device regulatory framework evolve privacy datum localization emerge cyber security law regulation world example increase regulation increase number state enact comprehensive privacy law federal regulator eg fda ftc hhs continue stress intersection health privacy compliance enforcement priority eu multiple directive law include nis ehds data act cyber resilience act ai act rapidly change privacy cybersecurity compliance requirement introduce new enforcement risk addition china introduce broad personal information protection datum security regulation anticipate increase chinas scrutiny company compliance datum transfer practice jurisdiction enact similar privacy law local datum protection authority force great accountability collection access use personal datum healthcare industry law restrict transfer datum border potentially impact datadriven health care solution develop deploy globally compliant manner result broad scale release availability artificial intelligence ai technology generative ai global trend comprehensive nuanced regulation eg white house executive order safe secure trustworthy development use artificial intelligence eu ai act ensure ethical use privacy security ai underway include standard transparency accountability fairness require compliance development enhancement regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case company subsidiary deem advisable initiate product recall regardless require direct fda regulatory agency globe increase enforcement activity fda conclude compliance applicable law regulation pharmaceutical product medical technology ineffective pose unreasonable health risk fda ban product detain seize adulterate misbrande product order recall repair replacement refund product refuse grant pende application marketing authorization require certificate foreign government export andor require notify health professional product present unreasonable risk substantial harm public health fda assess civil criminal penalty officer employee impose operating restriction companywide basis enjoin andor restrain certain conduct result violation applicable law fda recommend prosecution department justice adverse regulatory action depend magnitude restrict effectively market selling product limit ability obtain future clearance approval result substantial modification business practice operation equivalent enforcement mechanism exist different country conduct business cost human healthcare continue subject study investigation regulation governmental agency legislative body world attention focus state regulatory agency congress price profit overutilization quality cost healthcare generally law regulation enact require adherence strict compliance standard prevent fraud abuse healthcare industry increase focus interaction financial relationship healthcare company healthcare provider state federal transparency law regulation require disclosure payment transfer value certain healthcare practitioner include physician teach hospital certain nonphysician practitioner federal foreign law govern international business practice require strict compliance antibribery standard certain prohibition respect payment foreign government official payor pharmacy benefit manager pbms potent force marketplace increase attention pay impact pbm practice healthcare cost access business continue affect federal state legislation alter price coverage andreimbursement landscape federal level august president biden sign law inflation reduction act ira include provision effectively authorize government establish price certain highspend singlesource drug biologic reimburse medicare program start medicare drug medicare b drug august center medicare medicaid services cms publish select drug list include xarelto stelara imbruvica develop collaboration cocommercialize pharmacyclic llc abbvie company select drug list include medicine target disease state prevalent medicare population remain uncertainty federal government establish price select product ira specifies ceiling price minimum price event anticipate select product subject governmentestablishe price medicare population ira contain provision impose rebate certain price increase rate outpace rate inflation begin october medicare drug january medicare b drug separate ira provision redesign medicare benefit way include shift great portion cost manufacturer certain coverage phase replace coverage gap discount program new manufacturer discount program failure comply ira provision subject manufacturer penalty include civil monetary penalty july janssen pharmaceuticals inc janssen file litigation department health human service center medicare medicaid services challenge constitutionality inflation reduction act ira medicare drug price negotiation program litigation request declaration ira violate janssen right amendment fifth amendment constitution janssen subject ira mandatory pricing scheme impact ira business broad pharmaceutical industry remain uncertain litigation file janssen pharmaceutical company remain ongoing cms publicly announce maximum fair price select drug additionally expect continue scrutiny drug pricing government price report congress agency body federal state level result additional regulation mechanism increase pricing transparency control number additional bill pende congress healthcare reform proposal state level affect drug pricing include medicare medicaid program change legal landscape positive negative impact healthcare industry remain uncertain provision federal state law potential modification repeal law ultimately affect industry ira federal state legislative change affect price market condition product addition business practice healthcare industry come increase scrutiny particularly government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty note increase enforcement activity datum protection authority jurisdiction particularly european union significant fine levy company datum breach violation privacy requirement unlawful crossborder datum transfer federal trade commission step enforcement datum privacy significant settlement include settlement concern downstream share personal information use disclosure personal health datum material increase classaction lawsuit link collection use biometric datum use tracking technology company rely global supply chain production distribution process complex subject increase regulatory requirement affect source supply pricing material company product process subject complex lengthy regulatory approval annual report employee human capital management december number employee approximately employee fulltime equivalent fte position employee define individual work fulltime parttime exclude fix term employee intern coop employee employee datum include population recently acquire company individual longterm disability exclude contingent worker contractor subcontractor exclude fte represent total number fulltime equivalent position reflect total number individual employee work parttime employee region percentage strategy company believe employee critical continued success essential element longterm strategy management responsible ensuring policy process reflect reinforce company desire corporate culture include policy process relate strategy risk management ethic compliance company human capital management strategy build fundamental focus area attract recruit good talent develop retain talent empower inspire talent underpin focus area ongoing effort cultivate foster culture build diversity equity inclusion dei innovation health wellbeing safety company employee encourage succeed professionally personally help company achieve business goal culture employee engagement company employee guide credo set forth company responsibility patient consumer customer healthcare professional employee communities shareholder employee worldwide adhere companys code business conduct set basic requirement serve foundation company policy procedure guideline provide additional guidance expect employee behavior market operate company conduct global survey offer employee ability provide feedback valuable insight help address potential human resource risk identify opportunity improve global employee country participate credo survey offer language growth development lead change healthcare landscape crucial company continue attract retain talent company voluntary turnover rate company believe employee equip right knowledge skill provide opportunity grow develop career accordingly professional development program educational resource available employee company objective foster learning culture help shape person unique career path create robust pipeline talent deliver company longterm strategy furtherance objective company deploy global approach ensure development regardless career journey prioritize learn company recently hold johnson johnson global learning day employee encourage set aside day explore skillbuilde course area leadership business skill digital upskille dei wellbee jj learn company new learn platform diversity equity inclusion dei company commit workplace diversity cultivate foster advance culture equity inclusion company evidencedbase global enterprise diversity equity inclusion strategy recognize dei accelerate company ability meet change need community company serve outline credo company dei vision change world company dei mission diversity equity inclusion work everyday company enterprise dei strategy align dei vision mission rest core pillar build workforce individual diverse background culture ability perspective foster culture inclusion individual belong transform talent business process achieve equitable opportunity drive innovation growth business serve diverse market world company dei strategy guide internal external insight global good practice continual employee feedback recognize diversity change location inclusion annual report compensation benefit company total reward philosophy company offer competitive compensation benefit attract retain talent company commit fairness equitable treatment compensation benefit employee level company observe legal minimum wage provision exceed possible company total reward offering include array program support employee wellbee include annual performance incentive opportunitie pension retirement saving program health welfare benefit pay time leave program flexible work schedule employee assistance program recognition company commitment help employee balance personal professional responsibility company enhance caregiver bereavement volunteer pay leave benefit effective july health wellness safety company investment employee health wellbeing safety build conviction advance health humanity start advance health employee right awareness focus practice tool company ensure employee world temporary contractor visitor company site work safely company continuously expand health wellbeing program company globe incorporate new thinking technology offering bestinclass help employee achieve personal health goal program practice company advance total healthphysical mental emotional financialensure employee health protection emerge health risk company continue address employee need jj flex hybrid model empower company officebase employee find right productivity balance inperson remote work available information company main corporate website address wwwjnjcom company make sec filing available company website wwwinvestorjnjcomfinancialssecfiling soon reasonably practicable electronically file furnished sec company sec filing available secs website wwwsecgov investor public note company announce information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwlltmanagementinformationcom use website communicate investor public product litigation matter possible information post website deem material information encourage investor interested company review information post website conjunction wwwjnjcom company sec filing press release public conference call webcast addition amend restate certificate incorporation bylaw write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance sustainability committee science technology committee special committee board director company principle corporate governance code business conduct employee code business conduct ethic member board director executive officer corporate governance material available wwwinvestorjnjcomgovernancecorporategovernanceoverview company website provide charge shareholder submit write request provide information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwlltmanagementinformationcom deem report incorporate filing company make sec item risk factor investment company common stock debt security involve risk uncertainty company seek identify manage mitigate risk business uncertainty risk difficult predict outside company control eliminate addition information report company filing sec investor consider carefully factor set forth investor aware possible predict identify factor follow mean complete discussion potential risk uncertainty know unknown risk uncertainty materialize company business result operation financial condition adversely affect potentially material way risk relate business industry operation company business operate highly competitive product market competitive pressure adversely affect company earning company face substantial competition operate segment geographic market company business compete company size basis costeffectiveness technological innovation intellectual property right product performance real perceive product advantage price availability rate reimbursement company compete market participant secure right acquisition collaboration license agreement party competition right product candidate technology result significant investment acquisition cost onerous agreement term company competitor development effective costly product andor ability secure patent intellectual property right successfully market product ahead company negatively impact sale company exist product ability bring new product market despite significant prior investment relate product development company experience operational financial risk connection acquisition unable fully identify potential risk liability associate acquire business product successfully integrate operation employee successfully identify realize synergy exist business contain acquisitionrelated strain management operation financial resource company innovative medicine business loss patent exclusivity product follow substantial reduction sale competitor gain regulatory approval generic compete product enter market similar competition trigger loss exclusivity biological product company medtech business technological innovation product quality reputation customer service especially important competitiveness development company new improved product process technology threaten company product technology desirable economical obsolete company business operation negatively impact unable introduce new product technological advance safe effective effectively market outperform competitor interruption delay manufacture operation adversely affect company business sale reputation company manufacturing product require timely delivery sufficient amount complex highquality component material company subsidiary operate manufacturing facility source thousand supplier world company past future face unanticipated interruption delay manufacture internal external supply chain manufacturing disruption occur reason include regulatory action production quality deviation safety issue labor dispute labor shortage sitespecific incident fire natural disaster hurricane severe weather event raw material shortage political unrest terrorist attack epidemic pandemic delay difficulty manufacturing result product shortage decline sale reputational impact significant remediation relate cost associate address shortage company rely party manufacture supply certain product failure loss thirdparty manufacturer supplier result delay increase cost adversely affect business company rely party manufacture supply certain raw material component part product depend thirdparty manufacturer allocate portion manufacturing capacity sufficient meet need produce product acceptable quality acceptable manufacturing yield deliver product timely basis acceptable price guarantee thirdparty manufacturer able meet nearterm longterm manufacturing requirement result lose sale adverse effect business annual report risk associate reliance party manufacture product include reliance party regulatory compliance quality assurance misappropriation company intellectual property limit ability manage inventory possible breach manufacturing agreement party possible termination nonrenewal manufacturing agreement party time costly inconvenient party manufacturer suffer damage facility lose benefit material agreement experience power outage encounter financial difficulty unable secure necessary raw material supplier suffer reduction efficiency company experience significant business disruption event disruption company need seek source qualified thirdparty manufacturer likely result delay increase cost affect business adversely counterfeit version product harm patient negative impact revenue earning reputation business industry continues challenge vulnerability distribution channel illegal counterfeiting presence counterfeit product grow number market internet party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard distributor patient counterfeit product visually indistinguishable authentic version counterfeit medicine pose risk patient health safety condition manufacture unregulate unlicensed uninspected unsanitary site lack regulation content industry failure mitigate threat counterfeit medicine adversely impact business reputation impact patient confidence authentic product potentially result lose sale product recall increase threat litigation addition diversion product authorize market channel result reduced revenue negatively affect profitability global health crisis pandemic epidemic outbreak adversely disrupt impact certain aspect company business result operation financial condition subject risk associate global health crisis epidemic pandemic outbreak incident health crisis health crisis example covid pandemic adversely impact certain aspect company business result operation financial condition include low sale reduce customer demand usage certain product spread health crisis cause company modify business practice action require government authority company determine good interest patient customer employee business partner circumstance company robust business continuity plan place global supply chain network design help mitigate impact health crisis effort completely prevent business adversely affect event health crisis health crisis adversely impact company operation include thing manufacture operation supply chain thirdparty supplier sale marketing clinical trial operation factor adversely affect company business financial result global economic condition generally risk related government regulation legal proceeding global sale company innovative medicine medtech segment negatively impact healthcare reform increase pricing pressure sale company innovative medicine medtech product significantly affect reimbursement party payor government healthcare program private insurance plan manage care organization effort contain healthcare cost payor put downward pressure price product reimburse increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary continued consolidation healthcare provider result pricing pressure addition recent legislation ongoing political scrutiny pricing coverage reimbursement result additional pricing pressure specifically inflation reduction act ira subject certain product governmentestablishe price potentially impose rebate subject manufacturer fail adhere government interpretation law penalty increase thirdparty utilization b federal drug discount program expand interpretation statute negative impact company financial performance outside numerous major market include eu united kingdom japan china pervasive government involvement funding healthcare regard directly indirectly impose price control limit access reimbursement company product reduce value intellectual property protectionwe subject increase number costly complex governmental regulation country operation conduct materially adversely affect company financial condition business operation describe item business company subject increase number extensive government law regulation investigation legal action national state local government agency country operate example change fdas timing requirement approval clearance product negative impact ability bring new product market new law regulation impose deadline company thirdparty supplier manufacturer partner provider insufficient time implement change comply new regulation result manufacturing delay supply chain constraint company unable identify way mitigate delay constraint adverse effect sale access product company subject significant legal proceeding result significant expense fine reputational damage ordinary course business johnson johnson subsidiary subject numerous claim lawsuit involve issue product liability patent dispute claim product sale marketing pricing practice violate antitrust unfair trade practice andor consumer protection law company significant legal proceeding describe note legal proceeding note consolidated financial statement include item report litigation general security derivative action class action multidistrict litigation particular expensive disruptive matter include thousand plaintiff involve party seek large andor indeterminate amount include punitive exemplary damage remain unresolved year example company defendant numerous lawsuit arise use body powder contain talc primarily johnson baby powder company sale manufacturing marketing opioid company believe substantial defense matter feasible predict ultimate outcome litigation company future require pay significant amount result settlement judgment matter potentially excess accrual include matter company hold jointly severally liable defendant resolution increase accrual matter report period material adverse effect company result operation cash flow period company purchase thirdparty product liability insurance company utilize wholly own captive insurance company subject certain limit product reliability safety effectiveness concern significant negative impact sale result operation lead litigation cause reputational damage concern product safety raise internally litigant regulator consumer advocate base scientific evidence result safety alert product recall governmental investigation regulatory action fda counterpart country private claim lawsuit payment fine settlement decline sale reputational damage circumstance result damage brand image brand equity consumer trust company product product recall past future prompt government investigation inspection shutdown manufacture facility continue product shortage relate sale decline significant remediation cost reputational damage possible civil penalty criminal prosecution company face significant regulatory scrutiny impose significant compliance cost expose company government investigation legal action penalty rapid increase new government law regulation impose significant compliance cost company failure company timely implement change comply new law expose company investigation legal action penaltie regulatory issue compliance current good manufacturing practice cgmp comparable quality regulation foreign country manufacturer drug device lead fine penalty product recall product shortage interruption production delay new product approval litigation addition marketing pricing sale company product subject regulation investigation legal action include federal food drug cosmetic act medicaid rebate program federal state false claim act state unfair trade practice act consumer protection law scrutiny healthcare industry business practice government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment participation government healthcare program debarment material adverse effect company business result operation significant current investigation litigation bring government agency describe note legal proceedingsgovernment proceeding note consolidated financial statement include item report annual report change tax law exposure additional tax liability negatively impact company operating result change tax law regulation world include lead organization economic cooperation development recent enactment certain eu noneu country anticipate enactment additional country global minimum tax negatively impact company effective tax rate result operation change statutory tax rate certain international tax provision country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change tax law regulation occur time related expense benefit record material fiscal quarter year law change enact note income taxis note consolidated financial statement include item report additional information company conduct business file tax return numerous country address tax audits dispute tax authority connection government initiative company require disclose information tax authority operation world lead great audit scrutiny profit earn country company regularly assess likely outcome tax audits dispute determine appropriateness tax reserve tax authority position tax treatment contrary company expectation result tax liability excess reserve risk related intellectual property company face increase challenge intellectual property right central business company own license significant number patent proprietary right relate product manufacturing process right essential company business materially important company result operation public policy outside increasingly unfavorable intellectual property right company certain obtain adequate patent protection new product technologies united states important market protection grant long originally anticipate competitor routinely challenge validity extent company own licensed patent proprietary right litigation interference opposition proceeding inter part review ipr proceedings united states patent trademark office uspto proceeding absorb resource protract unpredictable addition challenge company product infringe patent party result injunction andor need pay past damage future royalty adversely affect competitive position sale product question company face increase patent challenge party seek manufacture market generic biosimilar version company key pharmaceutical product prior expiration applicable patent cover product manufacturer generic version innovative human pharmaceutical product challenge validity claim noninfringement innovator product abbreviate new drug application anda process fda relate anda litigation biologic price competition innovation act bpcia enact create new regulatory pathway approval fda biosimilar alternative innovatordevelope biological product create mechanism biosimilar applicant challenge patent innovator biologics ipr process uspto competitor challenge patent assert litigation event company successful defend patent challenge atrisk launch generic biosimilar firm product company lose major portion revenue reference product short period time current legal proceeding involve company patent intellectual property right describe note legal proceedingsintellectual property note consolidated financial statement include item report risk relate product development regulatory approval commercialization significant challenge delay company innovation development implementation new product technology indication adverse impact company longterm success company continue growth success depend ability innovate develop new differentiate product service address evolve healthcare need patient provider consumer development successful product technology necessary offset revenue loss company exist product lose market share factor competition loss patent exclusivity new product introduce past year account approximately sale company certain able develop license acquire company product technology particular product candidate grant regulatory approval approve product commercially successful company pursue product development internal research development collaboration acquisition joint venture license arrangement party context develop new product particularly pharmaceutical biotechnology product medical device require significant investment resource year biopharmaceutical research development program result commercially viable product process depend factor include ability discern patient healthcare provider future need develop promise new compound strategy technology achieve successful clinical trial result secure effective intellectual property protection obtain regulatory approval timely basis reach market successfully differentiate company product compete product approach treatment new product enhancement exist product accept quickly significantly marketplace product price competition change customer preference healthcare purchasing pattern resistance healthcare provider uncertainty thirdparty reimbursement follow initial regulatory approval success product adversely impact safety efficacy finding large realworld patient population market entry competitive product company leverage use datum science machine learn form ai emerge technology vary part business operation introduction incorporation ai result unintended consequence new expand risk liability ai technology continuously evolve ai technology develop adopt obsolete early plan investment technology result benefit anticipate enable obtain maintain competitive advantage application machine learning ai business emerge evolve alongside new law regulation entail significant cost ultimately limit ability continue use technology technology carry inherent risk relate datum privacy security describe risk relate financial economic market condition company face variety financial economic legal social political risk associate conduct business internationally company extensive operation business activity world accompany certain financial economic legal social political risk include list foreign currency exchange fiscal approximately company sale occur outside approximately europe western hemisphere exclude asiapacific africa region change nonus currency relative dollar impact company revenue expense company use financial instrument mitigate impact fluctuation currency exchange rate cash flow unhedged exposure continue subject currency fluctuation addition weaken strengthen dollar result significant favorable unfavorable translation effect operating result company nonus business activity translate dollar inflation currency devaluation risk company face challenge maintain profitability operation economy experience high inflation rate specifically company account operation argentina turkey venezuela highly inflationary prior threeyear cumulative inflation rate surpass company strive maintain profit margin area cost reduction program productivity improvement periodic price increase mightexperience operating loss result continued inflation addition impact currency devaluation annual report country experience high inflation rate significant currency exchange fluctuation negatively impact company operate result illegal importation pharmaceutical product illegal importation pharmaceutical product country government price control market dynamic result low price adversely affect company sale profitability country company operate exception limited quantity prescription drug personal use foreign import pharmaceutical product illegal current law volume illegal import continue rise ability patient customer obtain lowerprice import grow significantly antibribery regulation company subject federal foreign law govern international business practice respect payment government official law include foreign corrupt practice act fcpa prohibit publicly trade company promise offering give value foreign official corrupt intent influence foreign official purpose help company obtain retain business gain improper advantage company business heavily regulate involve significant interaction foreign official country outside healthcare provider prescribe human pharmaceutical employ government purchaser human pharmaceutical government entity company interaction prescriber purchaser subject regulation fcpa addition application enforcement fcpa jurisdiction company operate law regulation include uk bribery act aim prevent penalize corrupt anticompetitive behavior enforcement activity law subject company additional administrative legal proceeding action include claim civil penalty criminal sanction administrative remedy include exclusion healthcare program financial economic legal social political risk risk inherent conduct business globally include local regional economic environment policy market serve include interest rate monetary policy inflation economic growth recession commodity price currency control limitation ability expatriate cash protective economic policy take government trade protection measure increase antitrust reporting requirement enforcement activity importexport licensing requirement compliance local regulation law include country regulatory requirement restrict company ability manufacture sell product relevant market diminish protection intellectual property contractual right certain jurisdiction potential nationalization expropriation company foreign asset political social upheaval economic instability repression human right issue geopolitical event include natural disaster disruption market war armed conflict terrorism epidemic pandemic international nature company business geopolitical economic change event include global tension war adversely affect business result operation financial condition describe company extensive operation business activity world global tension conflict andor war country conduct business distribute product result foreign currency volatility decrease demand product affect country challenge global supply chain relate increase cost material input product supplier recently experience expect continue experience impact company business result russiaukraine war rise conflict middle east increase tension china response heighten conflict russiaukraine war government impose export control broad financial economic sanction business operation impact imposition trade protection measure policy adopt country favor domestic company technology foreign competitor additional sanction measure impose global community include limited limitation ability file prosecute maintain patent trademark intellectual property right furthermore countrie russia action take allow company individual exploit invention own patent holder united states country consent compensation able prevent party practice company invention russia sell import product russia weak financial performance failure maintain satisfactory credit rating disruption financial market adversely affect liquidity capital position borrowing cost access capital market currently maintain investment grade credit rating moodys investor service standard poor rating service rating agency routinely evaluate rating longterm shortterm debt base number factor downgrade credit rating credit rating agency result action factor control increase cost borrowing indebtedness incur reduce market capacity commercial paper require post additional collateral derivative contract assurance able maintain credit rating additional actual anticipate change downgrade credit rating include announcement rating review downgrade negative impact liquidity capital position access capital market risk business depend ability recruit retain talente highly skilled employee diverse workforce continue growth require recruit retain talented employee represent diverse background experience skill set market highly skilled worker leader industry extremely competitive ability compete depend ability hire develop motivate highly skilled personnel area organization maintain brand reputation diverse equitable inclusive work environment enable attract talent successful recruiting effort retain highly skilled worker key leader ability develop deliver successful product service adversely affect addition effective succession plan important longterm success unsuccessful implementation succession plan failure ensure effective transfer knowledge smooth transition involve key employee adversely affect business financial condition result operation climate change legal regulatory market measure address climate change negatively affect business result operation climate change result increase concentration carbon dioxide greenhouse gas atmosphere present risk operation include adverse impact global temperature weather pattern frequency severity extreme weather natural disaster natural disaster extreme weather condition hurricane tornado earthquake wildfire flooding pose physical risk facility disrupt operation supply chain impact change climate water resource result water scarcity limit ability access sufficient highquality water certain location increase operational cost concern climate change result new additional legal regulatory requirement design reduce greenhouse gas emission andor mitigate effect climate change environment law regulation stringent current legal regulatory obligation experience disruption increase cost associate source manufacture distribution product adversely affect business result operation financial condition impact climate change influence customer preference failure provide climatefriendly product potentially result loss market share information security incident include cybersecurity breach negative impact company business reputation meet business objective company rely internal information technology system network party vendor process store sensitive datum include confidential research business plan financial information intellectual property personal datum subject legal protection ensure continuity company supply chain operation extensive information security cybersecurity threat affect company globally pose risk security availability system network include customer product connect rely system network confidentiality integrity availability company sensitive datum company assess threat make investment increase internal protection detection response capability ensure company thirdparty provider require capability control address risk frequently change attack technique increase volume sophistication attack potential company adversely impact impact result reputational competitive operational business harm financial cost regulatory action increase use ai increase risk company maintain cybersecurity insurance event information security cyber incident coverage sufficient cover financial legal business reputational loss annual report result increase global tension company expect continue increase risk information security cybersecurity incident include cyberattack perpetrate adversary country company maintain operation give potential sophistication attack company able address threat information security cybersecurity incident proactively implement adequate preventative measure able detect address disruption security breach promptly adversely affect business result operation financial condition threat impact thirdparty partner result compromise company system network datum negatively affect company breach privacy law unauthorized access loss misuse personal datum negative impact company business reputation company subject privacy datum protection law globe impose broad compliance obligation collection use storage access transfer protection personal datum breach requirement result substantial fine penalty private right action claim damage reputation business new privacy law expect territory great privacy enforcement governmental authority globally particularly datum localization requirement international datum flow company establish privacy compliance program control business worldwide require comply technology datadriven initiative prioritize company involve multiple vendor party potential risk control impose cross border datum flow unauthorized access loss personal datum internal external threat impact business operation research activity company unable achieve anticipate strategic financial benefit follow separation kenvue inc kenvue include respect company remain ownership interest company incur significant expense connection kenvue separation separation addition company able achieve strategic financial benefit expect result separation anticipate benefit separation base number assumption prove incorrect company hold ownership interest kenvue company predict trading price share kenvue common stock market value kenvue share subject market volatility factor outside company control company intend div ownership interest kenvue assurance ultimate timing divestiture unanticipated development delay prevent adversely affect divestiture include limited financial market condition separation result substantial tax liability company receive private letter rule irs taxfree nature separation internal revenue code amend notwithstanding private letter rule opinion tax advisor irs determine certain step transaction qualify taxfree treatment federal income tax purpose result tax liability company shareholder substantial separation qualify taxfree treatment country world result trigger substantial tax liability company item b unresolved staff comment applicable item c cybersecurity risk management strategy company document cybersecurity policy standard assess risk cybersecurity threat monitor information system potential cybersecurity issue protect company information system cybersecurity threat company use security tool support protection detection response capability company maintain cybersecurity incident response plan help ensure timely consistent response actual attempt cybersecurity incident impact company company identify assess thirdparty risk enterprise company use thirdparty service provider range area include datum security supply chain structure thirdparty risk management program company maintain formal information security training program employee include training matter phishe email security good practice employee require complete mandatory training datum privacy evaluate enhance cybersecurity program company periodically utilize thirdparty expert undertake maturity assessment company information security program date company aware cybersecurity incident reasonably likely material impact company business operation frequently change attack technique increase volume sophistication attack potential company adversely impact impact result reputational competitive operational business harm financial cost regulatory action refer risk factor caption information security incident include cybersecurity breach negative impact company business reputation item risk factor additional description cybersecurity risk potential relate impact company governance management responsibility company take riskbased approach cybersecurity implement cybersecurity control design address cybersecurity threat risk chief information officer cio member companys executive committee chief information security officer ciso responsible assess manage cybersecurity risk include prevention mitigation detection remediation cybersecurity incident company ciso coordination cio responsible leading company cybersecurity program management cybersecurity risk current ciso twentyfive year experience information security background include technical experience strategy architecture focus role cyber threat experience leadership role governance board oversight company board director oversee overall risk management process include cybersecurity risk directly committee regulatory compliance sustainability committee rcsc board primarily responsible oversight risk cybersecurity threat oversee compliance applicable law regulation company policy relate privacy cybersecurity rcsc meeting include discussion specific risk area year include relate cybersecurity ciso provide update year rcsc cybersecurity matter report include overview cybersecurity threat landscape key cybersecurity initiative improve company risk posture change thelegal regulatory landscape relative cybersecurity overview certain cybersecurity incident occur company industry annual report item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand innovative medicine medtech worldwide total facility innovative medicine segment medtech segment outside facility innovative medicine segment medtech segment location manufacture facility major geographic area world follow number square feet geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss company maintain numerous office warehouse facility world company subsidiary generally seek lease manufacturing facility principally nonus location lease office warehouse facility lease company engage contract manufacturer company commit maintain property good operating condition segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement include item report item legal proceeding information call item incorporate reference information set forth note legal proceeding note consolidated financial statement include item report item safety disclosure applicable executive officer registrant list executive officer company family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal age position vanessa broadhurst member executive committee executive vice president global corporate affairs joaquin duato chairman board chief executive officer b peter fasolo phd member executive committee executive vice president chief human resource officer c elizabeth forminard member executive committee executive vice president general counsel william n hait md ph member executive committee executive vice president chief external innovation medical officer e john c reed md phd member executive committee executive vice president innovative medicine rd f tim schmid member executive committee executive vice president worldwide chairman medtech g james swanson member executive committee executive vice president chief information officer h jennifer l taubert member executive committee executive vice president worldwide chairman innovative medicine kathryn e wengel member executive committee executive vice president chief technical operation risk officer j joseph j wolk member executive committee executive vice president chief financial officer k ms v broadhurst name executive vice president global corporate affair appoint executive committee ms broadhurst rejoin company appoint company group chairman global commercial strategy organization hold general manager role amgen inflammation cardiovascular cardiovascular bone prior role amgen serve leadership role company b mr j duato chairman board director january subsequent appointment chief executive officer director january mr duato appoint executive committee name executive vice president worldwide chairman pharmaceutical subsequently serve vice chairman executive committee mr duato join company janssenfarmaceutica sa spain subsidiary company hold executive position increase responsibility business sector multiple geography function c dr p fasolo appoint executive committee name executive vice president chief human resource officer join company worldwide vice president human resource medtech segment subsequently serve company chief talent officer leave johnson johnson join kohlberg kravis roberts co chief talent officer return company vice president global human resource ms e forminard appoint executive vice president general counsel member executive committee october ms forminard join company serve role increase responsibility include general counsel medical device diagnostic general counsel consumer group supply chain worldwide vice president corporate governance immediate past role general counsel pharmaceutical e dr w hait appoint executive vice president chief external innovation medical safety global public health officer member executive committee join company serve number leadership role include annual report global head janssen research development global head johnson johnson global external innovation f dr j c reed join company executive vice president innovative medicine rd member executive committee prior join company dr reed hold executive leadership position sanofi roche serve respective executive committee serve ceo sanfordburnham medical research institute sanford burnham prebys establish multiple therapeutic areaaligne research center platform technology center g mr schmid name executive vice president worldwide chairman medtech appoint executive committee october join company serve leadership position johnson johnson medtech include chief strategic customer officer president ethicon recently serve company group chairman medtech asia pacific h mr j swanson appoint executive vice president chief information officer member executive committee rejoin company chief information officer johnson johnson bayer crop science serve member executive leadership team chief information officer head digital transformation mr swanson hold position increase responsibility company include project manager director sr director vice president chief information officer ms j l taubert appoint executive vice president worldwide chairman innovative medicine pharmaceutical member executive committee join company worldwide vice president hold executive position increase responsibility pharmaceutical sector include company group chairman north america company group chairman americas j ms k e wengel appoint executive vice president chief technical operation risk officer subsequent appointment executive committee name executive vice president chief global supply chain officer ms wengel join company project engineer engineering supervisor janssen subsidiary company tenure company hold variety strategic leadership executive position include role operation quality engineer new product information technology technical business function k mr j j wolk appoint executive vice president chief financial officer member executive committee july join company finance manager business development orthomcneil subsidiary company tenure company hold variety senior leadership role segment function company subsidiary include vice president finance chief financial officer janssen pharmaceutical company vice president investor relation ii item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference follow section report note common stock stock option plan stock compensation agreement note consolidated financial statement include item item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information issuer purchase equity security september company announce board director approve share repurchase program authorize company purchase billion company common stock repurchase program complete fiscal quarter follow table provide information respect common stock purchase company fiscal fourth quarter common stock purchase open market systematic plan meet need company compensation program repurchase include stockforstock option exercise settle fiscal fourth quarter total number share maximum number approximate total number avg price unit purchase dollar value share unit share pay publicly announce purchase fiscal period purchase share plan program plan programs october october october november november december total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock openmarket transaction purchase systematic plan meet need company compensation program item reserved annual report item management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment innovative medicine medtech innovative medicine segment focus follow therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use medtech segment include broad portfolio product orthopaedic surgery interventional solution vision field product distribute wholesaler hospital retailer principally professional field physician nurse hospitals eye care professional clinic executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie innovative medicine medtech business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research management objective credo foundation company purpose blend heart science ingenuity profoundly impact health humanity company believe health company strength healthcare innovation empower build world complex disease prevent treat cure treatment smart invasive solution personal company expertise innovative medicine medtech company uniquely position innovate spectrum healthcare solution today deliver breakthrough tomorrow profoundly impact health humanity new product introduce past year account approximately sale billion invest research development reflect management commitment create lifeenhancing innovation create value partnership profoundly impact health humanity critical driver company success diversity employee worldwide employee empower inspire lead credo purpose guide allow employee use company reach size advance company purpose lead agility urgency leverage extensive resource enterprise enable company innovate execute excellence ensure company remain focused address unmet need society day invest endure impact ultimately deliver value patient consumer healthcare professional employee communitie shareholder research acquisition development net cash acquire include acquisition process research development asset account business combination dividend pay share result operation analysis consolidate sale discussion result operation financial condition pertain fiscal year company annual report fiscal year end january item management discussion analysis result operation financial condition prior period disclose recast reflect continue operation company worldwide sale increase billion compare increase sale change consist follow sale increasedecrease volume price currency total net impact acquisition divestiture worldwide sale growth positive impact impact sale company billion billion represent increase sale international company billion billion represent increase decrease fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale company europe experience decline compare prior year include operational decline positive currency impact fiscal net impact covid vaccine loss exclusivity zytiga european region change operational sale negative sale company western hemisphere exclude achieve growth compare prior year include operational growth negative currency impact sale company asiapacific africa region achieve growth compare prior year include operational growth negative currency impact annual report company utilize wholesaler distribute product segment represent approximately total consolidated revenue company wholesaler distribute product segment represent approximately total consolidated revenue sale geographic region billion sale segment billion note value rounded analysis sale business segment innovative medicine segment innovative medicine segment sale billion increase include operational growth negative currency impact sale billion increase international sale billion decrease include operational decline negative currency impact acquisition divestiture net negative impact operational sale growth worldwide innovative medicine segmentmajor innovative medicine therapeutic area sale total operation currency dollar million change change change total immunology remicade simponisimponi aria stelara tremfya immunology total infectious disease covid vaccine edurantrilpivirine prezista prezcobixrezolsta symtuza infectious disease total neuroscience concertamethylphenidate invega sustennaxeplioninvega trinzatrevicta spravato neuroscience total oncology carvykti darzalex erleada imbruvica zytiga abiraterone acetate oncology total pulmonary hypertension opsumit uptravi pulmonary hypertension total cardiovascular metabolism xarelto total innovative medicine sale percentage greater meaningful previously refer pharmaceutical inclusive risperdal consta previously disclose separately inclusive invokana previously disclose separately annual report immunology product achieve sale billion represent increase compare prior year increase sale stelara ustekinumab primarily drive patient mix market growth continue strength inflammatory bowel disease growth tremfya guselkumab market growth continue strength psopsa psoriasis psoriatic arthritis patient mix additionally simponisimponi aria growth drive growth outside low sale remicade infliximab biosimilar competition biosimilar version remicade introduce united states certain market outside united states additional competitor continue enter market continue infliximab biosimilar competition result reduction sale remicade sale stelara united states approximately billion fiscal party file abbreviate biologic license application fda seek approval market biosimilar version stelara company settle certain litigation biosimilar price competition innovation act result settlement agreement separate party company anticipate launch biosimilar version stelara january united states infectious disease product sale billion decline compare prior year primarily drive decline covid vaccine revenue loss exclusivity prezista neuroscience product sale billion represent increase compare prior year growth spravato esketamine drive ongoing launch increase physician confidence patient demand growth partially offset decline risperdalrisperdal consta paliperidone longacte injectable outside xeplion loss exclusivity european union oncology product achieve sale billion represent increase compare prior year sale darzalex daratumumab drive continued share gain region market growth growth erleada apalutamide continued share gain market growth metastatic castration resistant prostate cancer sale carvykti ciltacabtagene autoleucel drive ongoing launch share gain capacity improvement additionally sale launch tecvayli teclistamabcqyv talvey talquetamabtgvs include oncology contribute growth growth partially offset zytiga abiraterone acetate loss exclusivity imbruvica ibrutinib global competitive pressure pulmonary hypertension product sale billion represent increase compare prior year sale growth favorable patient mix share gain market growth uptravi selexipag opsumit macitentan partially offset decline pulmonary hypertension cardiovascularmetabolismother product sale billion decline compare prior year decline xarelto rivaroxaban sale primarily drive unfavorable patient mix access change company maintain policy end customer permit direct delivery product location billing location policy impact contract pharmacy transaction involve nongrantee b cover entity company drug subject multiple exception grantee nongrantee cover entity maintain certain contract pharmacy arrangement policy exception company continue offer b discount cover entity cover outpatient drug believe policy improve ability identify inappropriate duplicate discount diversion prohibit b statute b drug pricing program federal government program require drug manufacturer provide significant discount cover outpatient drug cover entity policy discount implication positively impact sale customer company advanced pipeline regulatory submission approval new drug additional indication exist drug follow product eu eu chemical indication approval approval filing file akeega niraparib firstandonly dual action tablet treatment abiraterone acetate patient brcapositive metastatic castration resistant prostate cancer magnitude balversa erdafitinib treatment patient locally advanced metastatic urothelial carcinoma select fibroblast growth factor receptor gene alteration thor carvykti ciltacabtagene treatment relapse refactor multiple myeloma autoleucel pl cartitude edurant rilpivirine treatment pediatric patient year old hiv erleada tablet reduction apalutamide opsumit macitentan treatment pediatric pulmonary arterial hypertension opsynvi treatment pulmonary arterial hypertension mecitentantadalafil stct rybrevant combination chemotherapy firstline amivantamab treatment adult patient advance nonsmall cell lung cancer activate egfr exon insertion mutation papillon rybrevant lazertinib treatment nonsmall cell lung cancer l mariposa rybrevant lazertinib treatment nonsmall cell lung cancer l mariposa tecvayli teclistamab treatment patient relapse refractory multiple myeloma biweekly dose talvey talquetamab treatment patient relapse refractory multiple myeloma annual report medtech segment medtech segment sale billion increase include operational growth negative currency impact sale billion increase compare prior year international sale billion increase compare prior year include operational growth negative currency impact net impact acquisition divestiture medtech segment worldwide operational sale growth positive primarily relate abiome acquisition major medtech franchise sale total operation currency dollar million change change change surgery advanced general orthopaedic hip knee trauma spine sport interventional solution electrophysiology abiome interventional solution vision contact lensesother surgical total medtech sale percentage great meaningful surgery franchise sale billion represent increase growth advanced surgery primarily drive biosurgery global procedure growth strength portfolio uptake new product endocutter energy growth partially offset competitive pressure volumebase procurement impact endocutter energy growth general surgery primarily drive increase procedure couple technology penetration benefit differentiate wound closure portfolio orthopaedic franchise sale billion represent increase growth hip reflect global procedure growth continue strength portfolio partially offset volumebased procurement impact russia sanction growth knee primarily drive procedure benefit recent product addition attune portfolio pull related velys robotic assist solution partially offset stocking dynamic primarily outside growth trauma drive global procedure adoption recently launch product partially offset volumebased procurement impact growth spine sport primarily drive digital solution shoulder sport craniomaxillofacial product partially offset russia sanction supply constraint primarily outside interventional solution franchise achieve sale billion represent increase include sale abiome acquire december electrophysiology grow double digit global procedure growth new product performance commercial execution partially offset impact volumebase procurement china abiome sale reflect strength commercialize region continue adoption impella impella rp vision franchise achieve sale billion represent increase contact lensesother growth primarily drive continued strong performance acuvue oasys day family include recent launch commercial execution partially offset impact stock dynamic russia sanction impact strategic portfolio decision supply challenge surgical operational growth primarily drive cataract procedure growth continue strength recent innovation reduction prior year stocking outside partiallyoffset soft refractive premium iol market russia sanction analysis consolidate earning provision taxis income consolidated earning provision taxis income billion billion year respectively percent sale consolidated earning provision taxis income respectively earning provision taxis dollar billion percentage chart percent total sale cost product sell sell marketing administrative expense cost product soldselle marketing administrative dollar billion percentage chart percent total sale cost product sell cost product sell increase percent sale drive commodity inflation unfavorable product mix restructure relate excess inventory cost abiome amortization medtech business partially offset favorable patient mix low onetime covid vaccine manufacture relate exit cost innovative medicine business intangible asset amortization expense include cost product sell billion billion fiscal year respectively annual report sell marketing administrative expense selling marketing administrative expense decrease slightly percent sale drive leverage sell marketing expense innovative medicine medtech business partially offset increase administrative cost research development expense research development expense segment business follow dollar million sale sale innovative medicine medtech total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product upfront payment developmental milestone improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product research development flat percent sale primarily drive high milestone payment innovative medicine business acquire inprocess research development asset laminar acquisition medtech business fiscal year offset portfolio prioritization innovative medicine business inprocess research development impairment iprd fiscal year company record charge approximately billion include billion relate market dynamic associate nonstrategic asset acquire acquisition momenta pharmaceutical fiscal year company record intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment atopic dermatitis ad hidradenitis suppurativa hs additional information efficacy ad indication hs indication available lead company decision terminate development bermekimab ad hs company acquire right bermekimab xbiotech inc fiscal year income expense net income expense net account company record gain loss relate sale writedown certain investment equity security hold johnson johnson innovation jjdc inc jjdc change fair value security investment incomeloss relate employee benefit program gain loss divestiture certain transactional currency gain loss acquisition divestiture relate cost litigation accrual settlement royalty income income expense net fiscal year unfavorable billion compare prior year primarily follow dollar billionsincomeexpense change litigation relate change fair value security covid vaccine manufacturing exit relate cost acquisition integration divestiture relate employee benefit plan relate total income expense net primarily relate approximately billion charge talc note consolidated financial statement detail favorable intellectual property relate litigation settlement approximately billion primarily relate pelvic mesh fiscal include billion relate unfavorable change fair value remain stake kenvue billion relate partial impairment idorsia convertible debt change fair value idorsia equity security hold primarily relate impairment ponvory onetime integration cost relate acquisition abiome primarily cost relate acquisition abiome interest income expense interest income fiscal year billion compare interest income billion fiscal year primarily high rate interest earn cash balance interest expense fiscal year billion compare interest expense billion fiscal year primarily high interest rate debt balance cash cash equivalent marketable security total billion end average billion compare cash cash equivalent marketable security total billion billion average balance total debt balance end billion average debt balance billion compare billion end average debt balance billion low average cash cash equivalent marketable security primarily acquisition abiome late december low average debt balance primarily repayment commercial paper income tax segment income loss tax segment business follow income tax segment sale percent segment sale dollar millions innovative medicine medtech segment earning tax expense allocate segment worldwide income tax note consolidated financial statement detail amount allocate segment include interest income expense general corporate income expense fiscal include approximately billion charge relate talc matter approximately billion unfavorable change fair value retain stake kenvue annual report innovative medicine segment innovative medicine segment income tax percent sale versus increase income tax percent sale primarily drive follow low onetime covid vaccine relate exit cost billion versus billion low inprocess research development impairment billion versus billion unfavorable change fair value security billion compare billion low litigation relate expense billion leverage selling marketing expense rd portfolio prioritization partially offset restructuring charge billion versus billion impairment ponvory high milestone payment medtech segment medtech segment income tax percent sale versus decrease income tax percent sale primarily drive follow high amortization expense billion relate abiome expense billion acquire process research development asset laminar acquisition commodity inflation partially offset income litigation settlement billion versus expense billion low integrationacquisition cost relate abiome billion versus billion leverage selling marketing expense restructure fiscal year company complete prioritization research development rd investment innovative medicine segment focus promise medicine great benefit patient result exit certain program therapeutic area rd program exit primarily infectious disease vaccine include discontinuation respiratory syncytial virus rsv adult vaccine program hepatitis hiv development pretax restructuring charge approximately billion fiscal year million record restructuring million record cost product sell consolidated statement earning include termination partner nonpartnere program cost asset impairment fiscal year company initiate restructure program orthopaedic franchise medtech segment streamline operation exit certain market product line distribution network arrangement pretax restructure expense billion fiscal year million record restructuring million record cost product sell consolidated statement earning primarily include inventory instrument charge relate market product exit company record pretax charge billion related restructuring program global supply chain global supply chain program announce second quarter complete fiscal fourth quarter note consolidated financial statement additional detail relate restructuring program provision taxis income worldwide effective income tax rate continue operation december european union eu member states formally adopt eus pillar directive generally provide minimum effective tax rate establish organization economic cooperation development oecd pillar framework support country worldwide december eu noneu country enact pillar legislation initial effective date january aspect law effective late company estimate result legislation effective tax rate increase approximately basis point compare fiscal legislation guidance regulation issue fiscal business event impact estimate discussion relate fiscal provision taxis refer note consolidated financial statement liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary source use cash contribute billion increase dollar billion q cash cash equivalent balance cash generate operating activity net cash investing activity net cash financing activity effect exchange rate round q cash cash equivalent balance addition company billion marketable security end fiscal year billion end fiscal year note consolidated financial statement additional detail cash cash equivalent marketable security cash flow operation billion result dollar billion net earning gain kenvue separation net gain sale assetsbusinesse defer tax provision partially offset noncash expense adjustment primarily depreciation amortization stockbase compensation asset writedown charge purchase process research development asset increase current noncurrent liability increase current noncurrent asset increase account payable accrue liability increase account receivable inventory cash flow operation annual report cash flow investing activity billion primarily dollar billion addition property plant equipment proceed disposal assetsbusinesse net purchase inprocess research development asset net sale investment credit support agreement activity net net cash investing activity cash flow financing activity billion primarily dollar billion dividend shareholder repurchase common stock net repayment short long term debt proceed stock option exercisedemployee withholding tax stock award net credit support agreement activity net proceed short longterm debt net issuance cost relate debt transfer kenvue separation proceed kenvue initial public offering cash transfer kenvue separation round net cash financing activity december company note payable longterm debt excess cash cash equivalent marketable security december net debt position billion compare prior year billion debt balance end billion compare billion consider recent market condition company reevaluate operate cash flow liquidity profile foresee significant incremental risk company anticipate operate cash flow ability raise fund external source borrowing capacity exist committed credit facility access commercial paper market continue provide sufficient resource fund operating need include company remain balance pay agreement settle opioid litigation approximately billion establishment approximately billion reserve talc matter note consolidated financial statement additional detail addition company monitor global capital market ongoing basis time time raise capital market condition favorable kenvue complete initial public offering ipo result issuance share common stock par value share kenvue common stock initial public offering share net proceed billion excess net proceed ipo net book value johnson johnson divest interest billion record additional paidin capital closing ipo johnson johnson own approximately total outstanding share kenvue common stock july noncontrolle interest billion associate kenvue reflect equity attributable noncontrolle interest consolidate balance sheet august johnson johnson complete disposition additional ownership kenvue common stock exchange offer result johnson johnson acquire share companys common stock exchange share kenvue common stock billion johnson johnson common stock receive exchange offer record treasury stock follow exchange offer company own total outstanding share kenvue common stock record asset continue operation fair market value billion august billion december johnson johnson divest net asset billion august accumulate comprehensive loss attributable consumer health business date billion additionally date exchange offer johnson johnson decrease noncontrolle interest billion record deconsolidation kenvue result gain exchange offer billion record net earning discontinue operation net taxis consolidate statement earning fiscal quarter onetime gain include gain billion kenvue common stock retain johnson johnson gain exchange offer qualifie taxfree transaction federal income tax purpose september company announce board director approve share repurchase program authorize company purchase billion company common stock fiscal year approximately billion repurchased program fiscal year billion repurchase repurchase program complete follow table summarize company material contractual obligation aggregate maturity december satisfy obligation company intend use cash operation tax legislation interest dollar millions tcja debt obligation debt obligation total total tax matter note consolidated financial statement annual report finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract billion conversely depreciation dollar december market rate decrease unrealized value company forward contract billion scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately billion scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party investment grade credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote company enter credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement note consolidated financial statement additional detail credit support agreement company invest fix rate float rate interest earn security carry degree interest rate risk fair market value fix rate security adversely impact rise interest rate float rate security produce income predict interest rate fall basis point change spread company interest rate sensitive investment increase decrease unrealized value cash equivalent current marketable security billion company access substantial source fund numerous bank worldwide september company secure new day credit facility billion expire september company early terminate additional day revolve credit facility billion expiration november interest charge borrowing credit line agreement base secure overnight financing rate sofr reference rate applicable market rate allow plus applicable margin commitment fee agreement material total borrowing end billion billion respectively decrease debt balance repayment commercial paper net debt cash current marketable security net debt billion compare net debt billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend summary borrowing find note consolidated financial statement dividend company increase dividend st consecutive year cash dividend pay share share january board director declare regular cash dividend share payable march shareholders record february information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock base awards revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer governmental clawback provision account variable consideration record reduction sale product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return innovative medicine segment exclusively resalable sale return certain franchise medtech segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company annual net trade sale fiscal year promotional program product list allowance record period relate sale include volumebase sale incentive program volumebase incentive program base estimate sale volume incentive period record product sell arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer profitshare payment total revenue fiscal year total revenue fiscal year include sale customer addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative selling price upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impact annual report table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end december january innovative medicine segment balance balance beginning payment end dollar million period accrual credit period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset include prior period adjustment medtech segment balance balance beginning payment end dollar million period accrual credit period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million january record contra asset income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate tax effect repatriation approximately billion currently enact tax law regulation current currency exchange rate include possible benefit foreign tax credit substantially offset cost note note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate annual report note consolidated financial statement information product liability legal proceeding longlive intangible asset company assess change qualitatively quantitatively economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset mortality rate expect salary increase healthcare cost trend rate attrition rate note consolidated financial statement detail rate stock base compensation company recognize compensation expense associate issuance equity instrument employee service base type equity instrument fair value estimate date grant blackschole option valuation model combination blackschole option valuation model monte carlo valuation model expense financial statement service period input assumption determine fair value expect life expect volatility riskfree rate expect dividend yield performance share unit fair market value calculate component goal date grant adjust operational earning share relative total shareholder return fair value earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt december economic market factor company aware product environment decade policymaker consumer business express concern rise cost healthcare response concern company longstande policy pricing product responsibly period weight average compound annual growth rate company net price increase healthcare product prescription overthecounter drug hospital professional product consumer price index cpi company operate certain country economic condition continue present significant challenge company continue monitor situation appropriate action inflation rate continue effect worldwide economy consequently way company operate company account operation argentina venezuela turkey begin fiscal second quarter highly inflationary prior threeyear cumulative inflation rate surpass material impact company result period face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase december argentine government devalue peso approximately company record charge approximately million related operation argentina application highly inflationary accounting december company argentine subsidiary represent company consolidate asset liability revenue profit continue operation effect change exchange rate expect material adverse effect company fullyear result july janssen pharmaceuticals inc janssen file litigation department health human service center medicare medicaid services challenge constitutionality inflation reduction act ira medicare drug price negotiation program litigation request declaration ira violate janssen right amendment fifth amendment constitution janssen subject ira mandatory pricing scheme russiaukraine war longterm implication russias invasion ukraine difficult predict time financial impact conflict fiscal year include account receivable inventory reserve material fiscal year end december january business company russian subsidiary represent company consolidated asset represent revenue company maintain ukraine subsidiary subsequent kenvue separation early march company take step suspend advertising enrollment clinical trial additional investment russia company continue supply product rely patient healthcare purpose conflict middle east longterm implication israel conflict difficult predict time financial impact conflict fiscal year include account receivable inventory reserve material fiscal year end december business company israel subsidiary represent company consolidated asset represent revenue company expose fluctuation currency exchange rate change value dollar compare foreign currency company sale income expense increase decrease translation foreign sale approximately billion net income approximately billion government world consider proposal change tax law include increase decrease exist statutory tax rate connection government initiative company require disclose information tax authority operation world lead great audit scrutiny profit earn country change statutory tax rate country result revaluation company defer tax asset liability relate particular jurisdiction period new tax law enact change result expense benefit record company consolidate statement earning company closely monitor proposal arise country operate change statutory tax rate occur time related expense benefit record material fiscal quarter year law change enact company face worldwide healthcare change continue result pricing pressure include healthcare cost containment government legislation relate sale promotion pricing reimbursement healthcare product change behavior spend pattern purchaser healthcare product service include delay medical procedure ration prescription medication reduce frequency physician visit forego healthcare insurance coverage continue impact company business annual report company operate environment increasingly hostile intellectual property right firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset risk competitor launch generic biosimilar version product issue follow regulatory approval valid patent place legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial employment indemnification matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc contingency litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve extent adverse award judgment verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period note consolidated financial statement include item report information legal proceeding common stock company common stock list new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosure market risk information call item incorporate reference item management discussion analysis result operation financial condition liquidity capital resource finance market risk report note summary significant accounting policy financial instrument note consolidated financial statement include item report item financial statement supplementary datum index audit consolidated financial statement consolidate b alance heet consolidate tatement e arning consolidate tatement c omprehensive ncome consolidate tatement e quity consolidated tatement c ash f low note c onsolidate f inancial tatement report ndependent r egistere p ublic ccounting f irm pcaob d management r eport nternal c ontrol ver f inancial r eporte annual report johnson johnson subsidiaries consolidate balance sheet december january dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance inventory note prepay expense receivables current asset discontinue operation note total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset noncurrent asset discontinue operation note total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income note current liability discontinue operation note total current liability longterm debt note defer taxis income note employee relate obligation note longterm taxis payable note liability noncurrent liability discontinue operation note total liability commitment contingency note shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income loss note retain earning additionalpaidincapital common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development impairment interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning continue operation net earning discontinue operation net tax note net earning net earning share note continue operation basic discontinued operation basic total net earning share basic continue operation dilute discontinued operation dilute total net earning share diluted average share outstanding note basic diluted note consolidated financial statement annual report johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service credit cost net amortization gain loss net amortization consumer settlement curtailment effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income tax effect comprehensive income fiscal year respectively foreign currency translation million million million employee benefit plan million million million derivative hedge million million million note consolidated financial statement amount present recast exclude discontinue operation johnson johnson subsidiaries consolidate statement equity dollar million note retain accumulate common earning stock treasury additional comprehensive issue stock total paidin capital income loss balance january net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january net earning cash dividend pay share employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january net earning cash dividend pay share employee compensation stock option plan repurchase common stock kenvue separation ipo note comprehensive income loss net tax balance december note consolidated financial statement annual report johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation asset writedown charge purchase inprocess research development asset gain kenvue separation net gain sale assetsbusinesse defer tax provision credit loss account receivable allowance change asset liability net effect acquisition divestiture increase account receivable increase inventory increase account payable accrue liability increasedecrease current noncurrent asset increasedecrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal assetsbusinesse net acquisition net cash acquire note purchase inprocess research development asset note purchase investment sale investment credit support agreement activity net include capitalize license milestone net cash fromuse investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt repayment shortterm debt proceed longterm debt net issuance cost repayment longterm debt proceed exercise stock optionsemployee withholding tax stock award net credit support agreement activity net proceed short longterm debt net issuance cost relate debt transfer kenvue separation proceed kenvue initial public offering cash transfer kenvue separation net cash financing activity effect exchange rate change cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent continue operation begin period cash cash equivalent discontinue operation begin period cash cash equivalent begin year note cash cash equivalent continue operation end period cash cash equivalent discontinue operation end period cash cash equivalent end year note supplemental cash flow datum cash pay year interest interest net capitalize income taxis inclusive discontinue operation supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed employee withholding tax stock award acquisition fair value asset acquire fair value liability assume net cash pay acquisition note note consolidated financial statement amount present recast exclude discontinue operation annual report note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate column row table add round percentage calculate actual nonrounde figure description company business segment company approximately employee worldwide engage research development manufacture sale broad range product healthcare field company conduct business virtually country world primary focus product relate human health wellbee kenvue iposeparation discontinue operation kenvue complete initial public offering ipo result issuance share common stock par value share kenvue common stock initial public offering share net proceed billion excess net proceed ipo net book value johnson johnson divest interest billion record additional paidin capital closing ipo johnson johnson own approximately total outstanding share kenvue common stock july noncontrolle interest billion associate kenvue reflect equity attributable noncontrolle interest consolidate balance sheet fiscal second quarter august johnson johnson complete disposition additional ownership share kenvue exchange offer follow exchange offer company own share kenvue account equity investment carry fair value continue operation historical result consumer health business previously represent consumer health business segment reflect discontinued operation company consolidate financial statement date exchange offer note additional detail indicate information note consolidated financial statement refer johnson johnsons continue operation business segment follow completion exchange offer company organize business segment innovative medicine medtech innovative medicine segment focus follow therapeutic area include immunology infectious disease neuroscience oncology pulmonary hypertension cardiovascular metabolic disease product segment distribute directly retailer wholesaler distributor hospitals healthcare professional prescription use medtech segment include broad portfolio product orthopaedic surgery interventional solution vision field product distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic new accounting standard recently adopt accounting standard asu liabilitiessupplier finance program topic disclosure supplier finance program obligation company adopt standard begin fiscal year require buyer supplier finance program disclose additional information program financial statement user company agreement supplier finance program thirdparty financial institution program provide participate supplier ability finance payment obligation company thirdparty financial institution company party arrangement supplier thirdparty financial institution companysobligation supplier include amount schedule payment date general payment term day affect participate supplier decision participate program december january billion valid obligation program obligation present account payable consolidated balance sheet recently issue accounting standard adopt december asu segment report topic improvement reportable segment disclosure update require expand annual interim disclosure significant segment expense regularly provide chief operating decision maker include report measure segment profit loss update effective fiscal year begin december apply retrospectively period present financial statement early adoption permit accounting standard impact disclosure material impact company consolidate financial statement asu income taxis topic improvement income tax disclosure update standardize category effective tax rate reconciliation require disaggregation income taxis additional income taxrelate disclosure update require effective company fiscal period begin december accounting standard impact disclosure material impact company consolidate financial statement cash equivalent company classify highly liquid investment state maturity month date purchase cash equivalent highly liquid investment state maturity great month date purchase current marketable security company policy make investment commercial institution investment grade credit rating company invest cash primarily government security obligation corporate debt security money market fund reverse repurchase agreement rra rra collateralized deposit form government security obligation value company record asset liability company permit sell repledge associate collateral company policy collateral equivalent credit rating company utilize party custodian manage exchange fund ensure collateral receive maintain value rra daily basis rra state maturity great month date purchase classify marketable security investment investment classify hold maturity investment report amortize cost realize gain loss report earning investment classify availableforsale debt security carry estimate fair value unrealize gain loss record component accumulate comprehensive income availableforsale security available current operation classify current asset classify long term management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company review investment impairment adjust investment fair value earning require property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset year building building equipment year land leasehold improvement year machinery equipment company capitalize certain computer software development cost include machinery equipment incurredin connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability annual report carry value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale obligation term contract customer satisfy generally occur transfer control good customer company global payment term typically day provision certain rebate sale incentive trade promotion coupon product return discount customer governmental clawback provision account variable consideration record reduction sale liability recognize accrue rebate return promotion consolidate balance sheet product discount grant base term arrangement direct indirect market participant market condition include consideration competitor pricing rebate estimate base contractual term historical experience patient outcome trend analysis project market condition market serve significant portion liability relate rebate sale company pharmaceutical product primarily manage care medicare medicaid program amount billion billion december january respectively company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall sale return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return innovative medicine segment exclusively resalable sale return certain franchise medtech segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company annual net trade sale fiscal year promotional program product list allowance record period relate sale include volumebase sale incentive program volumebase incentive program base estimate sale volume incentive period record product sell arrangement evaluate determine appropriate amount defer record reduction revenue company earn profitshare payment collaborative arrangement certain product include sale customer profitshare payment total revenue fiscal year total revenue fiscal year include sale customer note consolidated financial statement disaggregation revenue shipping handle shipping handling cost incur billion billion billion fiscal year respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost net realizable value determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset warrant purchase inprocess research development write partially impair depend underlie program intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument lease company determine arrangement lease contract inception establish contract convey right control use identify property plant equipment period time exchange consideration right use rou assets lease liability operating lease include asset accrue liability liability consolidate balance sheet rou asset represent right use underlie asset lease term lease liability represent obligation lease payment arise lease commitment finance lease significant include property plant equipment loan note payable longterm debt consolidate balance sheet rou assets lease liability recognize lease commencement date base present value minimum lease payment lease term company use incremental borrowing rate base information available commencement date determine present value lease payment implicit rate readily determinable lease term include option extend terminate lease option include lease term reasonably certain company exercise option operating lease expense recognize straightline basis lease term company elect follow policy election adoption use portfolio approach lease asset master service agreement exclusion short term lease balance sheet separate lease nonlease component company primarily operate lease space vehicle manufacture equipment datum processing equipment rou asset pertaining lease continue operation billion fiscal year lease liability continue operation billion fiscal year operating lease cost continue operation billion fiscal year cash pay amount include measurement lease liability continue operation billion fiscal year product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information actuarially determine estimate applicable accrual adjust periodically additional information available company accrue estimate legal defense cost need defend matter cost probable reasonably estimate extent adverse verdict render company company record accrual loss determine probable reasonably estimate annual report company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate research development research development expense expense incur accordance asc research development upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research development marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product profit share payment receive sale customer royaltiesmilestone pay collaborative partner post cost product sell regulatory approval royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner research development expense preregulatory approval research development payment collaborative partner research development expense research development payment receive reduction research development expense collaborative partner government entity milestone capitalize intangible asset amortize cost product sell useful life year present individual project represent great total annual consolidated research development expense company number product compound develop collaboration strategic partner include xarelto codevelope bayer healthcare ag imbruvica develop collaboration comarketed pharmacyclic llc abbvie company separately company number license arrangement product compound include darzalex license genmab advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion fiscal year respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position united states enact law new tax legislation tax cut job act tcja law include provision comprehensive overhaul corporate income tax code include reduction statutory corporate tax rate effective january tcja include provision tax previously undistribute earning company locate foreign jurisdiction undistribute earning form cash cash equivalent tax rate earning tax rate tax payable year accrue interest payment begin continue remain balance end approximately billion billion classified noncurrent reflect longterm taxis payable company balance sheet tcja include provision tax global intangible lowtaxed income gilti gilti describe excess shareholder total net foreign income deem return tangible asset provide tcja january fasb issue guidance allow company elect accounting policy record tax effect gilti period tax liability generate ie period cost provide defer tax asset liability relate basis difference exist expect effect gilti inclusion future year reversal ie defer method company elect account gilti defer method defer tax amount record base evaluation temporary difference expect reverse gilti incur future period company record defer tax liability undistribute earning prior december international subsidiary company provide defer taxis undistribute earning subsequent january certain international subsidiary earning consider indefinitely reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company estimate tax effect repatriation approximately billion currently enact tax law regulation current currency exchange rate include possible benefit foreign tax credit substantially offset cost note consolidated financial statement information income taxis net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis withhold taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week include additional shipping day case fiscal year case fiscal year annual report cash cash equivalent current marketable security end fiscal year cash cash equivalent current marketable security comprise current carry unrecognized estimate cash cash marketable dollar million loss fair value equivalent security cash nonus sovereign security reverse repurchase agreement corporate debt security money market fund time deposit subtotal security agency sovereign security corporate debt security subtotal available sale total cash cash equivalent current marketable security current carry unrecognized estimate cash cash marketable dollar million loss fair value equivalent security cash reverse repurchase agreement corporate debt security money market fund time deposit subtotal security agency corporate debt security subtotal available sale total cash cash equivalent current marketable security hold maturity investment report amortize cost realize gain loss report earning available sale debt security report fair value unrealize gain loss report net taxis comprehensive income fair value government security obligation corporate debt security estimate quote broker price significant observable input contractual maturity available sale debt security december follow dollar million cost basis fair value year year year year year total debt security company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution investment grade credit rating inventory end fiscal year inventory comprise dollar million raw material supply good process finish good total inventory property plant equipment end fiscal year property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net company capitalize interest expense cost construction facility equipment interest expense capitalize fiscal year million million million respectively depreciation expense include amortization capitalize interest fiscal year billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning annual report intangible asset goodwill end fiscal year gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademark net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net majority comprise customer relationship goodwill december january allocate segment business follow innovative dollar million medicine medtech total goodwill january goodwill relate acquisition goodwill relate divestiture currency translationother goodwill january goodwill relate acquisition goodwill relate divestiture currency translationother goodwill december include purchase price allocation adjustment abiome weight average amortization period patent trademark approximately year weight average amortization period customer relationship intangible asset approximately year amortization expense amortizable asset include cost product sell billion billion billion tax fiscal year end december january january respectively intangible asset writedown include income expense net estimate amortization expense relate intangible asset approve product tax succeed year approximately dollar million note consolidated financial statement additional detail relate acquisition divestiture fair value measurement company use forward foreign exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company primarily use interest rate swap instrument manage interest rate risk relate fix rate borrowing derivative designate fair value hedge company use cross currency interest rate swap forward foreign exchange contract designate net investment hedge additionally company use forward foreign exchange contract offset exposure certain foreign currency asset liabilitie forward foreign exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature company maintain credit support agreement csa certain derivative counterpartie establish collateral threshold base respective credit rating netting agreement december january total cash collateral pay company csa amount billion billion net respectively relate net investment cash flow hedge ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company primarily enter agreement commercial institution investment grade credit rating refer table significant financial asset liability measure fair value contain footnote receivables payable commercial institution december company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively january company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective foreign exchange contract designate cash flow hedge account forward method gainslosse associate contract recognize income statement hedge item impact earning change fair value derivative record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gain loss associate interest rate swap change fair value hedge debt attributable change interest rate record interest expense period occur gain loss net investment hedge account currency translation account accumulate comprehensive income portion exclude effectiveness testing record interest income expense spot method ongoing basis company assess derivative continue highly effective offset change hedge item derivative long expect highly effective hedge accounting discontinue company designate euro denominate note issue date range net investment hedge company investment certain international subsidiary use euro functional currency order reduce volatility cause change exchange rate december balance defer net loss derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially amount relate forward foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate contract net investment hedge ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative annual report follow table summary activity relate derivative hedge fiscal year end december january net tax december january cost interest cost interest product rd income income product rd income income dollar million sale sell expense expense expense sale sell expense expense expense effect fair value net investment cash flow hedge gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument gain loss net investment hedging relationship cross currency interest rate swap contract gain loss recognize income derivative exclude effectiveness testing gain loss recognize aoci gain loss cash flow hedging relationship forward foreign exchange contract gain loss reclassify aoci income gain loss recognize aoci cross currency interest rate swap contract gain loss reclassify aoci income gain loss recognize aoci december january follow amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge cumulative fair value hedge line item consolidate balance sheet adjustment include carry hedge item include carrying hedge liability hedge liability dollar million december january december january longterm debt follow table effect derivative designate hedge instrument fiscal year end december january location gain loss gainloss recognize income recognize dollar million derivative income derivative derivative designate hedge instrument december january foreign exchange contract income expense follow table effect net investment hedge fiscal year end december january location gain loss gainloss reclassify accumulate gainloss reclassify recognize comprehensive income accumulate oci accumulate oci income income december january december january dollars million debt interest income expense cross currency interest interest income expense rate swap company hold equity investment readily determinable fair value equity investment readily determinable fair value company measure equity investment readily determinable fair value cost minus impairment plus minus change result observable price change orderly transaction identical similar investment issuer follow table summary activity relate equity investment fiscal year end december january january december change fair sale value reflect non current purchasesother dollar million carry value net income carry value asset equity investment readily determinable value equity investment readily determinable value annual report january january change fair sale value reflect non current purchasesother dollar million carry value net income carry value asset equity investment readily determinable value equity investment readily determinable value record incomeexpense include impact currency include remain stake kenvue billion unfavorable change fair value investment separation date end fiscal year fiscal year end december january equity investment readily determinable market value million million respectively change fair value reflect net income result impairment offset impact million million respectively change fair value reflect net income change observable price gain disposal investment fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability accordance asc threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument ie forward foreign exchange contract interest rate contract aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level debt security classify level company hold acquisition relate contingent liability base certain regulatory commercial event classify level value determine discount cash flow methodology similar technique determination fair value require significant judgment estimation follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input company significant financial asset liability measure fair value fiscal year end december january follow dollar million level level level total total derivative designate hedge instrument asset forward foreign exchange contract interest rate contract total liability forward foreign exchange contract interest rate contract total derivative designate hedge instrument asset forward foreign exchange contract liability forward foreign exchange contract available sale investment equity investment debt security liability contingent consideration gross net derivative reconciliation dollar million total gross asset credit support agreement csa total net asset total gross liability credit support agreement csa total net liability annual report summarize information change liabilitie contingent consideration follow dollar million begin balance change estimate fair value addition paymentsother end balance asset liability classify level exception equity investment million classify level contingent consideration million classify level include cross currency interest rate swap interest rate swap classify noncurrent asset classify cash equivalent current marketable security include million million million classified noncurrent liability december january january respectively include million million classify current liability january january respectively fiscal year company record million contingent consideration relate abiomed note financial asset liability hold carrying consolidate balance sheet borrowing component longterm debt follow effective effective rate rate dollar million debenture note note note mm euro mm euro note mm gbp mm gbp note note note note note note mm euro mm euro note note note debenture note note b euro b euro note note note debenture note debenture note note note note note note note note subtotal current portion total longterm debt weight average effective rate annual report translation rate december translation rate january excess carrying value fair value debt billion billion end fiscal year fiscal year respectively fair value longterm debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility billion expire september company early terminate additional day revolve credit facility billion expiration november interest charge borrowing credit line agreement base term sofr reference rate applicable market rate allow term agreement plus applicable margin commitment fee agreement material fiscal year company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion billion end fiscal year respectively current portion long term debt billion billion respectively remainder commercial paper local borrowing international subsidiary current debt balance december include billion commercial paper weight average interest rate weight average maturity approximately month current debt balance january include billion commercial paper weight average interest rate weight average maturity approximately month aggregate maturity longterm debt obligation commence dollar million income taxis provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income comparison income tax expense statutory rate fiscal year company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation tax settlement tax international income tax benefit loss capital asset tax benefit sharebase compensation effective rate international operation reflect impact operation jurisdiction statutory tax rate different particularly ireland switzerland belgium puerto rico favorable impact effective tax rate compare statutory rate include impact gilti tax foreignderive intangible income deduction foreign income taxable tax code include impact certain provision tcja effective fiscal include impact certain foreign subsidiary defer tax remeasurement legislative election amount include reorganization international subsidiary describe fiscal year effective tax rate decrease compare fiscal year effective tax rate company record certain nonrecurre favorable tax item fiscal year compare prior fiscal year fiscal fourth quarter company settle internal revenue service audit tax year result favorable impact rate settlement partially offset company recording billion decrease expect foreign tax credit unfavorable effective rate impact reflect current tax expense tax international income company effective tax rate reconciliation fiscal year company certain nonrecurring impact result legislative tax election certain international subsidiary result change company tax basis certain asset result defer tax remeasurement net impact nonrecurre item net benefit company annual effective tax rate comprise follow item approximately billion tax benefit local defer tax asset record remeasurement increase tax basis benefit reflect international operation company effective tax rate reconciliation benefit offset approximately billion defer tax expense gilti defer tax liability result remeasurement defer tax asset reflect tax international income company effective tax rate reconciliation approximately billion defer tax benefit gilti defer tax result international subsidiary make election change treatment local defer tax asset refundable tax credit reflect tax international income company effective tax rate reconciliation company tax rate benefit certain provision tax cut job act effective fiscal company low income high tax jurisdiction vs fiscal year primarily company record approximately billion charge relate talc matter united states effective tax rate information note consolidated financial statement fiscal year effective tax rate increase compare fiscal year effective tax rate company record certain nonrecurre favorable tax item fiscal year result unfavorable impact company fiscal effective tax rate compare prior fiscal year item describe company tax rate benefit impairment bermekimab ad iprd change fair value security company investment portfolio record statutory rate annual report fiscal year company reorganize ownership structure certain whollyowne international subsidiary reorganization company increase tax basis certain asset fair value accordance applicable local regulation net impact restructure approximately billion net benefit benefit company annual effective tax rate comprise follow item approximately billion local defer tax asset record remeasurement tax basis asset fair value benefit reflect international operation company effective tax rate reconciliation approximately billion defer tax expense relate gilti defer tax liability result remeasurement defer tax asset expense reflect tax international income company effective tax rate reconciliation fiscal fourth quarter company recognize loss certain affiliate relate previously impair book value certain intangible reduce effective tax rate approximately reflect tax benefit loss capital asset effective tax rate reconciliation additionally fiscal impact rate primarily drive litigation acquisition relate item follow company accrue additional legal expense approximately billion talc effective tax rate billion risperdal gynecomastia settlement effective tax rate note consolidated financial statement detail company record partial iprd charge billion ottava intangible asset acquire auris health acquisition effective rate temporary difference carryforward end fiscal year follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation property plant equipment goodwill intangible rd capitalize tax reserve liabilitie income report tax purpose net realizable operating loss carryforward undistribute foreign earning global intangible lowtaxed income miscellaneous international miscellaneous total deferred income taxis fiscal company change presentation income taxis accrue intercompany profit inventory own company prepay expense consolidate balance sheet net valuation allowance billion billion change valuation allowance drive approximately billion acquisition relate activity remainder normal operation fiscal year company whollyowne international subsidiary cumulative net loss company believe likely subsidiary generate future taxable income sufficient utilize defer tax asset certain jurisdiction valuation allowance record defer tax asset loss carryforward likely realize follow table summarize activity relate unrecognized tax benefit continue operation dollar million begin year increase relate current year tax position increase relate prior period tax position decrease relate prior period tax position settlement lapse statute limitation end year december company approximately billion unrecognized tax benefit company conduct business file tax return numerous country currently tax audits progress number tax authority respect united states internal revenue service complete audit tax year major jurisdiction company conduct business year remain open tax audits year company believe possible tax audits complete month tax authority jurisdiction include united states company able provide reasonably reliable estimate time future tax payment change uncertain tax position company classifie liability unrecognize tax benefit relate interest penalty longterm liabilitie interest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest expense million million million fiscal year respectively total accrue interest million million fiscal year respectively employee relate obligation end fiscal fiscal employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet annual report pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily healthcare eligible retire employee dependent international employee cover governmentsponsored program cost company significant nonunion pension benefit employee hire january primarily base employee compensation year retirement number year service final average pay formula pension benefit employee hire calculate different formula base employee compensation total year service retirement value formula january company announce effective january eligible nonunion employee regardless hire date earn benefit retirement value formula amendment affect benefit accrue final average pay formula service january international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree healthcare benefit advance right modify plan future company december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost recognize actuarial loss gain curtailment settlement net periodic benefit cost credit service cost component net periodic benefit cost present line item consolidate statement earning employee compensation cost report include cost product sell research development expense selling marketing administrative expense net earning discontinue operation net taxis relate separation kenvue component net periodic benefit cost present income expense net consolidated statement earning exception certain amount curtailment settlement report net earning discontinue operation net taxis relate separation kenvue note unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain loss benefit plan determine corridor great market value asset accumulate postretirement benefit obligation total unamortized gain loss excess corridor amortize average remain future service prior service costsbenefit pension plan amortize average remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment follow table represent weightedaverage actuarial assumption retirement plan benefit plan worldwide benefit plan net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation level expect longterm rate return plan asset benefit obligation discount rate rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liabilitie company methodology determine service interest cost use duration specific spot rate yield curve plan liability cash flow expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market follow table display assume healthcare cost trend rate individual healthcare plan healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate exclude ongoing negotiation healthcare cost service provider follow table set forth information relate benefit obligation fair value plan asset fiscal yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement restructure benefit pay plan effect exchange rate project benefit obligation end year annual report change plan asset plan asset fair value begin year actual return loss plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year actuarial gainslosse retirement plan primarily drive change discount rate primarily drive kenvue separation include approximately million transfer group annuity contract issue thirdparty insurer salary pension plan retirement plan benefit plan dollar million amount recognize net periodic benefit cost comprehensive income net periodic benefit cost credit net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rate total lossincome recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december december respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan follow table display project future minimum contribution unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow annual report percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low net asset value nav base value underlie asset own fund minus liability divide number share outstanding financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment fund cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value nav provide administrator fund nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input equity security equity security value closing price report major market individual security trade substantially equity security classify level valuation hierarchy commingle fund investment vehicle value nav provide fund administrator asset level category quote market price asset asset represent primarily limit partnership investment vehicle value nav provide fund administrator asset exchange list actively trade classified level inactively trade asset classify level follow table set forth retirement plan investment measure fair value december december quote price significant active significant investment market observable unobservable measure net identical asset input input asset value level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund asset investment fair value activity level asset significant year present company benefit plan unfunded commingle fund level million million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december saving plan company voluntary k saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan employee eligible total company match contribution plan million million million fiscal year respectively annual report capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance january employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock balance january employee compensation stock option plan repurchase common stock kenvue share exchange note balance december aggregate share common stock issue approximately share end fiscal year cash dividend pay share fiscal year compare dividend share fiscal year share fiscal year january board director declare regular cash dividend share payable march shareholders record february september company announce board director approve share repurchase program authorize company purchase billion company share common stock repurchase program complete fiscal quarter accumulate comprehensive income loss component comprehensive income loss consist follow total gain accumulate foreign gain loss currency loss employee derivative comprehensive dollar million translation security benefit plan hedge income loss january net change january net change january net change kenvue separationipo december amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail comprehensive income consolidated statement comprehensive income detail reclassification accumulate comprehensive income gainloss security reclassification release income expense net employee benefit plan reclassification include net periodic benefit cost note additional detail gainloss derivative hedge reclassifications earning record account hedge transaction note additional detail include impact curtailment settlement connection separation kenvue international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency majority company subsidiary local currency functional currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income current noncurrent asset line statement cash flow include impact foreign currency translation equity account include result translate certain balance sheet asset liability current exchange rate account historical rate locate highly inflationary economy argentina venezuela begin fiscal second quarter company account operation turkey highly inflationary translation balance sheet account highly inflationary economy reflect operating result rollforward change fiscal year foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million fiscal year respectively annual report earning share follow reconciliation basic net earning share dilute net earning share fiscal year end december january january millions share amount basic net earning share continue operation basic net earning share discontinue operation total net earning share basic average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method adjust average share outstanding diluted diluted net earning share continue operation dilute net earning share discontinuing operation total net earning share dilute diluted net earning share calculation fiscal year exclude million share relate stock option exercise price option great average market value company stock dilute net earning share calculation fiscal year include share relate stock option exercise price option average market value company stock common stock stock option plan stock compensation agreement december company stockbase compensation plan share outstanding contract company longterm incentive plan longterm incentive plan longterm incentive plan expire april award stock option restrict share unit performance share unit grant subsequent date longterm incentive plan longterm incentive plan company issue million share common stock million share common stock issue subject stock option stock appreciation right million share common stock issue subject value award award generally count basis share reserve provide million value award grant value award excess million count basis share reserve share available future grant longterm incentive plan million end fiscal year compensation cost charge income plan million million million fiscal year respectively total income tax benefit recognize income statement sharebase compensation cost million million million fiscal year respectively company recognize additional income tax benefit million million million fiscal year respectively option exercise restrict share vest total unrecognized compensation cost million million million fiscal year respectively weight average period cost recognize year year year fiscal year respectively sharebase compensation cost capitalize inventory insignificant period company settle employee benefit equity issuance treasury share treasury share replenish market purchase year number share settle employee benefit equity issuances stock option stock option expire year date grant vest service period range month year option grant longterm incentive plan grant average high low price company common stock new york stock exchange date grant option grant longterm incentive plan grant closing price company common stock new york stock exchange date gran fair value option award estimate date grant blackschole option valuation model use assumption note follow table grant expect volatility represent blend rate year weekly historical overall volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant fiscal year respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year expect dividend yield summary option activity plan december present aggregate weight intrinsic outstanding average exercise value share thousand share price dollar million share january option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million fiscal year respectively include share option cancel result conversion johnson johnson stock option hold kenvue employee kenvue stock option annual report follow table summarize stock option outstanding exercisable december share thousand outstanding exercisable weighted weight average average exercise price range option average life exercise price option exercise price average contractual life remain year stock option outstanding january january average life year average life year respectively stock option exercisable january january average price average price respectively restrict share unit performance share unit company grant restrict share unit vest service period range month year company grant performance share unit pay share johnson johnson common stock end year performance period performance share grant equallyweighte goal directly align help drive longterm total shareholder return adjust operational earning share relative total shareholder return number share actually earn end threeyear period vary base actual performance target number performance share unit grant summary restrict share unit performance share unit activity plan december present outstanding outstanding share thousand restrict share unit performance share unit share january grant issue canceledforfeitedadjuste share december include share restrict share unit share performance share unit cancel result conversion johnson johnson restrict share unit performance share unit hold kenvue employee kenvue restrict share unit average fair value restrict share unit grant fiscal year respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit issue million million million respectively weight average fair value performance share unit grant fiscal year calculate weighted average fair market value component goal date grant fair value earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model fair value performance share unit issue million million million fiscal year respectively segment business geographic area follow separation consumer health business fiscal quarter company organize business segment innovative medicine refer pharmaceutical medtech segment result recast period reflect continue operation company sale customer change dollar million vs vs innovative medicine immunology international worldwide remicade exports international worldwide simponi simponi aria international worldwide stelara international worldwide tremfya international worldwide immunology international worldwide infectious disease international worldwide covid vaccine international worldwide annual report sale customer change dollar million vs vs edurant rilpivirine international worldwide prezista prezcobix rezolsta symtuza international worldwide infectious disease international worldwide neuroscience international worldwide concerta methylphenidate international worldwide invega sustenna xeplion invega trinza trevicta international worldwide spravato international worldwide neuroscience international worldwide oncology international worldwide sale customer change dollar million vs vs carvykti international worldwide darzalex international worldwide erleada international worldwide imbruvica international worldwide zytiga abiraterone acetate international worldwide oncology international worldwide pulmonary hypertension international worldwide opsumit international worldwide uptravi international worldwide pulmonary hypertension international worldwide annual report sale customer change dollar million vs vs cardiovascular metabolism international worldwide xarelto international worldwide international worldwide total innovative medicine international worldwide medtech interventional solution international worldwide electrophysiology international worldwide abiome international worldwide interventional solution international worldwide orthopaedic international worldwide hip international worldwide sale customer change dollar million vs vs knee international worldwide trauma international worldwide spine sport international worldwide surgery international worldwide advance international worldwide general international worldwide vision international worldwide contact lense international worldwide surgical international worldwide total medtech international worldwide annual report sale customer change dollar million vs vs worldwide international worldwide percentage greater meaningful previously refer pharmaceutical inclusive risperdal consta previously disclose separately inclusive invokana previously disclose separately acquire december income tax identifiable asset dollar millions innovative medicine medtech total expense allocate segment discontinue operation general corporate worldwide total addition property depreciation plant equipment amortization dollar millions innovative medicine medtech segment total discontinued operation general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total discontinued operation general corporate non longlived asset worldwide total note description segment company operate export sale significant fiscal year company utilize wholesaler distribute product segment represent approximately total consolidated revenue fiscal year company wholesaler distribute product segment represent approximately total consolidated revenue fiscal year company wholesaler distribute product segment represent approximately total consolidated revenue amount allocate segment include interest incomeexpense general corporate incomeexpense fiscal include approximately billion charge relate talc matter note legal proceeding additional detail billion relate unfavorable change fair value retain stake kenvue general corporate include cash cash equivalent marketable security innovative medicine include onetime covid vaccine manufacturing exit relate cost billion restructuring relate charge billion unfavorable change fair value security billion favorable litigation relate item billion loss divestiture billion intangible asset impairment charge approximately billion related market dynamic associate nonstrategic asset acquire acquisition momenta pharmaceutical medtech include acquire process research development asset billion relate laminar acquisition restructuring relate charge billion acquisition integration relate cost billion primarily relate acquisition abiome medical device regulation charge billion income litigation settlement billion innovative medicine include onetime covid vaccine manufacturing exit relate cost billion intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment atopic dermatitis ad hidradenitis suppurativa hs acquire acquisition xbiotech inc fiscal year additional information efficacy ad hs indication available lead company decision terminate development bermekimab ad hs litigation expense billion unfavorable change fair value security billion restructuring relate charge billion medtech include litigation expense billion primarily pelvic mesh relate cost restructure relate charge billion acquisition integration relate cost billion primarily relate acquisition abiome medical device regulation charge billion innovative medicine include litigation expense billion primarily relate risperdal gynecomastia divestiture gain billion gain billion relate change fair value security restructuring relate charge billion medtech include inprocess research development expense billion relate ottava restructure relate charge billion medical device regulation charge billion annual report litigation expense billion longlive asset include property plant equipment net fiscal year respectively intangible asset goodwill net fiscal year respectively acquisition divestiture fiscal quarter company announce enter definitive agreement acquire ambrx biopharma inc ambrx nasdaq amam clinicalstage biopharmaceutical company proprietary synthetic biology technology platform design develop nextgeneration antibody drug conjugate adcs allcash merger transaction total equity value approximately billion billion net estimate cash acquire company acquire outstanding share ambrxs common stock share merger ambrx subsidiary company closing transaction expect occur half subject receipt ambrx shareholder approval clearance hartscottrodino antitrust improvement act customary closing condition company expect transaction account business combination result operation include innovative medicine segment acquisition date fiscal year company acquisition qualified business combination fiscal year asset acquisition inprocess research development approximately billion cash primarily consist acquisition laminar inc billion closed november laminar inc privatelyheld medical device company focus eliminate left atrial appendage laa patient nonvalvular atrial fibrillation afib fiscal year certain business acquire billion cash billion liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition excess purchase price estimate fair value tangible asset acquire amount billion assign identifiable intangible asset residual record goodwill fiscal year acquisition primarily include abiome inc abiome remain acquisition material december company complete acquisition abiome lead firsttomarket provider cardiovascular medical technology firstinkind portfolio treatment coronary artery disease heart failure extensive innovation pipeline lifesave technology transaction broaden company position grow cardiovascular innovator advance standard care heart failure recovery healthcare large area unmet need transaction account business combination result operation include medtech segment date acquisition acquisition complete tender offer outstanding share consideration pay acquisition consist upfront payment share cash amount billion net cash acquire nontradeable contingent value right cvr entitling holder receive share cash respect cvrs total approximately billion aggregate certain commercial clinical milestone achieve corresponding enterprise value take account cvrs approximately billion include cash cash equivalent marketable security acquire milestone cvr consist share payable net sale abiome product exceed billion johnson johnson fiscal second quarter fiscal quarter threshold meet period subsequently meet roll quarter period end johnson johnsons fiscal quarter share b share payable fda premarket application approval use impella product stelevate myocardial infarction stemi patient cardiogenic shock january c share payable publication class recommendation use impella product high risk pci stemi cardiogenic shock year respective clinical endpoint publication date case later december fiscal fourth quarter company finalize purchase price allocation fiscal purchase price allocation adjustment net approximately billion offsetting increase goodwill fair value acquisition allocate asset acquire billion net billion cash acquire primarily goodwill billion amortizable intangible asset billion iprd billion marketable security billion andliabilitie assume billion include fair value contingent consideration mention billion defer taxis billion goodwill primarily attributable commercial acceleration expansion portfolio expect deductible tax purpose contingent consideration record liability adjust fair value fiscal year end consolidated balance sheet amortizable intangible asset primarily comprise inmarket product impella platform average weight life year iprd asset value technology program unapprove product value iprd calculate probabilityadjuste cash flow projection discount risk inherent project probability success factor range discount rate apply company record acquisition relate cost tax approximately billion primarily record incomeexpense company record acquisition relate cost tax approximately billion record incomeexpense fiscal year company material acquisition qualified business combination accordance gaap standard relate business combination goodwill intangible asset supplemental pro forma information fiscal year provide impact aforementione acquisition material effect company result operation divestiture fiscal year company execute divestiture result approximately billion proceed result gain loss material fiscal year end company hold asset primarily intangible consolidated balance sheet expect divest approximately billion primarily related acclarent ponvory fiscal year company material divestiture fiscal year separate transaction company divest brand outside innovative medicine segment company recognize pretax gain record income expense net approximately billion legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial indemnification matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate december company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc contingency litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve extent adverse award judgment verdict render company company record accrual loss determine probable reasonably estimate company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period annual report matter concern talc significant number personal injury claim allege talc cause cancer assert johnson johnson consumer inc successor ltl management llc know llt management llc company arise use body powder contain talc primarily johnson baby powder talc case previously go trial company obtain number defense verdict verdict company reverse appeal june missouri court appeal reverse affirm july verdict billion ingham v johnson johnson et al ed mo app reduce overall award billion application transfer case missouri supreme court subsequently deny june petition certiorari seek review ingham decision united states supreme court deny june company pay award include interest total approximately billion fact circumstance include term award unique ingham decision representative claim bring company company continue believe strong legal ground contest talc verdict appeal notwithstanding company confidence safety talc product certain circumstance company settle case october johnson johnson consumer inc old jjci implement corporate restructure corporate restructuring result restructure old jjci cease exist new entity create ltl management llc north carolina limited liability company ltl debtor b royalty llc north carolina limited liability company direct subsidiary ltl ram c debtor direct parent johnson johnson consumer inc new jersey company new jjci debtor receive certain old jjcis asset solely responsible talcrelate liability old jjci include liability relate way injury damage allege injury damage sustain incur purchase use exposure talc include talc contain product risk responsibility damage injury liability exclusive remedy provide worker compensation statute act talcrelate liability october notwithstanding company confidence safety talc product debtor file voluntary petition united states bankruptcy court western district north carolina charlotte division seek relief chapter bankruptcy code ltl bankruptcy case litigation ltl old jjci new jjci company corporate affiliate identify retailer insurance company certain party protect party stay ltl agree lift stay small number appeal appeal bond file ltl bankruptcy case transfer united states bankruptcy court district new jersey claimants file motion dismiss ltl bankruptcy case follow multiple day hear new jersey bankruptcy court deny motion march claimant subsequently file notice appeal denial motion dismiss ltl bankruptcy case extension stay protect party january circuit reverse bankruptcy court rule remand bankruptcy court dismiss ltl bankruptcy ltl file petition rehear circuit decision deny march ltl subsequently file motion circuit stay mandate direct new jersey bankruptcy court dismiss ltl bankruptcy pende filing disposition petition writ certiorari united states supreme court circuit deny motion stay mandate issue mandate april new jersey bankruptcy court dismiss ltl bankruptcy case effectively lift stay party return talc litigation tort system ltl refiled united states bankruptcy court district new jersey seek relief chapter bankruptcy code ltl bankruptcy case result new filing talc claim ltl automatically stay pursuant section bankruptcy code additionally new jersey bankruptcy court issue temporary restraining order stay litigation ltl old jjci new jjci company identify retailer certain party new protect party april new jersey bankruptcy court issue decision grant limited injunctive relief company new protect party ltl preliminary injunction ltl preliminary injunction remain force late august follow bankruptcy court extension initial ltl preliminary injunction june ltl preliminary injunction case file federal court ovarian cancer multidistrict litigation discovery personal injury wrongful death matter permit proceed furthermore april talc claimants committee file motion dismiss ltl bankruptcy follow similar motion claimant hearing motion dismiss occur june july court dismiss ltl bankruptcy case day company state intent appeal decision continue effort obtain resolution talc claim september bankruptcy court enter order grant ltl leave seek direct appeal circuit court appeal october circuit grant ltls petition direct appeal briefing ongoingfollowe dismissal ltl new lawsuit file case country stay reactivate majority case pende federal court organize multidistrict litigation mdl united states district court district new jersey mdl casespecific discovery proceeding expectation trial occur early separately discovery pretrial activity underway individually file set case country activity case centralize new jersey california original bankruptcy case company agree provide funding ltl payment amount new jersey bankruptcy court determines owe ltl establishment billion trust furtherance purpose company establish reserve approximately billion connection aforementione trust bankruptcy proceeding ltl deconsolidate company ltl bankruptcy case company agree contribute additional add prior billion total reserve approximately billion payable year nominal value approximately billion discount rate resolve current future talc claim approximate billion reserve encompass actual contemplate settlement approximately onethird record current liability record remain company good estimate probable loss dismissal party reach resolution talc matter company unable estimate possible loss range loss accrue class action advance claim relate industrial talc file company new jersey state court edley class action edley class action assert thing company fraudulently defend past asbestos personal injury lawsuit arise exposure industrial talc mine mill manufacture january company wholly own subsidiary windsor minerals inc currently debtor imery bankruptcy describe company remove edley class action federal court district new jersey october company file motion dismiss deny certification class pursue edley class action new jersey district court argument motion hear november company resolve matter february company talc supplier imery talc america inc affiliate imery talc vermont inc imerys talc canada inc collectively imery file voluntary petition relief chapter united states code bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imery bankruptcy relate imeryss potential liability personal injury exposure talcum powder sell imery bankruptcy imery allege claim company indemnification right joint insurance proceed bankruptcy imery propose chapter plan imery plan contemplate talcrelate claim channel trust allege indemnification right company follow confirmation consummation plan trust pay talc claim pursuant propose trust distribution procedure tdp seek indemnification company february cyprus mines corporation cyprus own certain imery talc mine file voluntary petition relief chapter bankruptcy code file disclosure statement plan cyprus plan cyprus plan contemplate settlement imery talc claimants cyprus monetary contribution trust establish imery plan exchange injunction talc claim assert certain affiliate party imery plan proceed solicitation early imery plan receive requisite number vote confirm bankruptcy court rule certain vote cast favor imery plan disregard imery subsequently cancel confirmation hearing imery imery tort claimants committee imery future claimant representative cyprus cyprus tort claimants committee cyprus future claimants representative collectively mediation party engage mediation shortly confirmation hearing cancel october september bankruptcy court enter order extend term mediation mediation party end december bankruptcy court authorize imery cyprus proceed mediation certain insurer end december september imerys cyprus file amend plan reorganization amend plan contemplate similar construct prior imery cyprus plan include talc claim imery cyprus certain protect party channel trust imeryss cypruss allege indemnification right company january imerys cyprus file revised tdp february imery cyprus file certain motion relate disclosure statement february security class action lawsuit file company certain name officer united states district court district new jersey allege company violate federal security law fail disclose alleged asbestos contamination body powder contain talc primarily johnson baby powder purchaser company share suffer loss result april company move dismiss complaint annual report december court deny motion dismiss april briefing plaintiff motion class certification complete case stay pursuant ltl bankruptcy case reopen december court grant plaintiff motion class certification january defendant file petition circuit federal rule civil procedure f permission appeal court order grant class certification fact discovery proceed lawsuit bring company superior court california county san diego allege violation california consumer legal remedy act clra relate johnson baby powder lawsuit plaintiff allege company violate clra fail provide require proposition warning july company file notice removal united states district court southern district california plaintiff file second amend complaint shortly october company move dismiss second amend complaint failure state claim relief grant response motion plaintiff file amend complaint december company move dismiss amend complaint failure state claim relief grant april court grant motion dismiss grant leave amend plaintiff file fourth amend complaint indicate file motion leave file fifth amend complaint plaintiff file fifth amend complaint august company move dismiss fifth amend complaint failure state claim relief grant january court issue order opinion ruling company favor grant motion dismiss prejudice february plaintiff file notice appeal ninth circuit plaintiff file open brief july company file responsive brief october notice suggestion bankruptcy file ninth circuit stay impose court hold reply deadline abeyance september stay lift briefing complete court expect schedule oral argument issue decision time june mississippi attorney general file complaint chancery court judicial district hind county mississippi company johnson johnson consumer companies inc know johnson johnson consumer inc collectively jjci complaint allege jjci violate mississippi consumer protection act fail disclose allege health risk associate female consumer use talc contain johnson baby powder johnson shower shower product divest seek injunctive monetary relief february trial court set case trial begin february october ltl bankruptcy court issue order staying case march circuit issue mandate dismiss ltl bankruptcy case april new jersey bankruptcy court dismiss ltl bankruptcy case effectively lift stay matter state request new trial set later april trial court set new trial date april company file summary judgment daubert motion state file limited daubert motion party agree court request mediation pretrial conference set february trial schedule april company actively engage resolution discussion concern matter january state new mexico file consumer protection case allege company deceptively market sell talcum powder product make misrepresentation safety product presence carcinogen include asbestos march new mexico court deny company motion compel state new mexico engage discovery state agency deny company request interlocutory appeal decision company file petition writ superintend control request stay new mexico supreme court issue state new mexico discovery obligation april view effort resolve talcrelate claim ltl bankruptcy case company state agree day stay matter pende writ new mexico supreme court expire june company move enjoin prosecution case ltl bankruptcy case october bankruptcy court issue order staying case december state file appeal circuit concern stay order separately september new mexico supreme court grant company request stay pende briefing scope state new mexico discovery obligation march circuit issue mandate dismiss ltl bankruptcy case april new jersey bankruptcy court dismiss ltl bankruptcy case effectively lift stay matter state notify new mexico supreme court lift stay litigation april court take action notify lift stay remain effect fortytwo state district columbia include mississippi new mexico commence joint investigation company market talcum powder product time multistate group assert claim company state issue civil investigative demand seek document information company produce document arizona north carolina texas washington enter confidentiality agreement company receive follow request states march fortytwo state agree mediation claim ltl bankruptcy case july new mexico mississippi indicate long voluntarily submit mediation ltl bankruptcy proceed respective case state court march mediation terminate january company reach agreement principle multistate group state attorney general subject ongoing negotiation nonmonetary term unique procedural history status new mexico mississippi matter specifically discuss abovein addition company receive inquiry subpoena request produce document talc matter ltl bankruptcy case governmental authority company produce document respond inquiry continue cooperate government inquiry matter concern opioid begin continue present company janssen pharmaceuticals inc jpi pharmaceutical company name close lawsuit relate marketing opioid include duragesic nucynta nucynta er majority case file state local government similar lawsuit file private plaintiff organization include limited follow individual plaintiff behalf child bear neonatal abstinence syndrome nas hospital health insurerspayor date company jpi litigate case judgment prevail trial appeal october company announce propose agreement principle negotiate committee state attorney general settle remain government opioid litigation claim nationwide final national settlement agreement announce july company agree pay billion resolve opioid lawsuit future opioid claim state city county local school district special district tribal government contingent sufficient participation eligible government entity credit entity decline ineligible participate july company announce term agreement settle state subdivision claim finalize approximately allin settlement pay end fiscal expect payment schedule provide approximately billion payment pay end fiscal agreement admission liability wrongdoing provide release opioidrelate claim company jpi affiliate include company subsidiary tasmanian alkaloid pty ltd noramco inc january company jpi settled resolve opioid claim advanced government entity claimant city baltimore number school district claimant company jpi continue defend case bring remain government entity litigant case bring private litigant include nas claimant hospital health insurerspayor count private litigant case approximately remain opioid case company jpi state court remain case ohio mdl additional case federal court case dismiss appeal plaintiff certain schedule trial addition province british columbia file suit company canadian affiliate janssen inc industry member canada seek action certify opt class action behalf provincialterritorial federal government canada additional propose class action file canada company janssen inc industry member behalf people opioid personal injury municipality nation band action allege variety claim relate opioid marketing practice include false advertising unfair competition public nuisance consumer fraud violation deceptive act practice false claim unjust enrichment adverse judgment lawsuit result imposition large monetary penalty significant damage include punitive damage cost abatement substantial fine equitable remedy sanction june december company board director receive series shareholder demand letter allege breach fiduciary duty relate marketing opioid board retain independent counsel investigate allegation demand april independent counsel deliver report board recommend company reject shareholder demand step necessary appropriate secure dismissal relate derivative litigation board unanimously adopt recommendation independent counsel report november shareholder send demand file derivative complaint company nominal defendant certain current director officer defendant superior court new jersey complaint allege breach fiduciary duty relate marketing opioid company suffer damage result allege breach series additional derivative complaint make similar allegation similar defendant file new jersey state federal court state court case voluntarily dismiss february state court grant company motion dismiss case shareholder bring second case file notice dismissal shareholder complaint dismiss file motion reconsideration state court hold oral argument motion reconsideration subsequently deny motion shareholder appeal state court dismissal order annual report product liability company certain subsidiary involve numerous product liability claim lawsuit involve multiple product claimant case seek substantial compensatory available punitive damage company believe substantial defense feasible predict ultimate outcome litigation time time substantial defense company consider isolate settlement base variety circumstance company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc contingency company accrues estimate legal defense cost need defend matter cost probable reasonably estimate certain matter company accrue additional amount estimate cost associate settlement damage loss product liability accrual represent project product liability thousand claim world different litigation environment different fact pattern change accrual require future additional information available table contain significant case provide approximate number plaintiff united states direct claim pende lawsuit injury allegedly relevant product product category december product product category number plaintiff body powder contain talc primarily johnson baby powder depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic mesh ethicon physiomesh flexible composite mesh risperdal elmiron number pende lawsuit expect fluctuate certain lawsuit settle dismiss additional lawsuit file additional claim file medtech depuy asr xl acetabular system asr hip resurfacing system august depuy orthopaedics inc depuy announce worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system asr hip hip replacement surgery claim personal injury depuy company case file federal court united states organize multidistrict litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia ireland germany india italy november depuy reach agreement courtappointe committee lawyer represent asr hip plaintiff establish program settle claim eligible asr hip patient unite states surgery replace asr hips know revision surgery august depuy reach additional agreement february march extend settlement program include asr hip patient revision surgery august prior february settlement program resolve claim bring resolution significant asr hip litigation activity united states lawsuit united states remain settlement program address litigation outside united states australia class action settlement reach resolve claim majority asr hip patient country canada company reach agreement settle class action file country company continue receive information respect potential additional cost associate recall worldwide basis company establish accrual cost associate united states settlement program asr hiprelated product liability litigation depuy pinnacle acetabular cup system claim personal injury depuy orthopaedics inc company collectively depuy relate pinnacle acetabular cup system hip replacement surgery product liability lawsuit continue file company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united statesdistrict court northern district texas texas mdl beginning june judicial panel multidistrict litigation cease transfer new case texas mdl case pende federal court outside texas mdl litigation file state court country outside united states quarter depuy establish united states settlement program resolve case settlement program adverse verdict settle company establish accrual product liability litigation associated pinnacle acetabular cup system relate settlement program ethicon pelvic mesh claim personal injury ethicon inc ethicon company arise ethicon pelvic mesh device treat stress urinary incontinence pelvic organ prolapse company continue receive information respect potential cost additional case case file federal court united states organized multi district litigation mdl united states district court southern district west virginia march mdl court enter order closing mdl mdl court remand case trial jurisdiction case originally file additional pelvic mesh lawsuit file remain outside mdl company settle resolve majority united states case estimate cost associate settlement remain case reflect company accrual addition class action individual personal injury case claim seek damage allege injury result ethicon pelvic mesh device commence country outside united states include claim case united kingdom netherlands belgium france ireland italy spain slovenia class action israel australia canada south africa november federal court australia issue judgment finding respect liability relation lead applicant generally relation design manufacture pre postmarket assessment test supply promotion device australia treat stress urinary incontinence pelvic organ prolapse september exhausting appeal company reach inprinciple agreement resolve pelvic mesh class action australia march federal court approve settlement class action canada discontinue result settlement group case agreement resolve israeli class action reach party israeli class action currently finalize term settlement motion approve settlement file court company establish accrual respect product liability litigation associate ethicons pelvic mesh product ethicon physiomesh follow june worldwide market withdrawal ethicon physiomesh flexible composite mesh physiomesh claim personal injury ethicon inc ethicon company allege personal injury arising use hernia mesh device case file federal court united states organize multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl form new jersey state court assign atlantic county case pende new jersey addition matter mdl mcl additional lawsuit pende united states district court southern district ohio mdl polypropylene mesh device manufacture cr bard inc lawsuit pende new jersey mcls form proceedproceed ventral patch prolene hernia system lawsuit pende outside united states ethicon lead counsel plaintiff enter term sheet resolve approximately physiomesh case cover approximately plaintiff pende mdl mcl time master settlement agreement msa enter september include case mdl mcl deadline trial setting proceeding currently stay pende completion settlement agreement case subject msa dismiss prejudice ethicon receive release plaintiff release continue submit settlement process postsettlement case physiomesh mdl mcl subject docket control order require early expert report discovery requirement ethicon enter additional settlement resolve claim physiomesh claimants settlement proceeding release return december physiomesh case mdl new jersey mcl include settlement remain subject docket control order claim file ethicon company allege personal injury arise proceed mesh proceed ventral patch hernia mesh product march new jersey supreme court enter order consolidate case pende new jersey mcl atlantic county superior court additional case file federal state court united states jurisdiction outside united states ethicon company subject claim personal injury arise prolene polypropylene hernia system january new jersey supreme court create mcl atlantic county superior court handle case case involve product file federal state court united states october agreement principle subject condition reach settle majority pende case involve proceed proceed ventral patch prolene hernia system relate multilayere mesh product number unfiled claim litigation activity new jersey mcls stay pende effectuation propose settlement future case file new jersey mcls subject docket control order require early expert report discovery requirement annual report company establish accrual respect product liability litigation associate ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch prolene polypropylene hernia system product innovative medicine risperdal claim personal injury janssen pharmaceuticals inc company arise use risperdal relate compound indicate treatment schizophrenia acute manic mixed episode associate bipolar disorder irritability associate autism lawsuit primarily file state court pennsylvania california missouri action pende court united states canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company successfully defend number case verdict company include verdict october billion punitive damage relate plaintiff trial judge reduce million january september company enter settlement principle counsel represent plaintiff matter substantially outstanding case united states cost associate settlement reflect company accrual elmiron claim personal injury number johnson johnson company include janssen pharmaceuticals inc company arise use elmiron prescription medication indicate relief bladder pain discomfort associate interstitial cystitis lawsuit allege elmiron contribute development permanent retinal injury vision loss file state federal court united states december lawsuit file federal court unite states include putative class action case seek medical monitoring organize multidistrict litigation united states district court district new jersey case multidistrict litigation active discussion resolution result activity stay addition case file state court new jersey coordinated multicounty litigation bergen county court common plea philadelphia coordinate grant mass tort designation activity take place new jersey state court litigation bellwether trial set philadelphia march april addition class action lawsuit file canada product liability lawsuit continue file company continue receive information respect potential cost anticipate number case company establish accrual defense indemnity cost associate elmiron related product liability litigation intellectual property certain subsidiary company subject time time legal proceeding claim relate patent trademark intellectual property matter arise business matter involve challenge coverage andor validity patent product allegation certain company product infringe patent party subsidiary believe substantial defense challenge allegation respect significant patent assurance outcome matter loss case adversely affect ability subsidiary sell product result loss sale loss market exclusivity require payment past damage future royalty result non cash impairment charge associate intangible asset innovative medicine litigation filer abbreviate new drug application anda company subsidiary bring lawsuit generic company file anda fda similar lawsuit outside united states seek market generic version product sell subsidiary company prior expiration applicable patent cover product lawsuit typically include allegation noninfringement andor invalidity patent list fdas publication approve drug product therapeutic equivalence evaluation commonly know orange book lawsuit company subsidiary seek order enjoin defendant marketing generic version product expiration relevant patent orange book list patent event company subsidiary successful action automatic statutory stay expire court ruling obtain generic company involve ability regulatory approval introduce generic version product market result potential substantial market share revenue loss applicable product result noncash impairment charge associate intangible asset addition fromtime time company subsidiary settle type action settlement involve introduction generic version product issue market prior expiration relevant patent inter part review ipr process united states patent trademark office uspto create america invents act time generic company conjunction anda lawsuit challenge applicable patent xarelto begin march janssen pharmaceuticals inc bayer pharma ag bayer ag bayer intellectual property gmbh file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version xarelto expiration certain orange book list patent follow entity name defendant dr reddys laboratories inc dr reddys laboratories ltd lupin limited lupin pharmaceuticals inc taro pharmaceutical industry ltd taro pharmaceuticals usa inc teva pharmaceuticals usa inc mylan pharmaceuticals inc mylan inc mankind pharma limited apotex inc apotex corp auson pharmaceuticals inc macleod pharmaceuticals ltd macleods pharma usa inc indoco remedy limit fpp hold company llc umedica laboratories pvt ltd aurobindo pharma limited aurobindo pharma usa inc cipla ltd cipla usa inc invagen pharmaceuticals inc follow patent include case patent consideration uspto ipr proceeding july uspto issue final write decision find claim patent invalid september bayer pharma ag file appeal court appeal federal circuit opsumit begin january actelion pharmaceuticals ltd actelion pharmaceutical inc file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version opsumit expiration certain orange book list patent follow entity name defendant sun pharmaceutical industry limited sun pharmaceutical industries inc msn laboratorie private limit msn pharmaceuticals inc mylan pharmaceuticals inc follow patent include case november company enter confidential settlement agreement msn laboratorie private limit msn pharmaceuticals inc december company enter confidential settlement agreement sun pharmaceutical industry limited sun pharmaceuticals industries inc invega sustenna begin january janssen pharmaceutica nv janssen pharmaceuticals inc file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version invega sustenna expiration orange book list patent follow entity name defendant teva pharmaceuticals usa inc mylan laboratories limited pharmascience inc mallinckrodt plc specgx llc tolmar inc accord healthcare inc follow patent include case begin february janssen inc janssen pharmaceutica nv initiate statement claim section patent medicine notice compliance regulation generic manufacturer file andss seek approval market generic version invega sustenna expiration list patent follow entity name defendants pharmascience inc apotex inc follow canadian patent include case invega trinza begin september janssen pharmaceuticals inc janssen pharmaceutica nv janssen research development llc file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version invega trinza expiration orange book list patent follow entity name defendant mylan laboratories limited mylan pharmaceuticals inc mylan institutional llc follow patent include case district court issue decision find mylan propose generic product infringe assert patent patent invalid mylan appeal verdict symtuza beginning november janssen products lp janssen sciences ireland unlimited company gilead sciences inc gilead sciences ireland uc file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version symtuza expiration certain orange book list patent follow entity name defendant lupin limited lupin pharmaceuticals inc msn laboratories annual report private ltd msn life sciences private ltd msn pharmaceuticals inc apotex inc apotex corp follow patent include case erleada begin aragon pharmaceuticals inc janssen biotech inc collectively janssen sloan kettering institute cancer research ski regents university california file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version erleada expiration certain orange book list patent follow entity name defendant lupin limited lupin pharmaceuticals inc zydus worldwide dmcc zydus pharmaceuticals usa inc zydus lifesciences limited sandoz inc eugia pharma speciality limited aurobindo pharma usa inc auromedics pharma llc hetero labs limited unit v hetero usa inc follow patent include case reissue december janssen ski voluntarily dismiss case lupin limited lupin pharmaceuticals inc uptravi beginning november actelion pharmaceutical inc actelion pharmaceuticals ltd nippon shinyaku co ltd file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version uptravi intravenous expiration certain orange book list patent follow entity name defendant alembic pharmaceutical limit alembic pharmaceuticals inc lupin ltd lupin pharmaceuticals inc cipla limited cipla usa inc msn laboratories private ltd msn pharmaceuticals inc follow patent include case november company enter confidential settlement agreement alembic pharmaceutical limit alembic pharmaceuticals inc spravato beginning janssen pharmaceuticals inc janssen pharmaceutica nv file patent infringement lawsuit united states district court generic manufacturer file anda seek approval market generic version spravato expiration certain orange book list patent follow entity name defendant sandoz inc hikma pharmaceuticals inc usa hikma pharmaceuticals plc alkem laboratories ltd follow patent include case stelara november biocon biologics inc file petition inter parte review uspto seeking review patent relate method treat ulcerative colitis ustekinumab medtech march abiome inc abiome file declaratory judgment action maquet cardiovascular llc maquet district court district massachusetts seek declaration impella infringe certain maquet patent currently patent nos maquet counterclaim infringement patent claim construction maquet allege infringement patent september court grant abiomed motion summary judgment noninfringement patent september district court enter final judgment favor abiome patentsinsuit maquet appeal government proceeding like company pharmaceutical medical technology industry company certain subsidiary subject extensive regulation national state local government agency united states country operate regulation basis government investigation litigation significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation medtech july public prosecution service rio de janeiro representatives brazilian antitrust authority cade inspect office company include johnson johnson brasil indstria e comrcio de produtos para sade ltda authority appear investigate allegation possible anticompetitive behavior possible improper payment medical device industry company continue respond inquiry foreigncorrupt practice act united states department justice united states securities exchange commission july department justice doj issue civil investigative demand company johnson johnson surgical vision inc johnson johnson vision care inc collectively jj vision connection civil investigation false claim act relate free discount intraocular lense equipment eye surgery phacoemulsification laser system jj vision begin produce document information responsive civil investigative demand jj vision ongoing discussion doj inquiry innovative medicine july company janssen product lp serve qui tam complaint pursuant false claim act file united states district court district new jersey allege offlabel promotion hiv product prezista intelence antikickback violation connection promotion product complaint file seal december federal state government decline intervene lawsuit prosecute relator court deny summary judgment claim december daubert motion grant deny january case proceed trial trial schedule march janssen biotech inc jbi receive civil investigative demand united states department justice false claim act investigation concern management advisory service provide rheumatology gastroenterology practice purchase remicade simponi aria august united states department justice notify jbi closing investigation subsequently united states district court district massachusetts unseal qui tam false claim act complaint serve company department justice decline intervene qui tam lawsuit august company file motion dismiss grant deny discovery underway time time company receive request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request information general litigation company subsidiary party proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek company agreement implement remediation activity designate hazardous waste site reimburse government party cost incur perform remediation site october certain united states service member family bring complaint number pharmaceutical medical device company include johnson johnson certain subsidiary united states district court district columbia allege defendant violate united states antiterrorism act complaint allege defendant provide fund terrorist organization sale practice pursuant pharmaceutical medical device contract iraqi ministry health july district court dismiss complaint january united states court appeal district columbia circuit reverse district court decision june defendant file petition writ certiorari united states supreme court february putative class action file company pension benefit committee johnson johnson certain name officer employees united states district court district new jersey complaint allege defendant breach fiduciary duty employee retirement income security act erisa allegedly mismanage company prescriptiondrug benefit program complaint seek damage relief medtech october fortis advisor llc fortis capacity representative stockholder auris health inc auris file complaint company ethicon inc certain name officer employee collectively ethicon court chancery state delaware complaint allege breach contract fraud cause action ethicon connection ethicon acquisition auris complaint seek damage relief december court grant deny defendant motion dismiss certain cause action claim individual defendant dismiss trial hold january decision pende annual report innovative medicine june united states federal trade commission ftc issue civil investigative demand company janssen biotech inc collectively janssen connection investigation janssen remicade contracting practice violate federal antitrust law company produce document information responsive civil investigative demand janssen ongoing discussion ftc staff inquiry february united states federal trade commission ftc issue civil investigative demand johnson johnson janssen biotech inc collectively janssen connection investigation advertising practice remicade violate federal law janssen produce document information responsive civil investigative demand janssen ongoing discussion ftc staff inquiry june genmab file notice arbitration international institute conflict prevention resolution cpr janssen biotech inc seek milestone extend royalty term darzalex faspro april arbitration panel rule janssen favor dismiss genmab claims january genmab appeal dismissal deny october separate putative class action file actelion pharmaceutical ltd actelion pharmaceutical inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violate state federal antitrust unfair competition law allegedly refuse supply generic pharmaceutical manufacturer sample tracleer tracleer subject risk evaluation mitigation strategy require food drug administration impose restriction distribution product january plaintiff dismiss district columbia case file consolidated complaint united states district court district maryland december putative class action lawsuit file company janssen biotech inc collectively janssen united states district court eastern district virginia complaint allege janssen violate federal state antitrust law state law delay biosimilar competition stelara janssen enforcement patent right cover stelara complaint seek damage relief june janssen pharmaceuticals inc file demand arbitration emergent biosol ution inc et al ebsi american arbitration association allege ebsi breach party manufacture service agreement company covid vaccine july emergent file answer statement counterclaim hear schedule july restructure fiscal company commence restructuring action innovative medicine medtech segment amount detail current year program include fiscal company complete prioritization research development rd investment innovative medicine segment focus promise medicine great benefit patient result exit certain program certain therapeutic area rd program exit primarily infectious disease vaccine include discontinuation respiratory syncytial virus rsv adult vaccine program hepatitis hiv development pre tax restructuring expense million fiscal year include termination partner nonpartnere development program cost asset impairment estimate cost total activity million million expect complete end fiscal year fiscal company initiate restructure program orthopaedic franchise medtech segment streamline operation exit certain market product line distribution network arrangement pretax restructure expense million fiscal year primarily include inventory instrument charge relate market product exit estimate cost total program million million expect complete end fiscal year follow table summarize restructuring expense fiscal year pretax dollar million innovative medicine segment medtech segment total program include million restructuring million cost product sell consolidated statement earning include million restructuring million cost product sell consolidated statement earning restructuring reserve december january insignificant annual report kenvue separation discontinue operation kenvue complete initial public offering ipo result issuance share common stock par value share kenvue common stock initial public offering share net proceed billion excess net proceed ipo net book value johnson johnson divest interest billion record additional paidin capital closing ipo johnson johnson own approximately total outstanding share kenvue common stock july noncontrolle interest billion associate kenvue reflect equity attributable noncontrolle interest consolidate balance sheet fiscal second quarter august johnson johnson complete disposition additional ownership kenvue common stock exchange offer result johnson johnson acquire share companys common stock exchange share kenvue common stock billion johnson johnson common stock receive exchange offer record treasury stock follow exchange offer company own total outstanding share kenvue common stock record asset continue operation fair market value billion august subsequent change reflect incomeexpense amount billion expense december johnson johnson divest net asset billion august accumulate comprehensive loss attributable consumer health business date billion additionally date exchange offer johnson johnson decrease noncontrolle interest billion record deconsolidation kenvue result noncash gain exchange offer billion record net earning discontinue operation net taxis consolidate statement earning fiscal quarter onetime gain include gain billion kenvue common stock retain johnson johnson gain exchange offer qualifie taxfree transaction federal income tax purpose connection separation johnson johnson kenvue enter separation agreement enter agreement provide certain transaction effect transfer asset liability consumer health business kenvue govern interim ongoing relationship kenvue johnson johnson follow completion kenvue ipo include transition service agreement tsas transition manufacturing agreement tmas trademark agreement intellectual property agreement employee matter agreement tax matter agreement tsas johnson johnson provide kenvue service similarly kenvue provide johnson johnson service provision service tsa generally terminate month follow kenvue ipo additionally johnson johnson kenvue enter tmas pursuant johnson johnson manufacture supply kenvue certain product similarly kenvue manufacture supply johnson johnson certain product term tmas range initial duration month year amount related tsas tma include consolidated statement earning immaterial fiscal year additionally amount kenvue agreement material december result consumer health business previously report separate business segment associate gain reflect discontinued operation company consolidated statement earning net earning discontinue operation net taxis prior period recast reflect presentation result separation kenvue johnson johnson incur separation cost million million million fiscal year respectively include net earning discontinue operation net taxis cost primarily relate external advisory legal accounting contractor incremental cost directly relate separation activity fiscal plan separation company consumer health business company recognize approximately billion net incremental tax cost january asset liabilities associate consumer health business classify asset liability discontinue operation consolidated balance sheet detail net earning discontinue operation net taxis follow dollar million sale customer cost product sell gross profit selling marketing administrative expense research development expense interest income interest expense net portion capitalize income expense net gain separation kenvue restructuring earning discontinue operation provision taxis income provision taxis income net earning discontinue operation company cease consolidate result consumer health business august date exchange offer continue reflect separation cost incur discontinue operation end fiscal fourth quarter follow table present depreciation amortization capital expenditure discontinue operation relate kenvue dollar million depreciation amortization capital expenditure annual report detail asset liability discontinue operation follow january asset cash cash equivalent account receivable trade allowance doubtful account inventory prepaid expense receivables total current asset discontinue operation property plant equipment net intangible asset net goodwill defer taxis income asset total noncurrent asset discontinue operation liability loan note payable account payable accrue liability include accrue taxis income accrue rebate return promotions accrue compensation employee relate obligation total current liability discontinue operation longterm debt defer taxis income employee relate obligation liability total noncurrent liability discontinue operation select quarterly financial datum unaudite select unaudited quarterly financial datum recast discontinue operation year summarize dollar million second fourth second fourth share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer innovative medicine medtech total sale gross profit earning loss provision taxis income net earning loss continue operation net earning loss discontinue operation net tax net earning loss basic net earningsloss share basic net earning loss share continue operation basic net earning loss share discontinue operation basic net earning loss share dilute net earning loss share dilute net earning loss share continue operation dilute net earning loss share discontinue operation dilute net earning loss share fiscal quarter include billion charge relate talc matter fiscal quarter include noncash gain exchange offer billion record net earning discontinue operation net taxis billion relate unfavorable change fair value retain stake kenvue billion relate partial impairment idorsia convertible debt change fair value idorsia equity security hold fourth quarter include favorable change fair value security billion fiscal quarter company record intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj fiscal fourth quarter include onetime covid vaccine relate exit cost billion annual report report independent register public accounting firm board director shareholders johnson johnson opinions financial statement internal control financial reporting audit accompany consolidated balance sheet johnson johnson subsidiaries company december january relate consolidated statement earning comprehensive income equity cash flow fiscal year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december january result operation cash flow fiscal year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company consolidate financial statement company internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deterioratecritical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement ii involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate pharmaceutical rebate reserve manage care medicare medicaid describe note consolidated financial statement company recognize revenue product sale obligation term contract customer satisfy rebate discount provide customer account variable consideration record reduction sale liability rebate discount recognize accrue rebate return promotion consolidate balance sheet significant portion liability relate rebate sale pharmaceutical good primarily manage care medicare medicaid program amount billion december significant rebate program include manage care medicare medicaid rebate program rebate discount estimate management base contractual term historical experience patient outcome trend analysis project market condition pharmaceutical market principal consideration determination perform procedure relate pharmaceutical rebate reserve manage care medicare medicaid critical audit matter significant judgment management significant measurement uncertainty involve develop reserve high degree auditor judgment subjectivity audit effort perform procedure evaluate assumption relate contractual term historical experience patient outcome trend analysis project market condition pharmaceutical market addressing matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate pharmaceutical rebate reserve manage care medicare medicaid include control assumption estimate rebate procedure include develop independent estimate rebate utilize party information price market condition pharmaceutical market term specific rebate program historical experience trend analysis actual rebate claim pay ii testing rebate claim process company include evaluate claim consistency contractual mandate term company rebate arrangement iii compare independent estimate management estimate litigation contingency talc describe note consolidated financial statement company record accrual loss contingency associate legal matter include talc probable liability incur loss reasonably estimate extent adverse award judgment verdict render company management record accrual loss determine probable reasonably estimate matter management unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption include time relate payment ability estimate judgment affect factor include thing damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute procedural jurisdictional issue uncertainty unpredictability number potential claim ability achieve comprehensive multiparty settlement complexity relate crossclaim counterclaim andor numerous party involve management continue believe company strong legal ground contest talc verdict appeal notwithstanding management confidence safety company talc product certain circumstance company settle case company recognize total provision approximately billion approximately onethird record current liability encompass actual contemplate settlement record remain company good estimate probable loss dismissal party reach resolution talc matter company unable estimate possible loss range loss remain accrue principal consideration determination perform procedure relate talc litigation critical audit matter significant judgment management assess likelihood loss incur determine reasonable estimate loss range loss future exist talc claim determine timing settlement payment turn lead high degree auditor judgment subjectivity effort perform procedure evaluate management assessment loss contingency associate litigation annual report address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate management evaluation talc litigation include control determine loss probable loss reasonably estimate financial statement disclosure procedure include gain understanding company process accounting report talc litigation ii obtain evaluate certain execute settlement agreement relate talc litigation iii discuss status significant know actual potential litigation settlement activity company inhouse legal counsel external counsel deem necessary iv obtain evaluate letter audit inquiry internal external legal counsel significant litigation v evaluate reasonableness management assessment unfavorable outcome reasonably possible probable reasonably estimable vi evaluate sufficiency company litigation contingency disclosure pricewaterhousecooper llp florham park new jersey february serve company auditor able determine specific year begin serve auditor company management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear j duato j j wolk joaquin duato joseph j wolk chairman board director executive vice president chief financial officer chief executive officer annual report shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors healthcare equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poor healthcare equipment index dividend reinveste year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnson johnson sp index sp pharmaceutical index sp healthcare equipment index annual report item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure joaquin duato chairman chief executive officer joseph j wolk executive vice president chief financial officer review participate evaluation base evaluation messrs duato wolk conclude end period cover report company disclosure control procedure effective report internal control financial reporting information call item incorporate reference management report internal control financial reporting attestation internal control financial reporting include report independent register public accounting firm include item report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting company continue monitor assess effectiveness design operation disclosure control procedure company implement multiyear enterprisewide initiative integrate simplify standardize process system human resource information technology procurement supply chain finance function enhancement support growth company financial share service capability standardize financial system initiative response identify deficiency weakness company internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information security trading plan director executive officer fiscal fourth quarter director officer define rule af exchange act inform adoption termination rule b trading arrangement nonrule b trading arrangement define item regulation sk item c disclosure foreign jurisdiction prevent inspection applicable iii item director executive officer corporate governance information call item incorporate reference discussion audit committee caption item election director board committee material caption item election director applicable delinquent section report proxy statement material caption executive officer registrant report company code business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act code business conduct available company website wwwjnjcomcodeofbusinessconduct copy available shareholder charge write request secretary company principal executive office substantive amendment code business conduct waiver code grant chief executive officer chief financial officer controller post company website wwwjnjcomcodeofbusiness conduct business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company website wwwinvestorjnjcomgovernancecorporategovernanceoverviewcodeofbusinessconductethics copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovernancecorporategovernanceoverview codeofbusinessconductethic business day retain website year item executive compensation information call item incorporate reference material caption item election director director compensation item compensation committee report compensation discussion analysis executive compensation table proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent company specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption item stock ownership proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement item report annual report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan number security weight average number security issue exercise price remain available exercise outstanding future issuance outstanding option equity compensation plan category option right right plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder longterm incentive plan longterm incentive plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption item election director relate person transaction director independence proxy statement item principal accountant fee service information call item incorporate reference material caption item ratification appointment independent register public accounting firm proxy statement iv item exhibit financial statement schedule follow document file report financial statement consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidate statement comprehensive income fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm schedule omit applicable require information include financial statement note exhibit require file item l regulation sk information call item incorporate reference exhibit index report item summary registrant voluntarily include summary information require item company elect include summary information annual report signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant j duato j duato chairman board chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date j duato chairman board february j duato chief executive officer principal executive officer j j wolk chief financial officer february j j wolk principal financial officer r j decker jr controller chief accounting officer february r j decker jr principal accounting officer adamczyk director february adamczyk c beckerle director february c beckerle davis director february davis j doudna director february j doudna signature title date hewson director february hewson p johnson director february p johnson h joly director february h joly b mcclellan director february b mcclellan mulcahy director february mulcahy weinberger director february weinberger n west director february n west e woods director february e woods annual report exhibit index reg sk exhibit table description item exhibit agreement plan merger date october johnson johnson athos merger sub inc abiome inc incorporate reference exhibit registrant form k current report file november restate certificate incorporation effective february incorporate reference exhibit registrant annual report fiscal year end january ii certificate amendment certificate incorporation johnson johnson effective april incorporate reference exhibit registrant form k current report file april iii bylaw company amend effective june incorporate reference exhibit registrant form k current report file june request securities exchange commission registrant furnish copy instrument define right holder longterm debt registrant b description security register pursuant section security exchange act incorporate reference exhibit registrant form k current report file august longterm incentive plan incorporate reference appendix registrant proxy statement file march b form stock option certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april c form restrict share unit certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april form performance share unit certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april e global nonqualified stock option award agreement longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april f global restrict share unit award agreement longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april g global performance share unit award agreement longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end april h global restrict share unit award agreement grant john reed longterm incentive plan file document domestic defer compensation certificate extra compensation plan incorporate reference exhibit g registrant annual report year end december j amendment certificate extra compensation plan effective january incorporate reference exhibit j registrant annual report year end december k certificate longterm performance plan incorporate reference exhibit registrant form q quarterly report quarter end september l amend restate deferred fee plan director amend january incorporate reference exhibit k registrant annual report fiscal year end january reg sk exhibit table description item exhibit johnson johnson executive income deferral plan amend restate effective january incorporate reference exhibit registrant form q quarterly report quarter end september n johnson johnson excess saving plan amend restate january incorporate reference exhibit l registrant annual report fiscal year end january excess benefit plan johnson johnson affiliate company amend restate january incorporate reference exhibit n registrant annual report fiscal year end january p executive life plan agreement incorporate reference exhibit registrant annual report fiscal year end january q executive life plan agreement closure letter incorporate reference exhibit registrant form q quarterly report quarter end march r longterm incentive plan incorporate reference appendix registrant proxy statement file march severance pay plan johnson johnson affiliate company amend restate october incorporate reference exhibit registrant form q quarterly report quarter end september amendment severance pay plan johnson johnson affiliate company amend restate effective october incorporate reference exhibit registrant form q quarterly report quarter end june u second amendment severance pay plan johnson johnson affiliate company amend restate effective october incorporate reference exhibit x registrant annual report fiscal year end january v contingent value right agreement date december johnson johnson american stock transfer trust company llc incorporate reference exhibit registrant form k current report file december w separation agreement date johnson johnson kenvue inc x tax matter agreement date johnson johnson kenvue inc employee matter agreement date johnson johnson kenvue inc z intellectual property agreement date johnson johnson kenvue inc aa trademark phaseout license agreement date april johnson johnson johnson johnson consumer inc ab transition service agreement date johnson johnson kenvue inc ac transition manufacturing agreement date johnson johnson kenvue inc ad registration right agreement date johnson johnson kenvue inc ae johnson johnson defer compensation plan af global performance share unit award agreement annual report reg sk exhibit table description item exhibit ag global restrict share unit award agreement ah global nonqualified stock option award agreement ai amendment johnson johnson excess saving plan amend restate effective january incorporate reference exhibit registrant form q quarterly report quarter end october aj johnson johnson executive incentive plan amend september incorporate reference exhibit registrant form q quarterly report quarter end october johnson johnson stock trading policy director executive officer insider amend april file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document certification chief financial officer pursuant section sarbanesoxley act furnish document johnson johnson clawback policy effective august file document exhibit exin instance document instance document appear interactive datum file xbrl tag embed inline xbrl document exsch inline xbrl taxonomy extension schema excal inline xbrl taxonomy extension calculation linkbase exlab inline xbrl taxonomy extension label linkbase expre inline xbrl taxonomy extension presentation linkbase exdef inline xbrl taxonomy extension definition document exhibit cover interactive datum filethe cover interactive datum file appear interactive datum file xbrl tag embed inline xbrl document management contract compensatory plan paper file certain exhibit schedule omit pursuant item bii biv regulation sk applicable copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive offices company pursuant item b iiia regulation sk company file exhibit certain longterm debt instrument include indenture total security authorize exceed total asset company subsidiary consolidate basis company agree furnish copy instrument sec request exhibit h johnson johnson longterm incentive plan global restrict share unit award agreement grant john christian reed grant grant type unit schedule vest date reed restrict share unit reed restrict share unit reed restrict share unit addition condition establish committee sole discretion consideration grant award term johnson johnson longterm incentive plan amend time time plan agree follow grant restrict share unit award subject term condition global restrict share unit award agreement include countryspecific term appendix hereto exhibit addendum document collectively agreement plan johnson johnson new jersey corporation corporation grant abovestate number restrict share unit rsus vested subject term condition agreement vest rsu receive share common stock corporation par value share common stock cash lieu thereof case subject accordance term section agreement context clearly indicate capitalize term shall definition assign agreement extent agreement define capitalize term plan rsus grant subject term condition plan term plan incorporate reference b condition grant rsus condition electronically accept grant website plan recordkeeper manner corporation establish permit time time ii opening maintain brokerage account permit use respect award grant plan case deadline establish corporation andor set forth website plan recordkeeper accept grant rsus confirmedyour acceptance allof term condition agreement accept grant rsus applicable deadline grant cancel vest rsus competition corporation group general provide section rsus grant shall vested abovestate schedule vest date accordance schedule set forth provide respect rsu employ applicable schedule vest date employ time grant date ii comply compliance term agreement determine corporation sole discretion b termination employment general prior applicable schedule vest date cease employ reason provide section c certain termination disability rsus shall forfeit consideration date termination c certain termination disability termination employment death die employ rsus shall immediately vested date death extent outstanding vest estate beneficiary person acquire rsus inheritance devise applicable shall receive number share common stock cash lieu thereof provide section settlement rsus tax withholding compliance security law compliance compensation recoupment policy ii disability disabled employ shall immediately vested rsus extent outstanding vest date disability iii termination cause limit generality section b notwithstanding provision section c cease employ reason include limitation result voluntary resignation connection follow occurrence event constitutes cause rsus award hold plan shall immediately forfeit consideration date termination follow date termination corporation aware conduct activity occur follow employment constituted cause rsus portion thereof award hold plan unvested unexercised payment benefit respect thereto date corporation aware conduct activity shall forfeit iv corporation determination event termination employment determination reason termination applicable treatment section shall corporation sole discretion competition corporation group order protect corporation group goodwill investment research development customer businessrelationship prevent disclosure corporation group confidential trade secret information promote longterm success corporation group business agree follow employment prior write consent corporation directly indirectly engage competitive activity ii period eighteen month follow date termination prior write consent corporation directly indirectly perform assist perform work competitor position geographic location disadvantage corporation group advantage competitor disclosure use corporation group confidential trade secret information andor b use corporation group customer relationship goodwill iii rescission forfeiture understand agree corporation determine violate section di andor section dii andor non competition nonsolicitation agreement member corporation group addition injunctive relief damage equitable legal right remedy rsus shall forfeit consideration early date violation section di andor section dii noncompetition nonsolicitation agreement member corporation group b corporation demand shall immediately deliver corporation number share common stock equal number rsus vest settle form common stock avoidance doubt reduction share common stock withhold andor sell satisfy applicable withholding taxis ii gross cash pay avoidance doubt reduction amount withhold satisfy applicable withholding taxis rsus settle form cash case respect rsus vest month period time immediately precede early date violation section di andor section dii noncompetition non solicitation agreement member corporation group extent date corporation demand repayment hold number share common stock sufficient satisfy obligation set forth clause shall pay corporation cash equal result x number share require deliver corporation pursuant clause ii number share actually deliver corporation pursuant clause multiply fair market value share common stock business day immediately precede date corporation demand repayment agree deliver execute document include applicable share certificate corporation deem necessary effect repayment obligation refer section diiib iv understand agree remedy set forth section diii shall corporation group exclusive remedy event breach noncompetition obligation set forth section di andor section dii applicable noncompetition nonsolicitation agreement member thecorporation group corporation group reserve right remedy available law equity e condition vest follow termination employment eligibility vest rsus follow date termination employment shall subject compliance noncompetition obligation section di andor section dii andor applicable noncompetition nonsolicitation agreement member corporation group ii required member corporation group time termination employment execution separation agreement andor general release claim favor corporation subsidiary affiliate contain provision form require corporation group effective prior late date settlement rsus set forth section early date corporation group require event separation agreement andor release claim require corporation group rsus vest date termination ii vest date fall period provide release claim b period rsus settle pursuant section span calendar year settlement vest rsus second calendar year right common stock prior delivery share common stock pursuant section applicable shall right respect share common stock underlie rsus include limited voting right right receive dividend dividend equivalent pay distribution respect common stock settlement rsus tax withholding compliance security law compliance compensation recoupment policy general subject term agreement day follow vest date event later march th occur receive corporation share common stock rsu vest date discretion committee cash equivalent fair market value vest date reduce share common stock withhold sell cash withhold satisfy applicable federal state local income taxis social insurance payroll tax fringe benefit tax payment account taxrelate item relate participation plan legally applicable deem applicable taxrelated item determined corporation lieu forego corporation applicable member corporation group determine withholding taxrelated item shall satisfied method permit plan notwithstanding forego section officer corporation securities exchange act amend corporation satisfy applicable tax withholding obligation withholding share common stock relevant taxable event withholding obligation determine base applicable statutory withholding rate regard section c internal revenue code amend determined committee b registration list notwithstanding section hereof share common stock shall issue pursuant agreement vest date effect current registration statement amendment thereto security act asamende cover share common stock issue vest rsus share authorize list new york stock exchange security exchange determine corporation shall deem require corporation apply effect obtain registration list c compensation recoupment policy acknowledge agree rsus include cash andor share common stock deliver pursuant rsus subject corporation compensation recoupment policy amend andor restate time time current copy find corporation website httpwwwinvestorjnjcomgovcompensationrecoupmentpolicycfm term condition compensation recoupment policy incorporate reference agreement nontransferability rsus rsus right grant hereunder sell transfer assign pledge hypothecate way operation law law descent distribution accordance beneficiary designation procedure establish corporation shall right subject execution attachment similar process accordance term plan attempt sell transfer assign pledge hypothecate dispose rsus right grant contrary provision plan agreement levy attachment similar process rsus right rsus right shall election corporation forfeit consideration special employment right right award contain plan agreement shall construe deem person circumstance bind member corporation group continue employment vest period period create right employment corporation form amend employment service contract corporation interfere way right member corporation group terminate employment time acknowledge agree plan establish voluntarily corporation discretionary nature modify amend terminate corporation time provide plan ii participation plan voluntary voluntarily accept grant rsus iii rsus share common stock subject rsus income value constitute normal expect compensation salary purpose include limited calculate severance resignation termination indemnity redundancy dismissal endofservice payment bonuse longservice award pension retirement benefit welfare benefit similar payment event consider compensation way relate past service corporation group iv rsus share common stock subject rsus income value intend replace pension right compensation v grant rsus exceptional voluntary occasional create contractual right receive future grant rsus benefit lieu rsus rsus grant past vi agree corporation rsus share common stock subject rsus income value grant consideration connection service provide director subsidiary corporation vii future value underlie share common stock unknown indeterminable predict certainty viii noclaim entitlement compensation damage shall arise forfeiture recoupment rsu result termination employment service relationship regardless reason termination later find invalid breach employment law jurisdiction employ term employment agreement ix shall seek necessary approval required notification comply law rule regulation applicable ownership rsus applicable share common stock include currency exchange law rule regulation x corporation subsidiary affiliate shall liable foreign exchange rate fluctuation local currency dollar affect value rsus amount pursuant settlement rsus subsequent sale share common stock acquire settlement xi determination form award grant plan committee sole discretion xii corporation provide tax legal financial advice corporation make recommendation participation plan acquisition sale underlie share common stock consult personal tax legal financial advisor participation plan take action relate rsus notice corporation notifie write notice designation payment submit corporation connection rsus shall address equity compensation resource johnson johnson plaza new brunswick nj usa definition follow capitalize term shall definition set forth purpose agreement cause mean conviction plea nolo contendere commission felony federal state law ii act corporation opinion constitute fraud embezzlement dishonesty disclosure confidential information willful deliberate failure perform employment duty material respect conflict interest violation noncompetition obligation set forth section di agreement applicable noncompetition nonsolicitation confidentiality agreement obligation member corporation group violation standard conduct policy policy corporation group subject event inimical contrary good interest corporation group determination cause shall corporation sole discretion determination shall final bind b committee mean compensation benefit committee board director corporation successor committee person person committee delegate authority administer construe interpret term plan pursuant section planc competitor mean person entity include limited act behalf engage prepare engage research development production manufacturing marketing selling consulting product process technology machine invention service existence development resemble compete future compete substitute market substitute product process technology machine invention service corporation group existence plan development corporation shall determine individual entity competitor sole discretion determination shall final competitive activity mean activity include preparation compete intend compete adversely affect interfere corporation group business advantage competitor immediately future corporation shall determine conduct constitute competitive activity sole discretion determination shall final e corporation group mean corporation subsidiary affiliate determine corporation f customer mean entity client account person include employee agent representative forego entity person participate influence responsibility make purchasing decision behalf entity client account person contact solicit business sell render service assign responsibility receive commission compensation promote marketed product service eighteen month period time precede date termination corporation shall determine individual entity customer sole discretion determination shall final g date termination mean date employment terminate h disability disabled mean determine unable work disability last period excess twentysix week ii entitle longterm disability benefit longterm disability policy corporation applicable affiliate cover b policy determine disabled similar status corporation applicable affiliate accordance applicable procedure policy notwithstanding forego consider incurred disability identify disabled similar status accordance personnel andor human resource policy corporation applicable affiliate effect time time ii rsus subject section determine corporation consider incurred disability condition constitute disability mean treasury regulation section ai employ employment mean period time employee corporation group good standing determine corporation group accordance applicable practice policy record provide periodyou active employment status corporation group ii corporation groupapprove leave absence determined corporation group sole discretion avoidance doubt shall consider employ x period consider employee good stand pursuant corporation group practice policy record notice period salary continuation period require contract practice local law garden leave similar period severance period cover severance agreement arrangement z period leave approve corporation group determined corporation group sole discretion j grant date mean date rsus grant identify agreement k vest date mean respect rsu early extent applicable applicable schedule vest date ii date death event termination employment pursuant section ci termination death iii date disabled event disability describe section cii disability x date rsus vest payable pursuant applicable provision plan provide rsus subject section determine corporation payment occur early permissible date determine corporation result accelerate taxation andor tax penalty section miscellaneous amendment provide agreement amend modify evidence writing sign authorize representative corporation b thirdparty beneficiary acknowledge agree affiliate subsidiary corporation result future acquisition merger assignment interest employment compliance obligation section competition corporation group entity express thirdparty beneficiary agreement c bind effect agreement shall inure benefit bind party hereto respective heir executor administrator successor assign severability event section competition corporation group agreement invalidate enforce applicable law shall affect validity enforceability remain provision agreement plan extent section agreement unenforceable deem overbroad provision shall apply enforce limited manner full extent permissible applicable law understand agree event section agreement declare invalid void overbroad unenforceable reason shall remain bound noncompetition confidentiality nonsolicitation andor nondisclosure agreement previously enter member corporation groupe appendix notwithstanding provision agreement rsus shall subject additional term condition set forth appendix country relocate country include appendix additional term condition country apply extent corporation determine application term condition necessary advisable legal administrative reason appendix constitute agreement f data privacy consent accept grant unconditionally consent collection use transfer electronic form personal datum describe document applicable employing entity employer corporation corporation group exclusive purpose implement administer managing award issue plan understand corporation employer hold certain personal information include limited home address email address telephone number date birth social insurance number identification number salary nationality job title detail rsus entitlement share stock award cancel vest unvested outstanding favor datum purpose implement administer managing grant issue plan understand datum transfer party select corporation assist implementation administration management plan fulfillment agreement understand recipient datum locate united states recipient country different datum privacy law protection country understand reside outside united states request list name address potential recipient datum contact local human resource representative authorize recipient assist corporation presently future implement administering managing plan receive possess use retain transfer datum electronic form purpose implement administer managing grant plan fulfillment agreement understand datum hold long necessary implement administer manage grant plan agreement understand reside outside united states time view datum request information storage processing datum require necessary amendment datum refuse withdraw consent case cost contact write human resource representative understand consent provide purely voluntary basis consent later seek revoke consent employment status service affect consequence refuse withdraw consent corporation able grant rsus equity award administer maintain award understand refuse withdraw consent affect ability participate plan information consequence refusal consent withdrawal consent understand contact local human resource representative g entire agreement agreement plan constitute entire agreement party relate subject matter hereof previous agreement understand party respect thereto supersede agreement planh section intent party payment benefit agreement comply section internal revenue code amend regulation guidance issue thereunder section extent subject thereto accordingly maximum extent permit agreement shall interpret administer compliance therewith notwithstanding contrary plan agreement corporation reserve right revise agreement deem necessary advisable sole discretion consent comply section avoid imposition additional tax income recognition section prior actual payment cash share common stock pursuant rsus corporation make representation rsus subject section make undertaking preclude section apply rsus corporation shall liability plan agreement taxis penaltie interest amount pay payable pursuant plan agreement include taxis penaltie interest impose section purpose plan agreement extent necessary avoid accelerate taxation andor tax penalty section termination employment shall deem occur purpose settlement portion rsus termination constitute separation service meaning section purpose provision agreement reference termination termination employment similar term shall mean separation service pay agreement shall construed separately identify payment purpose section addition notwithstanding contrary deem date termination specify employee mean term section subject federal taxation extent settlement rsus follow termination employment consider payment nonqualifie defer compensation section payable account separation service exempt section settlement shall delay date early expiration sixmonth period measure date separation service ii date death acknowledgement elect accept agreement acknowledge receipt agreement confirm understand term set forth agreement event conflict term plan agreement term plan shall control corporation sole discretion decide deliver document include limitation information require deliver pursuant applicable security law relate current future participation plan electronic mean consent receive document electronic delivery agree participate plan online electronic system establish maintain corporation party designate corporation j language acknowledge proficient english language consult advisor proficient english language enable understand provision agreement plan receive agreement document relate plan translate language english mean translate version different english version english version controlk imposition requirement corporation reserve right impose requirement participation plan rsus share common stock acquire plan extent corporation determine necessary advisable order comply local law facilitate administration plan correction adjustment deem necessary appropriate require sign additional agreement undertaking necessary accomplish forego l waiver acknowledge waiver corporation breach provision agreement shall operate construe waiver provision agreement subsequent breach grantee govern law agreement shall govern construe accordance law state new jersey give effect conflict law principle extent supersede federal law set forth section provide primarily reside work california connection employment corporation group time accept agreement participation plan agreement shall govern construe accordance law state california ii section dii shall apply respect service render california involve use disclosure corporation group confidential trade secret information n submission jurisdiction waiver jury trial litigation bring party agreement shall bring federal state court locate state new jersey party submit exclusive jurisdiction court purpose litigation provide final judgment litigation shall conclusive enforce jurisdiction suit judgment matter provide law party agree assert objection venue federal state court locate state new jersey b claim litigation bring inconvenient forum c claim court jurisdiction respect litigation party waif right trial jury respect matter arise agreement award grant plan johnson johnson carolyn hoenish carolyn hoenisch senior finance director saving plan pension equity compensation operation johnson johnson johnson johnson plaza new brunswick nj usa appendix acountryspecific provision participant outside certain capitalize term define appendix shall meaning set forth plan andor agreement appendix attach term condition appendix include additional term condition govern rsus grant plan applicable law resident deem resident work country list furthermore additional term condition govern rsus grant hereunder apply transfer employment andor residency country list corporation shall discretion determine extent term condition contain shall apply notification appendix include notification relate exchange control security issue aware respect participation plan information base exchange control security law effect respective country october law complex change frequently result corporation strongly recommend rely notification source information relate consequence participation plan information outdate vest rsus acquire share common stock plan subsequently sell share common stock acquire plan addition notification general nature apply particular situation corporation position assure particular result accordingly strongly advise seek appropriate professional advice relevant law country apply situation finally citizen resident country currently reside andor working consider resident country local law purpose information contain applicable subject provision jurisdiction nonus jurisdiction notification insider trading restrictionsmarket abuse law acknowledge depend broker country residence share common stock list subject insider trading restriction andor market abuse law affect ability accept acquire sell dispose share common stock right share common stock eg rsus right link value share common stock eg phantom awards future time consider inside information corporation define law regulation country local insider trading law regulation prohibit cancellation amendment order place possess inside information furthermore prohibit disclose inside information party ii tip party causingthem buy sell security mind party include fellow employee restriction law regulation separate addition restriction impose applicable insider trading policy corporation acknowledge responsibility comply restriction advise speak personal advisor matter foreign assetaccount report country residence certain foreign asset andor account reporting requirement affect ability acquire hold share common stock plan cash receive participate plan include sale proceed arise sale share common stock brokerage bank account outside country require report account asset transaction tax authority country require repatriate sale proceed fund receive result participation plan country designate broker bank andor certain time receipt acknowledge responsibility comply regulation understand agree consult personal legal advisor detail european union european economic area country switzerland united kingdom term condition datum privacy follow provision replace section f data privacy consent agreement entirety corporation principal executive office johnson johnson plaza new brunswick new jersey usa controller responsible processing personal datum corporation party note data collection usage pursuant applicable datum protection law notify corporation collect process use certain personal information legitimate purpose implement administer managing plan generally administer award specifically home address email address date birth hire date rehire date applicable termination date applicable employee identification number work country pay frequency associate legal entity management report company share directorship hold corporation detail award entitlement share common stock award cancel exercise vested outstanding favor corporation receive employer personal datum grant rsus plan corporation collect process use disclose transfer collectively process personal datum purpose implement administer managing plan corporation legal basis process personal data corporation legitimate business interest manage plan administer award comply contractual statutory obligation necessity processing corporation perform contractual obligation agreement plan refusal provide personal datum impossible corporation perform contractual obligation affect ability participate plan byaccepte rsus voluntarily acknowledge process personal datum describe b stock plan administration service provider corporation transfer personal datum fidelity stock plan service llc fidelity independent service provider base relevant united states assist corporation implementation administration management plan future corporation select different service provider share personal datum company serve similar manner corporation service provider open account receive trade share common stock pursuant rsus processing personal datum place electronic nonelectronic mean personal datum accessible individual require access purpose implement administer operating plan receive personal datum applicable fidelity provide appropriate safeguard accordance eu standard contractual clause appropriate crossborder transfer solution participating plan understand service provider process personal datum purpose implement administer manage participation plan c international datum transfer plan rsus administer united states mean necessary personal datum transfer process united states transfer personal datum united states corporation provide appropriate safeguard accordance eu standard contractual clause appropriate crossborder transfer solution request copy appropriate safeguard fidelity corporation contact local human resource representative contact datum protection officer responsible country region applicable emailing emeaprivacyitsjnjcom datum retention corporation use personal datum long necessary implement administer manage participation plan require comply legal regulatory obligation include tax security law period extend point service corporation long need personal datum relate plan corporation remove system corporation keep personal datum long satisfy legal regulatory obligation corporation legal basis compliance relevant law regulation datum retention corporation use personal datum long necessary implement administer manage participation plan require comply legal regulatory obligation include tax security law period extend point service corporation long need personal datum relate plan corporation remove system corporation keep personal datum long satisfy legal regulatory obligation corporation legal basis compliance relevant law regulation e datum subject right extent provide law right subject certain exception request access copy personal datum corporation process ii request rectification incorrect personal datum iii request deletion personal datum iv place restriction process personal datum v lodge complaint competent authority country andor vi request list name andaddresse potential recipient personal datum receive clarification right exercise right contact local human resource representative right object ground relate particular situation process personal datum optout plan case cost contact local human resource representative writing provision personal datum contractual requirement understand consequence refuse provide personal datum corporation able administer rsus grant awards administer maintain award information consequence refusal provide personal datum contact local human resource representative writing contact datum protection officer responsible country region applicable emailing emeaprivacyitsjnjcom right lodge complaint relevant data protection supervisory authority argentina term condition labor law policy acknowledgement provision supplement section special employment right right award agreement accept grant rsus acknowledge agree grant rsus corporation employer sole discretion value rsus share common stock acquire plan shall constitute salary wage purpose argentine labor law include limited calculation labor benefit include limited vacation pay thirteenth salary compensation lieu notice annual bonus disability leave absence payment etc ii termination severance indemnity similar payment notwithstanding forego benefit plan consider salary wage purpose argentine labor law acknowledge agree benefit shall accrue frequently vest date notification security law information rsus underlie share common stock publicly offer list stock exchange argentina australia notifications tax information plan plan subdivision ac income tax assessment act cth act apply subject condition act security law information offer participate plan division corporation act cth note offer share common stock sale person entity resident australia offer subject todisclosure requirement australian law consult personal legal advisor disclosure obligation prior make offer belgium term condition shareholde agreement current belgian tax law understand enter agreement corporation hold share common stock year date share acquire vest rsus plan obtain specific tax treatment income receive plan interested learn information tax treatment plan income check personal tax advisor understand wish advantage specific tax treatment review execute shareholding agreement form provide corporation brazil term condition compliance law accept rsus acknowledge agree comply applicable brazilian law report pay applicable taxis associate receipt vest rsus sale share common stock acquire plan payment dividend share acknowledgement nature plan rsus provision supplement section special employment right right award agreement accept agreement acknowledge make investment decision ii value underlie share common stock fix increase decrease value vest period compensation canada term condition form settlement rsus payable common stock notwithstanding discretion plan contrary agreement rsus provide right resident canada receive cash payment shall pay share common stock condition vest follow termination employment provision replace subsection definition employ employment section agreement period follow date receive write notice termination employment notice period garden leave similar period period pay lieu notice salary continuation period requirement local law include limited statutory law regulatory law andor common lawthe follow provision apply resident quebec datum privacy notice consent provision supplement section f data privacy consent agreement resident quebec authorize corporation corporation representative discuss obtain relevant information personnel professional involve administration operation plan authorize corporation employer corporation group disclose discuss participation plan advisor authorize corporation employer record information employee file finally acknowledge authorize corporation party involve administration plan use technology profiling purpose automated decision impact administration plan notification security law information permit sell share common stock acquire plan designate broker appoint plan provide resale share common stock take place outside canada facilities stock exchange share list share common stock currently list new york stock exchange united states america chile notifications security law information offer conform general ruling n chilean commission financial market cmf offer deal security register registry security registry foreign security cmf security subject oversight issuer obligate provide public information chile foreign security security register cmf security shall subject public offering long register correspond registry security chile fulfill requirement set forth general ruling n cmf esta oferta se acoge la norma de carcter general n de la comision para el mercado financiero de chile la oferta versa sobre valores inscritos en el registro de valores en el registro de valores extranjeros que lleva la comision para el mercado financiero de chile por lo que tale valores estn sujeto la fiscalizacin de sta por tratar de valores inscritos existe la obligacin por parte del emisor de entregar en chile informacin pblica respecto de esos valores esos valores podrn ser objeto de oferta pblica mientras sean inscritos en el registro de valores correspondiente menos que se cumplan las condicione establecidas en la norma de carcter general n de la comision para el mercado financiero de chile chinathe follow term apply individual subject exchange control restriction people republic china prc determine corporation sole discretion term condition restriction vest permit vest share common stock necessary approval plan obtain state administration foreign exchange safe remain place determine corporation sole discretion corporation obligation issue share common stock corporation obtain safe approval safe approval subsequently invalid cease effect time vest rsus corporation reserve right settle rsus cash termination employment event termination employment corporation group corporation require sale share common stock hold share common stock hold issue pursuant award grant plan predecessor plan month follow date termination period require safe understand agree corporation authorize instruct designate broker assist mandatory sale share common stock behalf pursuant authorization expressly authorize designate broker complete sale share understand agree corporation designate broker obligation arrange sale share particular price agree sign agreement form consent reasonably request corporation corporation designate broker effectuate sale share common stock include limitation transfer proceed exchange control matter note cooperate corporation respect matter provide shall permit exercise influence sale occur sale share common stock corporation agree pay cash proceed sale brokerage fee commission subject obligation satisfy applicable tax relate item designate broker account share issue settlement rsus immediately sell acknowledge require maintain share common stock account designate broker select corporation share common stock sell corporation designate broker corporation change designate broker acknowledge agree corporation transfer share common stock issue plan new designate brokerage firm necessary legal administrative reason agree sign documentation necessary facilitate transfer share common stock exchange control requirement understand agree pursuant local exchange control requirement require immediately repatriate cash proceed sale share common stock relate rsus award grant plan predecessor plan china understand applicable law repatriation cash proceed need effectuate special exchange controlaccount establish corporation affiliate subsidiary consent agree proceed sale share common stock transfer special account prior deliver understand corporation face delay convert proceed local currency exchange control restriction china proceed pay dollar local currency corporation discretion proceed pay dollar require set dollar bank account china proceed deposit account proceed pay local currency corporation obligation secure particular currency conversion rate understand corporation face delay convert proceed local currency exchange control restriction china agree bear currency fluctuation risk time share sell time sale proceed distribute special exchange account agree comply requirement impose corporation future order facilitate compliance exchange control requirement china colombia term condition follow supplement section special employment right right award agreement labor law policy acknowledgement accept award rsus acknowledge pursuant article colombia labor code plan relate benefit constitute component salary purpose notifications security law information share common stock subject rsus register colombian registry publicly trade security registro nacional de valore emisore share common stock offer public colombia document construe make public offer security colombia denmark term condition danish stock option act acknowledge receive employer statement translate danish provide comply danish stock option act amend january france term conditionsqualifie tax treatment rsus grant pursuant addendum participant france qualified share unit qualified performance share unit french subplan rsus french subplan rsus modify term plan agreement event conflict term condition french subplan rsus plan agreement french subplan rsus shall prevail grant thereunder corporation undertake representation maintain qualified status rsus underlie share common stock condition vest settlement grant rsus pursuant french subplan rsus irrespective provision agreement case death disability define french subplan rsus rsus subject agreement shall vest prior date year grant date share common stock shall issue settlement vest rsus prior date year grant date minimum holding period grant rsus pursuant french subplan rsus issue share common stock pursuant agreement prior year anniversary grant date hold share common stock minimum period year grant date avoidance doubt twoyear hold period applicable share common stock vest follow year anniversary grant date sale restriction close period acknowledge share common stock issue deliver settlement rsus sell transfer dispose period set forth section french subplan rsus acknowledge agree personally responsible comply specific restriction termination employment death notwithstanding contrary provide section ci agreement grant rsus french subplan rsus corporation receipt month follow death write request heir form satisfactory corporation corporation shall transfer share underlie unvested rsus heir case share shall cease immediately subject abovementione minimum hold period termination employment disability prior vest date disabled employ definition section french subplan rsus shall immediately vested rsus date disability case share shall cease immediately subject abovementione minimum hold period language consent accept grant confirm read understand plan agreement provide english language accept term document accordinglyen acceptant lattribution vous confirmez avoir lu et compris le plan et le contrat qui ont communiqus en langue anglaise vous acceptez les terme de ce document en connaissance de cause notification exchange control information report french custom excise authority value cash security transfer france use financial institution value cash security equal exceed certain threshold foreign assetaccount report information require report foreign account open current closed french tax authority file annual tax return hong kong term condition form settlement rsus payable common stock notwithstanding discretion plan contrary agreement rsus provide right receive cash payment rsus shall pay share common stock sale common stock share common stock receive vest accept personal investment event common stock issue respect rsus month grant date agree offer public dispose share common stock prior month anniversary grant date notification security warn content document review regulatory authority hong kong exercise caution relation offer doubt content agreement include appendix plan obtain independent professional advice rsus share common stock issue respect rsus constitute public offering security hong kong law available eligible service provider plan agreement include appendix plan incidental communication material prepare accordance intend constitute prospectus public offer security applicable security legislation hong kong rsus documentation relate thereto intend solely personal use member award recipient distribute person indonesia term conditionslanguage consent notification accept grant rsus confirm read understand document relate grant ie plan agreement provide english language ii accept term document accordingly iii agree challenge validity document base law national flag language coat arm national anthem implement presidential regulation issue language consent notification dengan manikin tombol saya menerima atau dengan menandatangani dan mengembalikan dokumen ini yang memuat syarat dan ketentuan pemberian anda anda mengkonfirmasi bahwa anda telah membaca dan mengerti isi dokumen yang terkait dengan pemberian ini yang disediakan untuk anda dalam bahasa inggris ii anda menerima syarat dari dokumendokumen tersebut dan iii anda setuju bahwa anda tidak akan mengajukan keberatan atas keberlakuan dokumen ini berdasarkan undangundang tahun tentang bendera bahasa dan lambang negara serta lagu kebangsaan atau peraturan presiden pelaksana ketika diterbitkan ireland term condition acknowledgement nature plan rsus follow supplement section special employment right right award agreement accept agreement understand agree benefit receive plan take account redundancy unfair dismissal claim israel term condition provision supplement section agreement tax withholding israel accordance applicable law include tax ruling receive corporation andor israeli subsidiary follow provision apply participant israel grant date trustee arrangement agree rsus extent grant corporation israeli subplan plan shall allocate provision track refer capital gain track accord section b b israeli income tax ordinance shall hold trustee trustee period state section hold period acknowledge hold period sell share common stock issue settlement rsus tax treatment differ treatment apply hold period meet consult personal tax advisor regard italyterm condition acknowledgement nature agreement accept agreement acknowledge receive copy plan agreement appendix review applicable document entirety fully understand content thereof accept provision plan agreement appendix mexico term condition acknowledgement agreement accept rsus grant hereunder acknowledge receive copy plan review plan agreement include appendix entirety fully understand accept provision plan agreement include appendix acknowledge read specifically expressly approve term condition section special employment right right award agreement clearly provide follow participation plan constitute acquire right plan participation offer corporation wholly discretionary basis participation plan voluntary corporation subsidiary affiliate responsible decrease value share common stock acquire vest rsus labor law acknowledgement policy statement accept rsus grant hereunder expressly recognize corporation register office johnson johnson plaza new brunswick nj usa solely responsible administration plan participation plan acquisition share common stock constitute employment relationship corporation participate plan wholly commercial basis employer johnson johnson mexico sole employer base forego expressly recognize plan benefit derive participation plan establish right employer johnson johnson mexico form employment condition andor benefit provide johnson johnson mexico modification plan termination shall constitute change impairment term condition employment understand participation plan result unilateral discretionary decision corporation corporation reserve absolute right amend andor discontinue participation plan time liability youfinally declare reserve action right bring claim corporation compensation damage provision plan benefit derive plan grant broad release corporation affiliate shareholder officer agent legal representative respect claim arise spanish translation reconocimiento del contrato al aceptar el otorgamiento de las rsus uste reconoce que ha recibido una copia del plan que ha revisado el plan el contrato incluyendo este apndice en su totalidad que entiende acepta todas las disposicione del plan del contracto incluyendo este apndice adem uste reconoce que ha ledo que especfica expresamente aprueba de los trminos condiciones de la seccin del contrato que claramente dispone lo siguiente su participacin en el plan constituye un derecho adquirido el plan su participacin en el plan se ofrecen por la corporacin en de manera totalmente discrecional su participacin en el plan es voluntaria la corporacin sus subsidiarias afiliadas son responsable por ninguna disminucin del valor de las acciones en el momento de tener derecho conforme las rsus reconocimiento ley laboral declaracin de la poltica al aceptar el otorgamiento de las rsus uste reconoce expresamente que la corporacin con oficinas registradas en johnson johnson plaza new brunswick nj eeuu es nicamente responsable por la administracin del plan adem uste reconoce que su participacin en el plan cualquier adquisicin de acciones de conformidad con el plan constituyen una relacin laboral entre uste la corporacin ya que uste est participando en el plan sobre una base totalmente comercial que su empleador johnson johnson mexico es su nico patrn derivado de lo anterior usted reconoce expresamente que el plan los beneficios que le puedan derivar al participar en el plan establecen ningn derecho entre uste su patrn johnson johnson mexico que forman parte de las condiciones de trabajo yo prestaciones otorgadas por johnson johnson mexico que cualquier modificacin del plan la terminacin del mismo constituirn un cambio deterioro de los trminos condiciones de su empleo adem usted entiende que su participacin en el plan es resultado de una decisin unilateral discrecional de la corporacin por lo que la corporacin se reserva el derecho absoluto modificar yo discontinuar su participacin en el plan en cualquier momento sin responsabilidad alguna para con uste finalmente usted declara por la presente que se reserva accin derecho alguno para interponer una reclamacin demanda en contra de la corporacin por cualquier compensacin dao en relacin con cualquier disposicin del plan de los beneficios derivado del plan por lo tanto otorga un amplio total finiquito la corporacin susafiliadas accionistas funcionarios agente representante legales con respecto cualqui reclamacin demanda que pudiera surgir notifications security law information rsus grant share common stock acquire plan register national register security maintain mexican national banking security commission offer sell publicly mexico addition plan agreement document relate rsus publicly distribute mexico material address exist relationship corporation subsidiary affiliate corporation eg johnson johnson mexico material reproduce copied form offer contain material constitute public offer security constitute private placement security address specifically individual present employee johnson johnson mexico accordance provision mexican security market law right offering shall assign transfer new zealand notification security law information warning offer right receive share common stock settlement rsus subject term plan agreement rsus stake ownership corporation receive return dividend pay share common stock corporation run financial difficulty wound pay creditor pay lose investment new zealand law normally require people offer financial product information investor invest information design help investor informed decision usual rule apply offer employee share purchase scheme result give information usually require few legal protection investment ask question read document carefully seek independent financial advice commit participate plan interest rsus transfer legally beneficially assign mortgaged charge encumbered share common stock quote new york stock exchange mean acquire share common stock plan able sell new york stock exchange interested buyer invest price depend demand share common stocka copy corporation recent annual report recent publish financial statement quarterly report form q auditor report financial statement file securities exchange commission available online wwwsecgov corporation investor relation website httpwwwinvestorjnjcom copy document send free charge write request equity compensation resource johnson johnson plaza new brunswick nj usa note advise carefully read material provide make decision participate plan encourage contact tax advisor specific information concern personal tax situation regard plan participation philippine term condition restriction vest permit vest share common stock necessary security law approval plan obtain remain place determined corporation sole discretion corporation obligation issue share common stock corporation obtain necessary security approval approval subsequently invalid cease effect time vest rsus corporation reserve right settle rsus cash notification security law information aware risk participate plan include limitation risk fluctuation price share common stock new york stock exchange nyse risk currency fluctuation dollar local currency regard note value share common stock acquire plan decrease fluctuation foreign exchange rate local currency dollar affect value rsus amount vest settlement rsus sale share common stock acquire plan corporation make representation projection assurance value share common stock future information risk factor impact corporation business affect value share common stock refer risk factor discussion corporation annual report quarterly report form q file securities exchange commission available online wwwsecgov corporation investor relation website httpwwwinvestorjnjcom permit sell share common stock acquire plan designate broker appoint plan broker transfer share common stock provide resale share common stock acquire theplan take place outside philippine facilities stock exchange share common stock list eg nyse portugal term condition consent receive information english expressly declare knowledge english language read understand fully accept agree term condition establish plan agreement conhecimento da lingua por meio presente eu declaro expressamente que tem pleno conhecimento da lngua inglesa e que li compreendi e livremente aceitei e concordei com os termos e condie estabelecidas plano e acordo russia term condition security law requirement rsus grant hereunder agreement include appendix plan material receive participation plan rsus grant hereunder constitute advertising offer security russia issuance share common stock plan register russia share common stock offer place public circulation russia event share common stock acquire plan deliver russia share common stock maintain behalf united states permit sell share common stock acquire plan directly russian legal entity resident labor law acknowledgement acknowledge continue hold share common stock acquire plan involuntary termination employment eligible receive unemployment benefit russia data privacy notice acknowledge read understand term collection processing transfer datum contain section f data privacy consent agreement participate plan agree term regard request corporation employer agree provide execute datum privacy consent form employer corporation agreement consent require employer corporation corporation andor employer deem necessary obtain datum privacy law country future understand able participate plan fail execute consent agreement notificationsanticorruption legislation information individual hold public office russia spouse dependent child prohibit open maintain foreign brokerage bank account hold security acquire directly indirectly foreign company include share common stock acquire plan consult personal legal advisor determine restriction apply circumstance singapore term condition restriction sale transferability agree share common stock acquire pursuant rsus offer sale singapore prior sixmonth anniversary grant date sale offer pursuant exemption xiii division subdivision section security futures act chap ed sfa notifications security law information grant rsus pursuant qualifying person exemption section f sfa view rsus subsequently offer sale party plan lodge register prospectus monetary authority singapore south africa notifications security law information compliance south african security law acknowledge notify corporation annual report quarterly report form q file securities exchange commission available online wwwsecgov corporation investor relation website httpwwwinvestorjnjcom spain term condition labor law acknowledgement follow supplement section special employment right right award agreement accept rsus grant hereunder consent participation plan acknowledge receive copy plan understand corporation unilaterally gratuitously sole discretion decide grant rsus plan individual employee corporation group world decision limited decision enter express assumption condition rsu grant economically orotherwise bind corporation affiliate ongoing basis expressly set forth agreement include appendix consequently understand rsus grant hereunder give assumption condition shall employment contract corporation affiliate shall consider mandatory benefit salary purpose include severance compensation right whatsoever understand freely accept guarantee benefit whatsoever shall arise gratuitous discretionary grant rsus future value rsus underlie share common stock unknown unpredictable addition understand rsus grant hereunder assumption condition refer understand acknowledge freely accept assumption mistaken condition meet reason grant rsus right rsus shall null void vest rsus expressly condition active employment status corporation group service terminate rsus cease vest immediately forfeit effective date termination employment specifically provide section c certain termination agreement case example consider unfairly dismiss good cause ie subject despido improcedente dismiss disciplinary objective reason collective dismissal terminate service change work location duty employment contractual condition terminate service unilateral breach contract corporation affiliate corporation consequently termination employment reason automatically lose right rsus vest date termination employment describe section c agreement acknowledge read specifically accept condition refer section agreement notification security law information offer security public define spanish law take place place spanish territory agreement include appendix register comisin nacional del mercado de valores constitute public offering prospectus sweden term condition tax withholding provision supplement section agreement limit corporation employer authority satisfy withholding obligation taxrelate item set forth agreement accept rsus authorize corporation withhold share common stock sell share common stock deliverable vestingsettlement satisfy taxrelate itemsregardless corporation andor employer obligation withhold taxrelate item switzerland notification security law information document material relate rsus constitute prospectus accord article et seq swiss federal act financial service finsa ii publicly distribute publicly available switzerland person employee corporation iii file approve supervise swiss reviewing body accord article finsa swiss regulatory authority include swiss financial supervisory authority finma taiwan notifications security law information offer participation plan available employee offer participation plan public offer securities taiwanese company turkey notifications security law information plan available employee corporation affiliate offer participation plan private offer employee turkey rsus issuance share common stock plan take place outside turkey permit sell share common stock acquire plan turkey share common stock currently trade new york stock exchange locate outside turkey ticker symbol jnj shares common stock sell exchange united arab emirates notification security law information rsus plan grant select employee corporation affiliate purpose provide equity incentive plan agreement intend distribution employee deliver rely person conduct diligence rsus offer pursuant agreement understand content plan andor agreement consult authorize financial adviser emirate security commodity authority dubai financial service authority responsibility review verifying document connection plan ministry economy dubai department economic development approve plan theagreement take step verify information set responsibility document united kingdom term condition tax withholding provision supplement section agreement limitation section agreement agree liable tax relate item covenant pay taxrelated item request corporation different employer hm revenue customs hmrc tax authority relevant authority agree indemnify indemnify corporation different employer taxrelate item require pay withhold pay pay hmrc behalf tax authority relevant authority purpose agreement tax relate item include limitation employment income tax employee portion health social care levy notwithstanding forego director executive officer corporation mean section k exchange act understand able indemnify corporation income tax collect pay ninety day end uk tax year event give rise tax relate item occur consider loan constitute benefit additional income tax national insurance contribution nics health social care levy payable understand responsible reporting pay income tax additional benefit directly hmrc self assessment regime pay corporation andor employer appropriate employee nic health social care levy additional benefit recover mean refer section agreement uruguay term condition datum privacy acknowledgement provision supplement section f agreement understand datum collect employer transfer corporation johnson johnson plaza new brunswick nj usa andor financial institution broker involve management administration plan understand entity store data purpose administer participation plan venezuela term conditionssettlement rsus settlement vest rsus shall share common stock provide corporation discretion settle rsus cash determine cash settlement necessary advisable light change regulatory requirement venezuela event rsus settle cash cash payment vest settlement rsus shall base fair market value determine corporation share common stock subject vest rsus applicable taxrelated item investment representation condition grant rsus acknowledge agree share common stock acquire settlement rsus acquire intend investment resale share common stock conversion share foreign currency notification security law information rsus grant plan share common stock issue plan offer personal private exclusive transaction subject venezuelan government security regulationsexhibit johnson johnson stock trading policy director executive officer insider federal state law prohibit insider define buying sell security johnson johnson jj aware material nonpublic information jj pass tip information trade illegal activity commonly refer insider trading individual trade material nonpublic information tip information trade liable civil criminal penalty addition legal disciplinary action jj include dismissal cause stock trading policy policy director executive officer family member live household insider provide guideline respect transaction securities jj jj adopt policy security transaction help prevent insider trading protect reputation integrity ethical conduct policy apply general prohibition general prohibition trading tip aware material nonpublic information applicable blackout period start date week prior end fiscal quarter hour financial result fiscal quarter fiscal year announce insider trade jj security period trading allow call blackout period example fiscal quarter end september financial result release edt october trading prohibit policy september edt october ii cover policy section insider member board director b members executive committee c corporate controller family member live household section insider additional guidance section restrict insider treasurer corporate secretary individual designate time time general counsel company group chairman member group operate committee sector leadership team individual report directly chief financial officer exclude nonfinance staff member certain employee corporate controller group involve preparation financial statement determine chief financial officer investor relation professional family member live household restrict insider additional guidance section insider section insider restrict insider iii transaction prohibit policy trading jj security possession material nonpublic information trading jj security blackout period describe section iv gift jj security possession material nonpublic information blackout period permit section vii iv transaction prohibit blackout period open market purchase sale jj security purchase sale jj security broker accordance prearrange preapproved write plan irrevocable instruction additional guidance section sale exchange jj security connection exercise stock option include sale share subject stock option cashless exercise option sale exchange share generate consideration need fund exercise option pay taxis election change exist election dividend reinvestment plan switch exist balance jj stock fund company k saving plan increase decrease future contribution jj stock fund company k saving plan gift jj security permit section vii v transaction allow blackout period regular matching contribution jj stock fund company k saving plan regular reinvestment dividend dividend reinvestment plan transfer jj security trust regular purchase jj security employee stock purchase planvi preclearance stock transaction section insider time blackout period effect purchasing selling jj security engage transaction prohibit blackout period section insider preclear transaction jj security include gift write notify general counsel corporate secretary business day advance propose transaction addition chief executive officer notify transaction request section insider ii lead director board director nonexecutive chairman board directors applicable notify transaction request chief executive officer executive chairman board director transaction place business day receipt write preclearance general counsel corporate secretary vii gifts jj securities gifts jj security include gift trust estate planning purpose donation charitable organization gift security transaction avoid person make gift possession material nonpublic information depend circumstance surround gift accordingly encourage consult legal department contemplate gift section insider require obtain preclearance gift viii prearrange rule b trading plan insider trade jj security include exercise stock option sale exchange share underlie stock option blackout period accordance certain prearrange write plan irrevocable instruction trading plan meet requirement set forth section viii provide section insider subject stock ownership guideline use trading plan require ownership level meet propose trading plan enter good faith time insider possession material nonpublic information blackout period second propose trading plan specify number share purchase sell specific date provide write formula trading propose trading plan preapprove write general counsel corporate secretary business day prior entry trading plan modification thereof fourth propose trading plan comply sec rule b cfr b successor rule single plan insider enter multiple trading plan provide transaction overlap periods ii trading plan provide openmarket purchase sale total jj security plan single transaction month period forego restriction notapply eligible selltocover transaction sell share necessary satisfy tax withholding obligation arise exclusively vest certain type compensatory awards sec rule bciid waiting period trade trading plan place day follow entry trading plan section insider trade place later day follow entry trading plan ii business day follow jjs filing form q k sec complete fiscal quarter plan adopt subject maximum day follow entry trading plan early termination trading plan deemed terminate expiration term sale jj security subject trading plan trading plan terminate insider expiration term sale jj security subject trading plan early termination receipt write approval general counsel corporate secretary note new trading plan subject waiting period describe early termination strongly discourage certain limited circumstance general counsel corporate secretary consider early termination plan warrant amendment amendment modification trading plan receipt write approval general counsel corporate secretary addition insider amend trading plan possession material nonpublic information blackout period ii amendment effective day section insider long wait period describe amendment strongly discourage section insider representation new modify trading plan section insider include representation certify date adoption plan individual section insider aware material nonpublic information security jj ii adopt plan good faith plan scheme evade prohibition sec rule b notwithstanding forego adoption trading plan preclude trade outside trading plan accordance policy information trading plan contact corporate secretarys office ix additional guidance people cover policy actual knowledge financial result matter policy apply regardless actual knowledge financial result insider trade jj securities blackout period person knowledge current financial result trade know material nonpublic information sec rule jj code business conduct jj code business conduct ethic member board director executive officer prohibit buying sell jj security possession material nonpublic information company event cover policy trade jj security time knowledge ofmaterial information involve company disclose publicly event insider unsure news development information consider material question refrain trading jj security contact corporate secretary office state section insider require preclear trade derivative instrument person cover policy prohibit time buy selling option jj security short sale hedging transaction type derivative instrument link performance jj security family member live household family member people cover policy share household cover policy extent person cover policy addition child away college leave home remain financially dependent consider live household subject policy spouse child jj securities important advise policy family member live insider household aware restriction engage transaction involve jj security discuss insider jj security insider control policy apply investment decision people cover policy insider power direct purchase sale jj security virtue position shareholder director officer corporation notforprofit organization trustee trust executor estate purpose policy insider engage transaction jj security behalf corporation organization trust estate permit engage personal capacity policy exception policy exception policy grant extenuating circumstance exception approve general counsel require individual possession material nonpublic information urgent unexpected need money defense charge trading material nonpublic information posttermination transaction subject additional term condition restriction set forth agreement insider jj period time status jj terminate aspect policy include mandatory preclearance transaction jj security shall continue apply later end black period follow public release earning fiscal quarter insider status jj terminate ii begin second market trading day early public disclosure material nonpublic information know insider b time material nonpublic information know insider long material x contact question policy contact office corporate secretary email askcorpsecitsjnjcom questions amend board directors johnson johnson effective april exhibit subsidiary johnson johnson new jersey corporation international subsidiary show december johnson johnson subsidiary entity subsidiary jurisdiction subsidiarie abd hold company inc delaware abiome commercial llc delaware abiome rd inc delaware abiome inc delaware acclarent inc delaware actelion pharmaceutical inc delaware albany street llc new jersey alza corporation delaware alza land management inc delaware amo development llc delaware amo manufacturing usa llc delaware amo sales service inc delaware amo spain holdings llc delaware anakuria therapeutics inc delaware aortx inc delaware aragon pharmaceuticals inc delaware asia pacific holdings llc new jersey atrionix inc california aub holdings llc delaware auris health inc delaware bandol merger sub inc delaware benevir biopharm inc delaware biomedical enterprises inc texas biosense webster inc california breethe inc delaware cerenovus inc new jersey charm merger sub inc delaware coherex medical inc delaware cotherix inc delaware cre holdings inc delaware crossroads extremity system llc tennessee csats inc washington depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes institute llc delaware depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware dutch holding llc delaware ecl llc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon llc delaware ethicon llc texas ethicon inc new jerseyname subsidiary jurisdiction hansen medical international inc delaware hansen medical inc delaware d acquisition corp new jersey janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen product lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jevco holding inc new jersey jjhc llc delaware jnj international investment llc delaware jntl russia holdco llc delaware johnson johnson new jersey johnson johnson middle east inc new jersey johnson johnson singapore holdco llc delaware johnson johnson enterprise innovation inc delaware johnson johnson finance corporation new jersey johnson johnson gateway llc new jersey johnson johnson health care systems inc new jersey johnson johnson holdco na inc new jersey johnson johnson innovation jjdc inc delaware johnson johnson innovation llc delaware johnson johnson international new jersey johnson johnson medical devices diagnostic group latin america llc florida johnson johnson se inc new jersey johnson johnson services inc new jersey johnson johnson surgical vision inc delaware johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware laminar inc delaware llt management llc texas medical device business services inc indiana medical device diagnostic global services llc delaware megadyne medical products inc utah mentor partnership hold company llc delaware mentor texas gp llc delaware mentor texas lp delaware mentor worldwide llc delaware middlesex assurance company limit vermont momenta pharmaceuticals inc delaware netherlands hold company delaware neuwave medical inc delaware nuvera medical inc delaware omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware ortho biotech holding llc delaware patriot pharmaceuticals llc pennsylvanianame subsidiary jurisdiction percivia llc delaware princeton laboratories inc delaware prosidyan inc delaware pulsar vascular inc delaware regency urban renewal associate new jersey royalty llc north carolina rutan realty llc new jersey scios llc delaware serotiny inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware talco llc texas taris biomedical llc delaware tearscience inc delaware anspach effort llc florida tibotec llc delaware torax medical inc delaware verb surgical inc delaware wh development company llc georgia percivia llc delaware princeton laboratories inc delaware prosidyan inc delaware pulsar vascular inc delaware regency urban renewal associate new jersey royalty llc north carolina rutan realty llc new jersey scios llc delaware serotiny inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware talco llc texas taris biomedical llc delaware tearscience inc delaware anspach effort llc florida tibotec llc delaware torax medical inc delaware verb surgical inc delaware wh development company llc georgianame subsidiary jurisdiction international subsidiary abiome australia pty ltd australia abiome europe gmbh germany abiome europe gmbh aachen zweigniederlassung zug switzerland abiome japan kk japan abiome sarl france abiome singapore pte ltd singapore abiome ltd united kingdom actelion pharmaceuticals ltd switzerland actelion pharmaceutical trading shanghai co ltd china actelion treasury unlimited company ireland ais gmbh aachen innovative solution germany amo hangzhou co ltd china amo shanghai medical devices trading co ltd china amo asia limited hong kong amo australia pty limited australia amo canada company canada amo denmark aps denmark amo france france amo germany gmbh germany amo groningen bv netherlands amo international holding unlimited company ireland amo ireland cayman islands amo italy srl italy amo japan kk japan amo netherlands bv netherlands amo norway norway amo puerto rico manufacturing inc cayman islands amo singapore pte ltd singapore amo switzerland gmbh switzerland amo united kingdom ltd united kingdom amo uppsala ab sweden apsis france berna rhein bv netherlands biosense webster israel ltd israel c consumer product denmark ap denmark chromagenic bv netherlands cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag holding treasury unlimited company ireland cilagbiotech sl spain cordis de mexico sa de cv mexico corimmun gmbh germany depuy hellas sa greece depuy international limited united kingdom depuy ireland unlimited company ireland depuy mexico sa de cv mexico ecp entwicklungsgesellschaft mbh germany ees holdings de mexico de rl de cv mexico ees sa de cv mexico eit emerge implant technology gmbh germany ethicon endosurgery europe gmbh germany ethicon sarl switzerlandname subsidiary jurisdiction ethicon women health urology sarl switzerland ethnor proprietary limited south africa ethnor del istmo sa panama venezuela bolivarian ethnor farmaceutica sa republic finsbury development limited united kingdom finsbury instrument limit united kingdom finsbury medical limited united kingdom finsbury orthopaedics international limited united kingdom finsbury orthopaedic limit united kingdom fms future medical system sa switzerland gatt technologies bv netherlands gbsc division janssen biologics bv netherlands gh biotech holdings limited ireland gme healthcare bv belgium guangzhou bioseal biotech co ltd china hansen medical deutschland gmbh germany hansen medical uk limited united kingdom healthcare services shanghai ltd china innomedic gesellschaft fr innovative medizintechnik und informatik mbh germany j j company west africa limited nigeria jj argentina sa argentina jj pension trustees limit united kingdom jj productos medicos farmaceuticos del peru sa peru jc general services bv belgium janssen scientific office egypt janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen cilag spa italy janssen cilag spa algeria venezuela bolivarian janssen cilag republic janssen egypt llc egypt janssen farmaceutica portugal lda portugal janssen france treasury unlimited company ireland janssen inc canada janssen irish finance unlimited company ireland janssen japan treasury unlimited company ireland janssen korea ltd korea republic janssen mexico treasury unlimited company ireland janssen pharmaceutica proprietary limited south africa janssen pharmaceutica nv belgium janssen pharmaceutical kk japan janssen pharmaceutical sciences unlimited company ireland janssen pharmaceutical unlimited company ireland janssen rd ireland unlimited company ireland janssen sciences ireland unlimited company ireland janssen scientific office syria syrian arab republic janssen vaccines prevention bv netherlands janssen vaccines corp korea republic janssencilag france janssencilag new zealand limited new zealand janssencilag denmark janssencilag ag switzerland janssencilag aktiebolag sweden janssencilag norwayname subsidiary jurisdiction janssencilag bv netherlands janssencilag doo beograd serbia janssencilag de mexico de rl de cv mexico janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag international nv belgium janssencilag kft hungary janssencilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa colombia janssencilag sro czech republic janssencilag sa spain janssencilag sa de cv mexico janssenpharma sl spain jc health care ltd israel jj surgical vision spain sl spain jj surgical vision spain sl sucursal em portugal portugal jjc acquisition company bv netherlands jjsv belgium bv belgium jjsv manufacturing malaysia sdn bhd malaysia jjsv norden ab sweden jjsv norden ab filial finland finland jjsv produto oticos ltda brazil jnj global business service sro czech republic jnj holding emea bv netherlands johnson johnson angola limitada angola johnson johnson australia pty ltd australia johnson johnson canada inc canada johnson johnson china investment ltd china johnson johnson ecuador sa ecuador johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson mozambique limitada mozambique johnson johnson namibia proprietary limited namibia johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson private limited zimbabwe johnson johnson trinidad limit trinidad tobago johnson johnson vietnam co ltd vietnam johnson johnson ab sweden johnson johnson ag switzerland johnson johnson bulgaria eood bulgaria johnson johnson doo slovenia johnson johnson de chile sa chile johnson johnson de mexico sa de cv mexico johnson johnson de uruguay sa uruguayname subsidiary jurisdiction johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson dominicana sas dominican republic johnson johnson european treasury unlimited company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson export import llc egypt johnson johnson gt sociedad annima guatemala johnson johnson healthcare spc kuwait johnson johnson hemisferica sa puerto rico johnson johnson holding gmbh germany johnson johnson holdings austria gmbh austria johnson johnson innovation limited united kingdom johnson johnson international singapore pte ltd singapore johnson johnson international financial service unlimited company ireland johnson johnson irish finance company limited ireland johnson johnson kk japan johnson johnson kazakhstan limited liability partnership kazakhstan johnson johnson kft hungary johnson johnson llc russian federation johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical proprietary ltd south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical greece single member sa greece johnson johnson medical korea ltd korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical sas france johnson johnson medical saudi arabia limit saudi arabia johnson johnson medical taiwan ltd taiwan province china venezuela bolivarian johnson johnson medical scs republic johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson medtech thailand ltd thailand johnson johnson medtech colombia sas colombia johnson johnson medtech cr limitada costa rica johnson johnson mena rhq limited saudi arabia johnson johnson middle east scientific office united arab emirates johnson johnson middle east fzllc united arab emirates johnson johnson morocco societe anonyme morocco johnson johnson nordic ab sweden johnson johnson pakistan private limited pakistan johnson johnson pharmaceutical ltd china johnson johnson poland sp z oo poland johnson johnson private limited india johnson johnson romania srl romania johnson johnson se doo croatianame subsidiary jurisdiction johnson johnson sdn bhd malaysia johnson johnson sociedade previdenciaria non profit brazil johnson johnson surgical vision india private limited india johnson johnson taiwan ltd taiwan province china johnson johnson trading limited saudi arabia johnson johnson uk treasury company limited united kingdom johnson johnson ukraine ii llc ukraine johnson johnson vision care australia pty ltd australia johnson johnson vision care shanghai ltd china johnson johnson vision care ireland unlimited company ireland johnson johnson vision korea ltd korea republic johnson johnson lda portugal johnson johnson sa spain johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey la concha land investment corporation philippine mcneil panama llc panama medos international sarl switzerland medos sarl switzerland medos srl succursale de neuchtel branch switzerland menlo care de mexico sa de cv mexico mentor bv netherlands mentor deutschland gmbh germany mentor medical system bv netherlands neuravi limited ireland obtech medical mexico sa de cv mexico obtech medical sarl switzerland omj hold gmbh switzerland omrix biopharmaceutical ltd israel omrix biopharmaceutical nv belgium orthospin ltd israel orthotaxy france precardia france proleader sa uruguay pt johnson johnson indonesia indonesia respivert ltd united kingdom serhum sa de cv mexico spectrum vision limit liability partnership kazakhstan surgical process institute deutschland gmbh germany synthes costa rica scr limitada costa rica synthe gmbh germany synthe gmbh switzerland synthes holding ag switzerland synthes hold limited united arab emirates synthe medical immobilien gmbh germany synthe medical surgical equipment instrument trading llc united arab emirates synthe produktions gmbh switzerland synthes smp de rl de cv mexico synthes tuttlingen gmbh germany uab johnson johnson lithuania vision care finance unlimited company ireland xian janssen pharmaceutical ltd chinaname subsidiary jurisdiction xo limited united kingdomexhibit consent independent register public accounting firm consent incorporation reference registration statement form nos form johnson johnson report date february relate financial statement effectiveness internal control financial reporting appear form k spricewaterhousecooper llp florham park nj february exhibit certification chief executive officer pursuant section sarbanesoxley act joaquin duato certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting joaquin duato joaquin duato chief executive officer date february exhibit certification chief financial officer pursuant section sarbanesoxley act joseph j wolk certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting joseph j wolk joseph j wolk chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersign joaquin duato chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company joaquin duato joaquin duato chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit certification chief financial officer pursuant section sarbanesoxley act undersign joseph j wolk chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company joseph j wolk joseph j wolk chief financial officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit johnson johnson clawback policy board director board johnson johnson company determine appropriate company adopt clawback policy policy apply executive officer company effective date definition purpose policy follow definition shall apply committee mean compensation benefit committee board b company group mean company subsidiary applicable c covered compensation mean incentivebase compensation grant vest pay person serve executive officer time performance period incentivebase compensation receive effective date nyse list standard section ii person executive officer iii time company class security list national securities exchange national securities association effective date mean august e erroneously award compensation mean cover compensation grant vest pay person fiscal period applicable financial reporting measure relate cover compensation attain exceed cover compensation grant vested pay person determine base applicable restatement compute regard taxis pay ie pretax basis cover compensation base stock price total shareholder return erroneously award compensation subject mathematical recalculation directly information restatement committee determine cover compensation constitute erroneously award compensation base reasonable estimate effect restatement stock price total shareholder return cover compensation grant vest pay committee shall maintain documentation determination provide documentation nyse f exchange act mean securities exchange act g executive officer mean officer company define rule af section exchange act shall deem include individual identify company executive officer pursuant item b regulation sk exchange act current executive officer subject policy accordance term h financial reporting measure mean measure determine present accordance accounting principle prepare company financial statement measure derive wholly measure consist gaap nongaap financial measure define regulation g exchange act item regulation sk exchange act ii stock price iii total shareholder return financial reporting measure file sec present outside company financial statement management discussion analysis financial condition result operation performance graph require item e regulation sk exchange act home country mean company jurisdiction incorporation j incentivebase compensation mean compensation grant earn vest base wholly attainment financial reporting measure k lookback period mean complete fiscal year plus transition period month immediately follow complete fiscal year result change company fiscal year immediately precede date company require prepare restatement give report period date early date board committee board officer officer company authorize action board action require conclude reasonably conclude company require prepare restatement ii date court regulator legally authorize body direct company prepare restatement recovery erroneously award compensation policy dependent restatement actually file l nyse mean new york stock exchange receive incentivebase compensation deem receive company fiscal period financial reporting measure specify relate incentivebase compensation award attain grant vest payment incentivebase compensation occur end period n restatement mean require accounting restatement company financial statement material noncompliance company financial reporting requirement security law include correct error previously issue financial statement material previously issue financial statement commonly refer big r restatement ii correct error previously issue financial statement material previously issue financial statement result material misstatement error correct current period leave uncorrected current period commonly refer little r restatement mean exchange act rule nyse list standard section change companys financial statement represent error correction thencurrent relevant accounting standard notconstitute restatement recovery erroneously award compensation policy dependent fraud misconduct person connection restatement sec mean united states securities exchange commission p subsidiary mean domestic foreign corporation partnership association joint stock company joint venture trust unincorporated organization affiliate company directly indirectly intermediary control control common control company control purpose mean possession direct indirect power direct cause direction management policy person ownership vote security contract recoupment erroneously award compensation event restatement erroneously award compensation receive lookback period prior restatement thenoutstanding pay shall automatically immediately forfeit b pay person shall subject reasonably prompt repayment company group accordance section policy committee pursue shall discretion waive forfeiture andor repayment erroneously award compensation accordance section policy provide notwithstanding forego committee committee compose entirely independent director majority independent director serve board determine pursue forfeiture andor recovery erroneously award compensation person committee determine forfeiture andor recovery impracticable follow circumstance direct expense pay party example reasonable legal expense consult fee assist enforce policy exceed recover follow reasonable attempt company group recover erroneously award compensation documentation attempt provision documentation nyse ii pursuing recovery violate company home country law adopt prior november provide company obtain opinion home country counsel acceptable nyse recovery result violation provide opinion nyse iii recovery likely cause taxqualifie retirement plan benefit broadly available employee company group fail meet requirement usc usc regulation thereunder mean repayment event committee determine person shall repay erroneously award compensation committee shall provide write notice person email certify mail physical address file company group person person shall satisfy repayment manner term require committee company group shall entitle set repayment owe person company group require forfeiture award grant company group person necessary action reasonably promptlyrecoup repayment person case full extent permit applicable law include limitation section internal revenue code regulation guidance thereunder committee specify repayment timing write notice describe applicable person shall require repay erroneously award compensation company group wire cash cashier check later thirty day receipt notice indemnification person shall indemnify insured reimburse company group respect loss compensation person accordance policy shall person receive advancement expense dispute relate loss compensation person accordance policy person shall pay reimburse company group premium pay person thirdparty insurance policy cover potential recovery obligation policy purpose indemnification include modification current compensation arrangement mean de facto indemnification example provide person new cash award cancel effect recovery erroneously award compensation event shall company group required award person additional payment restatement result high incentive compensation payment miscellaneous policy generally administer interpret committee determination committee respect policy shall final conclusive bind interested party determination committee policy need uniform respect person selectively person person similarly situate policy intend satisfy requirement section doddfrank wall street reform consumer protection act amend time time relate rule regulation promulgate sec nyse include additional new requirement effective effective date effectiveness shall deem automatically amend policy extent necessary comply additional new requirement provision policy intend apply full extent law extent provision policy find unenforceable invalid applicable law provision apply maximum extent permit shall automatically deem amend manner consistent objective extent necessary conform applicable law invalidity unenforceability provision policy shall affect validity enforceability provision policy recoupment erroneously award compensation policy dependent company group satisfy condition policy include requirement provide applicable documentation nyse right company group policy seek forfeiture reimbursement addition lieu right recoupment remedy right recoupment available company group pursuant term lawgovernment regulation stock exchange list requirement policy code conduct employee handbook employment agreement equity award agreement plan agreement company group amendment termination extent permit manner consistent applicable law include sec nyse rules committee terminate suspend amend policy time discretion successor policy shall bind enforceable person respective beneficiary heir executor administrator legal representative respect cover compensation grant vested pay administer person entity